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Abstract
Poly(ADP-ribose)polymerase (PARP) is a nuclear enzyme involved in the repair of
DNA single strand breaks via the Base Excision Repair pathway (BER).
Temozolomide, a DNA alkylating agent recently licensed for the treatment of gliomas
and melanoma, produces DNA lesions which are targets for BER. Preclinical studies
demonstrate that PARP inhibitors increase the cytotoxicity and antitumour activity of
temozolomide suggesting that PARP inhibitors may have a clinical role as chemo-
potentiating agents.
This thesis describes the protocol development of a First-in-Human phase I clinical
trial of AGO 14699, a potent PARP inhibitor, in combination with temozolomide in
patients with advanced solid malignancies discussing the rationale for the study
design, definition of pharmacodynamic (PD) endpoints and starting dose. A two part
trial escalating first the dose of AG014699 then that oftemozolomide was designed
with PD endpoints for part 1 and classical toxicity endpoints for part 2.
The development and validation of two PARP activity assays to measure enzyme
activity and inhibition in human peripheral blood lymphocytes (PBLs) and
homogenised tumour biopsies are discussed. An established tumour cell line (L1210)
was evaluated to provide Quality Assurance, and preparation, storage and transport
stability of samples investigated. The first assay developed relied upon measuring
incorporation ofe2p] NAD+ into poly(ADP-ribose) (PAR), this assay proved robust
but depended upon the availability of large numbers of PBLs, limiting its clinical
application. An alternative assay based on detection of PAR with a monoclonal
antibody and electronic digitisation of the chemiluminescence signal was validated
and then assessed in a phase II mechanistic study of temozolomide alone in patients
with advanced malignant melanoma. This small study provided additional validation
for the assay and also data on DNA damage and repair after temozolomide which can
be used as control data to interpret the pharmacodynamic results of the First-in-
Human study.
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Chapter 1
Introduction
1.1 Background
Cancer is a major cause of morbidity and mortality in both children and adults. The
disease has enormous implications both for suffers and their families in terms of
physical, emotional and financial changes in their lives. For the National Health
Service the treatment of tumours and care of patients in the terminal phases of the
disease have major resource implications. In the last year total deaths from cancer
have overtaken those for heart disease as the major cause of adult mortality.
Improvement in cancer survival has been identified by the government as a key area
for action (1992). There are estimated to be >250,000 new diagnoses and >150,000
deaths per year in the United Kingdom (www.cancerresearchuk.org).
Treatments for cancer include surgery, radiotherapy, cytotoxic chemotherapeutic
drugs, biological agents, the newer targeted therapies - the signal transduction
modifying agents and supportive/palliative care. The majority of patients will receive
a combination of these treatment modalities for their tumour over the course of the
disease.
Over the last 50 years there have been great advances in the use of cytotoxic
chemotherapy, and high cure rates are achieved in a number of childhood cancers,
lymphoma and germ cell tumours. However the majority of adult solid tumours are
incurable with chemotherapy alone, and in the metastatic setting this treatment
remains palliative. The efficacy of cytotoxic drugs is limited by toxicity, in particular
myelosupression, lack of specificity and cancer cell drug resistance. A variety of
resistance mechanisms have been described or proposed, including decreased drug
uptake into cells, increased drug efflux (for example multi-drug resistance mediated
by P-glycoprotein expression), inactivation of the drug, alteration of the cellular
target, development of tolerance and repair of the drug-induced DNA damage
(DeVita, Hellman et al. 1997).
The development of better agents with which to treat cancer is a major goal both for
the pharmaceutical industry and also within academic research laboratories. It is
estimated that in the field of anticancer drug development there are approximately 500
compounds in development (Budman, Calvert et al. 2003). New agents are identified
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by screening natural products against tumour cell line panels, target identification and
rational drug design, or the use of computational drug design to improve existing
drugs or identify new compounds.
One potential target for the improvement in the efficacy of existing cytotoxic
chemotherapy would be inhibition of the DNA repair machinery. It is known that the
DNA damage caused by many chemotherapeutic agents is rapidly repaired, both in
normal tissues and the tumour. Inhibition of this repair in conjunction with
administration of DNA damage either by chemotherapy or radiotherapy could be a
mechanism for improving treatment outcomes.
The Drug Development Unit within the Northern Institute for Cancer Research has
been developing inhibitors ofpoly(ADP-ribose)polymerase (PARP) including PARP-
1, an enzyme involved in DNA repair, as a mechanism for potentiating the
cytotoxicity of both chemotherapy agents and radiation. The work reported in this
thesis has been performed within the Drug Development Unit and included
establishing optimum study design and the pharmacodynamic endpoints of PARP-l
inhibition. This introduction gives an overview of DNA repair mechanisms, PARP-l
and its role in DNA repair, the preclinical development of a potent PARP inhibitor
and discusses the development oftemozolomide, an oral monofunctional DNA
alkylating agent, which will be used in combination in the First-in-Human study of
the PARP-l inhibitor in cancer.
1.2 DNA repair mechanisms
Throughout the life of a mammalian cell there are various situations in which DNA
may be damaged, either by exogenous toxins, exposure to ionising radiation and from
endogenous sources such as products of cellular metabolism. It is estimated that the
average rate of damage is about 104 events per cell per day (Ames and Gold 1991). It
is therefore essential that the cell has mechanisms in place to preserve its genomic
integrity. There are reported to be at least 5 distinct pathways by which the cell can
detect and repair much of this damage; direct repair, mismatch repair (MMR), base
excision repair (BER), nucleotide excision repair (NER), non-homologous end joining
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(NHEJ) and homologous recombinational repair (HHR) (reviewed in (Lindahl, Karran
et al. 1997; Hansen and Kelly 2000; Christmann, Tomicic et al. 2003).
Direct repair describes the mechanism where the modified base is repaired by direct
reversal of the alteration without removal of the base itself. The main component of
the direct repair pathway is the alkytransferase protein which will be discussed in
detail in section 1.9 in relation to temozolomide.
Nucleotide excision repair is thought to be coupled with transcription, sometimes
termed "transcription-coupled repair" (TCR) and involves at least 11 proteins
(reviewed in (Wood 1996; Lindahl, Karran et al. 1997). A helix distorting lesion is
recognised by a three protein complex, other proteins are recruited and the DNA
backbone incised by XPF and XPG nucleases. An oligonucleotide of 25-32 bases is
released and the gap filled and DNA re-ligated. Its evolutionary role is thought to be
linked to the correction ofUV (sunlight) damage to DNA (Lindahl, Karran et al.
1997), and inherited lesions in this pathway are responsible for the photosensitivity
disorder xeroderma pigmentosum.
Double strand breaks are repaired by homologous recombination repair (HRR) or
non-homologous end-joining (NHEJ), the major proteins in these pathways being Rad
51, NBS, MREII, XRCC3 and BRCAI and BRCA2 (HRR); and Ku70, Ku86 and
DNA-PK in NHEJ (reviewed in (Bernstein, Bernstein et al. 2002).
The study reported here involves progress towards a phase I study of a PARP
inhibitor in combination with temozolomide, a DNA methylating agent used in the
treatment of melanoma and brain tumours ((Newlands, Stevens et al. 1997).
Temozolomide methylates DNA at 0 6-guanine, N7-guanine and N3-adenine in a ratio
1:14:2. 06-methylguanine is repaired by 06-alkylguanine-DNA alkyltransferase
(OGAT, ATase, MGMT) but ifunrepaired becomes a target for MMR. N7_
methylguanine and N3-methyladenine are repaired by BER. PARP-l is known to
have a role in BER. Hence these three mechanisms of DNA repair are discussed in
more detail below.
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1.2.1 Base excision repair
The base excision repair pathway is divided into short patch and long patch repair.
Despite these names BER involves removal of relatively short stretches of DNA,
between 1 and 15 nucleotides. Short patch base excision repair involves removal of
one base only whilst long patch repair removes 2-15 nucleotides; however they share
a common pathway. It is thought that short patch repair is involved in the repair of
methylation induced DNA damage whereas long patch repair corrects oxidative
damage (Hansen and Kelly 2000) these mechanisms having evolved to correct
endogenous DNA damage (Lindahl, Karran et al. 1997).
Short patch BER involves the removal of the incorrect or damaged base by a DNA
glycosylase, in eukaryotes 3-methyladenine DNA glycosylase (MPG) repairs N7_
methylguanine, N3-methyladenine and N3-methylguanine adducts, all of which are
formed by temozolomide ((Friedberg, Walker et al. 1995). Removal of the damaged
base generates an apurinic/apyrimidinic (AP) site which is cleaved by an AP
endonuclease/3' phosphodiesterase leaving a single strand break. Replacement of the
damaged base and religation of the DNA involves recruitment of a complex including
DNA polymerase {3, DNA ligase I or III/XRCC I (X-ray repair cross-complementing
1), PARP-l (Masson, Niedergang et al. 1998) and/or PARP-2 (Schreiber, Arne et al.
2002). The steps in the process are summarised in figure 1.1 (adapted from (Lindahl,
Karran et al. 1997), the role of PARP-l in the process will be discussed in more detail
below.
Long-patch repair is thought to be involved in the repair of oxidised or reduced AP
sites and is thought to be a minor, sub-pathway. 2-15 bases are excised, subsequent
repair involving DNA polymerases 0, E and {3, PCNAIRF-C, FEN I and DNA ligase I
(Hansen and Kelly 2000). There is no known role for PARP-l in this process.
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Figure 1.1 Schematic representations of the steps involved in BER, the common initial pathway
dividing into short-patch repair on the left and long-patch repair on the right.
1.2.2 Mismatch repair
Mismatch repair (MMR) recognises incorrectly paired oligonucleotides resulting in
their excision and the generation of a 100-1000 nucleotide gap in the daughter strand
with the incorrectly paired base, leaving the correct (in most cases) template strand
intact. The gap in the daughter strand is filled and the DNA ligated to complete the
repair process. MMR repair is defective in some inherited forms of cancer
(Hereditary non-polyposis coli, HNPCC; (Lynch, Smyrk et al. 1996)) and in a number
of sporadic cancers and is thought to lead to genetic instability and resistance to DNA
damage by a number of chemotherapeutic agents including temozolomide, 6-
thioguanine, cisplatin and carboplatin (Fink, Aebi et al. 1998).
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MMR repair was initially studied in bacteria and the major members of the pathway
characterised in Escherichia coli as MutS, MutL and MutH. Homologues of these
enzymes have now been characterised in mammalian species and are termed the MSH
and MLH genes, MSHI-6 (Fishel and Wilson, 1997) which act as heterodimers.
MLH 1 inactivation is common in human tumours. MSH2 and MSH6 heterodimers
preferentially recognise single base mispairs (Drummond, Li et al. 1995) and bind to
the 0 6-methylguanine residues formed by temozolomide. However it is the mispaired
thymine residue in the daughter strand which is excised and the 0 6-methylguanine
residue is left intact for further mis-pairing (Fink, Aebi et al. 1998). Loss of MMR
confers "methylation tolerance" and resistance to temozolomide. The consequences
of this are discussed in section 1.8 and the interaction between MMR and PARP-l
inhibiton in section 1.8.4
1.3 Poly(ADP-ribose)polymerase (pARP)
Poly(ADP-ribosyl)ation of nuclear and intra-cellular proteins occurs in most
eukaryotic cells in response to a variety of cellular stresses and was first reported in
1963 (Chambon, Wei I et al. 1963). It is now known that this process is due to a
family of enzymes known as poly(ADP-ribose) polymerase or PARP enzymes, 18
members of the family have been indentified so far. PARP 1,2, 3, V-PARP and
Tankyrase being the most intensively investigated (reviewed in (Smith 2001), with
PARP-l (EC 2.4.2.30) the most abundant and best characterised.
All the members of the family cloned so far show marked homology (25-60%
homology with PARP-l), with the NAD+ binding cleft being highly conserved
(Simonin 1993), figure 1.2 adapted from (Smith 2001). PARP-l (EC 2.4.2.30) is very
highly conserved between species; in particular the catalytic region shows 1000/0
homology between vertebrates and 92% homology among all species (de Murcia and
Menissier de Murcia 1994).
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Figure 1.2
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Figure 1.2 a) Schematic primary structures of PARP-1 to -5, homology to PARP- 1 largel y limited to C-
terminal region including catalytic domain . b) Amino acid identity of cata lytic domains, conserved
regions highlighted.
The family of enzymes has multiple roles within the cell, being involved in the
maintenance of genomic stability, regulation of DNA repair, telomere replication and
cellul ar transport (reviewed in (Burkle 2001; Chiarugi 2002) , and even longevity
(Burkle 2000). Their common action is to form long, often branched polymers of
ADP-ribose from NAD+on acceptor molecules, which include glutamate residues on
the PARP enzyme itself - automodification. The common mechanism of action of all
PARP enzymes is shown in figure 1.3, NAD+binds in the catalytic site and is cleaved
to release nicotinamide and ADP -ribose. This monomer subunit is attached to other
subunits to form long branched or linear polymers.
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Site of addition of the
next ADP-ribose unit
I Nicotinamide
OH +
Protein
acceptor
aCONH2 + H+
N N~)
9 ~ ~VN
J70 CHro-&o-z~cH2oOH Ho
P lbl b h si HO OHOSSI e ranc site on
subsequent ADP-ribose units
(a) ADP-ribosylation of a protein acceptor NAD+ H2
c;rCONH2 N(j)~ITeto-l~o-c~~N
~H~~ 0
o
HO OH
(b) Charge distribution on a branched poly(ADP-ribose) chain
Protein
acceptor
888888888888
P-P P- P P-P P- P P- P P-P
I I I I I I I I I I I IO-R!-R !-R !-Rll eR)eR!
P-P P-P
I I I I
R R-R R
I IA A
Figure 1.3 Catalytic mechanism of PARP enzymes. a) PARP cleaves AO+releasing nicotinamide and
covalently attaches linear and branched polymers of AOP-ribose, which may > I00 units long, to
acceptor proteins. b) charge distribution on polymer
PARP-1 is a protein of 1014 amino acid residues, which has three functional domain
(figure 1.4 from (Burkle 2001); the D A biding fragment (DBD) which contain tv 0
zinc finger motifs involved in D A strand break recognition and a nuclear location
signal, the central auto-modification domain which includes a BRCA-1 C-tenninal
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domain (BRCT) and the C-terminal catalytic fragment which binds TAD- (reviewed
in (Shall 2002). In humans the gene coding for PARP-I, designated ADPRT, lies on
chromosome Iq41-1 q42 (Cherney, Mc Bride et a1. 1987). The crystal structure of the
purified catalytic fragment of chicken PARP -1 has been identified (Ruf, Murcia et a1.
1996). Human PARP-1 can now be produced from c-DNA cloned in baculovirus
expression vectors (Knight and Chambers 2001).
Figure 1.4
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Figure 1.4 Functional domains of PARP-l
PARP -1 is a very abundant nuclear enzyme being present at the density of one
enzyme molecule per 1 kb DNA (Burkle 2001 ). It is constitutively expressed in
eukaryotic cells but has low basal activity unless activated by genotoxic stresses.
DNA binding increases the activity of the enzyme 500-fold. PARP-1 binds to DNA
strand breaks via the two zinc fingers at the aminoterminal DBD, its activity being
dependent on such binding (Boulikas 1991). The enzyme acts as a homodimer
(Mendoza-Alvarez and Alvarez-Gonzalez 1993) catalysing the transfer of ADP-ribose
from the substrate NAD+ to nuclear acceptors. These acceptors include histones,
topoisomerases, DNA polymerases I and II, Ca2+ and Mg 2+-endonucleases and D A
ligases, p53 , but in particular the PARP-1 enzyme itself (reviewe d in (Davidovic,
Vodenicharov et a1. 2001 ). Long pol ymers of up to 200 units, often high ly branching,
are formed, Modified PARP-1 is released from the DNA, this is presumed to be due
to the electrostatic repulsion of the now highly negatively charged complex and
results in inactivation of the enzyme. The po lymer is rapidly degraded by poly (ADP-
ribo se) glyco hydrolase (PARG) (Davido ic, Vodenicharov et al. 2001; Ro i, Denegri
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et al. 2002) releasing PARP-l for further activation. Although it was originally
proposed that PARP could not remove the final ADP-ribose residue, this being
removed by ADP-ribosyl protein lyase (Oka, Veda et al. 1984), recent studies using
purified PARG and PARG inhibitors suggest that PARG alone can degrade the entire
polymer (Jacobson M, PARP Conference, Lisbon, 2003).
There is much debate over the potential roles of PARP-1 and poly(ADP-ribosylation)
in the cells. The rapid production of polymer in response to DNA damage has led to
the suggestion that PARP-l plays an important part in the signalling of DNA damage
and, in fact, acts as a "molecular nick sensor", recruiting appropriate repair enzymes
(de Murcia and Menissier de Murcia 1994). There is compelling evidence for the
involvement of PARP-l in BER and increasing data suggesting a more complex
function in the regulation of DNA repair and induction of apoptosis.
1.4 Role ofPARP-l in DNA repair
1.4.1 Base excision repair
The fact that poly(ADP-ribosylation) plays a role in the recovery of proliferating cells
from DNA damage was demonstrated over 20 years ago (Durkacz, Omidiji et al.
1980). It is known that PARP-l is involved in the process ofbase excision repair
(BER) and PARP-l is part of the base excision repair complex (Molinete, Vermeulen
et al. 1993; Lindahl, Satoh et al. 1995; Dantzer, Schreiber et al. 1999). PARP-1 is
activated within minutes of DNA damage (Bernardi, Negri et al. 1995) and the
synthesis of poly(ADP-ribose) has been shown to be directly proportional to the
number of single and double DNA strand breaks (D'Amours, Desnoyers et al. 1999).
PARP-l has been shown to bind to single strand breaks via the second zinc finger (f
II), a single strand break introduces flexibility into the damaged region of DNA, and a
characteristic "V"-shape to the molecule is seen on dark-field electron microscopy.
PARP-l binds specifically to the centre of this "V", accentuating the distortion (de
Murcia and Menissier de Murcia 1994) and potentially easing access for the other
elements of the BER pathway.
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The polymer complex formed is very short lived, having a half life in vivo of
approximately 1 minute (Alvarez-Gonzalez and Althaus 1989). The close association
with PARG means that there is a dynamic system where PARP-1 is rapidly activated
by the DNA damage, polymer is formed, down stream processes are activated and
PARP-1 is released from the DNA. The polymer is then rapidly degraded by PARG
to free PARP-1, in the case of automodification, for further activation. The number of
PARP-1 molecules per cells means that the enzyme is ideally placed to act as a "nick
sensor", and then be released to detect other DNA damage (Masutani, Nozaki et al.
1995). This process causes a rapid depletion of cellular NAD+ and imposes a high
energy cost on the cell indicating its importance
It is proposed that PARP-1 has a role in regulating the response to DNA damage via a
"shuttling model", where the enzyme is closely associated with DNA, detects and
binds to strand breaks (Satoh and Lindahl 1992). This causes PARP activation and
formation of negatively charged polymer. Automodification of the enzyme means it
becomes progressively more negatively charged, a "point of repulsion" is reached
when it no longer can associate with DNA. Polymer is removed from the released
enzyme by PARG allowing further shuttling to signal DNA damage (Lindahl, Satoh et
al. 1995; D'Amours, Desnoyers et al. 1999). PARP-1 binds strongly to DNA, having
a high affinity for single strand breaks but also blunt ended DNA double strand
breaks, where it is proposed it may act to prevent inappropriate recombination prior to
DNA repair (D'Silva, Pelletier et al. 1999).
Poly(ADP-ribosylation) of histones also occurs in response to DNA damage.
Attachment of the negatively charged polymer leads to electrostatic repulsion and
opening up of the chromatin and allowing access of the BER complex, followed by
subsequent degradation of PAR and re-association of the histones with DNA
(reviewed in (D'Amours, Desnoyers et al. 1999) suggesting another mechanism by
which this enzyme is involved in DNA repair.
Further evidence to support a role for PARP-1 in BER has come from the studies by
Masson and colleagues (Masson, Niedergang et al. 1998) where a two-hybrid system
was used to demonstrate the close physical association of PARP-1 and XRCC 1,
which is a scaffold protein in the BER complex. XRCC 1 is know to interact with
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DNA ligase III and DNA polymerase {3, and the identification of its third partner as
PARP-1 has led to a new model comprising the BER multi-protein complex (figure
1.5).
Studies where PARP-l activity has been reduced, either by chemical inhibitors, trans-
dominant inhibition of PARP-1 by overexpression of the PARP DNA binding domain
(DBD), depletion ofPARP by antisense-RNA or mutation of the PARP-1 gene and
the generation of PARP-1 knockout mice, have provided more evidence for a role of
PARP-1 in BER. Data from studies with all of these mechanisms of PARP inhibition
have shown increased sensitivity to agents that cause DNA damage that is repaired by
BER - alkylating agents, ionising radiation, oxidative damage but not those repaired
by other pathways, for example ultraviolet light.
HeLa cell lines depleted in PARP have been generated by induction of PARP-
antisense RNA expression. These cells perform very limited DNA repair in response
to methylmethanesulfonate (which generates single strand breaks) induced DNA
damage (Ding and Smulson, 1994). Overexpression of the DBD has been established
in a number of cell lines. This causes trans-dominant inhibition of PARP-1 possibly
by blocking the DNA binding of the enzyme. This inhibition causes increased
sensitivity to DNA alkylating agents (N' -nitro-N-nitrosoguanidine, MNNG)
(Molinete, Vermeulen et al. 1993) and ionizing radiation (Kupper, Muller et al. 1995)
with a reduction in PARP activation, an increase in cell doubling time, G2/M
accumulation and reduction in cell survival (Schreiber, Molinete et al. 1992). All
these data provide further evidence for a critical role of PARP in BER repair of DNA
damage (reviewed in (Dantzer, Schreiber et al. 1999).
PARP-/- (PARP-1 knockout mice) have been developed in three laboratories by
homologous recombination in embryonic stem cells (Wang, Auer et al. 1995; de
Murcia, Niedergang et al. 1997; Masutani, Nozaki et al. 1999) disrupting exons 2, 4
and 1 respectively. These animals are phenotypically normal but are substantially
deficient in BER and hypersensitive to ionising radiation and DNA alkylating agents
(de Murcia, Niedergang et al. 1997; Wang, Stingl et al. 1997; Masutani, Nozaki et al.
1999) and have altered responses to cellular stress (Wang, Stingl et al. 1997). Cell
lines from these animals show increased genomic instability (Simbulan-Rosenthal,
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Haddad et al. 1999). In a cell-free DNA repair assay extracts from mouse embryonic
fibroblasts (MEF) from PARP-/- animals showed impaired repair of DNA sing1e-
strand breaks associated with a reduced expression of factors involved in long patch
BER (Sanderson and Lindahl 2002). All these data indicate that there is an alteration
in BER in these animals (Shall and de Murcia 2000).
Production ofpoly(ADP-ribose) polymers has been demonstrated in PARP-/- cells
(Shieh, Arne et al. 1998). The subsequent identification of the many other members
of the PARP family, has helped explain these results. It has been shown that PARP-2
is also a DNA damage-dependent poly(ADP-ribose) polymerase (Arne, Rolli et al.
1999) and that this family member is involved in BER (Schreiber, Arne et al. 2002)
and it is likely that the polymer production in response to DNA damage observed in
PARP-/- cells (Shieh, Arne et al. 1998) is due to this enzyme. PARP-/- cells can
repair irradiation induced DNA damage in an NAD+-independent manner. Addition
of purified PARP-1 to this cell free system led to a restoration of the NAD+-dependent
process of BER (Vodenicharov, Sallmann et al. 2000). PARP-1 deficient cells have
impaired short patch BER (50% normal) and dramatically reduced long patch repair
(80-90% reduction).
In summary, PARP-1 is now known to be a critical part of the BER pathway, binding
to the single strand break, signalling damage to other members of the repair pathway
and then being released to detect and signal further damage (figure 1.5). It has
recently been proposed that the degradation ofpoly(ADP-ribose) is the unique source
of ATP used by DNA ligase during base excision repair (Oei and Ziegler 2000).
1.4.2 Interactions of PARP-l and p53
There is increasing evidence for an interaction between PARP-1 and p53 (a tumour
suppressor protein) to promote effective repair of DNA damage and it is known that
p53 is an acceptor protein for poly(ADP-ribosylation) (reviewed in (Bernstein,
Bernstein et al. 2002). Human PARP-l and p53 have been shown to form a complex
which does not involve their active domains (Wesierska-Gadek, Wojciechowski et al.
2003). Mice deficient in p53 and PARP-l have a high frequency of epithelial
carcinomas and brain tumours suggesting that there may be an interaction to maintain
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genome integrity. p53 is also known to act in BER by stabilising the interaction
between DNA polymerase (3, Ref-1 and abasic DNA (Offer, Milyavsky et al. 2001).
The intimate association ofPARP-1 and p53, may indicate a more subtle role in
modulating the role ofp53 in apoptotic cell death (Chiarugi 2002). It is known that
poly(ADP-ribosylation) occurs in response to an apoptotic stimulus (Bernardi, Negri
et al. 1995). Poly(ADP-ribosylation) of p53 alters its binding to DNA (Malanga,
Pleschke et al. 1998), PARP-/- MEFs show decreased p53 accumulation and
activation following ionising radiation (Valenzuela, Guerrero et al. 2002) whereas
irradiation of PARP+/+ cells strongly induces p53 (reviewed in (Bouchard, Rouleau et
al. 2003). Trans-dominant inhibition ofPARP-1 by over expression of the DBD
attenuated p21 induction and suppresses the p53-mediated G1 arrest response to
ionising radiation (Wieler, Gagne et al. 2003); similar results having been previously
observed using chemical inhibitors (Masutani, Nozaki et al. 2000).
These data have led to a more complex model for regulation ofBER (figure 1.5 from
(Hoeijmakers 2001), p53 committing cells to cell cycle arrest and DNA repair or
apoptosis depending on the extent of DNA damage.
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Figure 1.5 Schematic diagram of BER. Damaged base is excised by glycosylase; recruitment of
signalling enzymes and Ref- l, an AP endon uclease, generates a single strand break. The BER
complex, including PARP-I is recruited and repair occurs.
1.5 Role of PARP-l in Apoptotic and Necrotic Cell death
PARP -1 activation is protective in proliferating cells because of its role in DNA
repair, however in non-proliferating cells excessive activation of the enzyme leads to
cell death. Exposure of quiescent cells to ischaemia or bacterial endotoxins causes
widespread liberation of reactive oxygen species (ROS). Consequent DNA damage
leads to over activation ofPARP-1 , NAD+depletion and necrotic or at least caspase-
independent, non-apoptotic, cell death . Maintenance of AD+prevents this type of
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cell death (Ying, Garnier et al. 2003). It has been suggested that the decrease in pH
associated with proton release from hydrolysis ofNAD+ may also contribute to the
cell death (Affar, Shah et al. 2002). PARP-1 knockout mice are resistant to these
insults, with a decrease in the size of the necrotic area after cerebral artery ligation,
reduced myocardial reperfusion injury and enhanced survival after endotoxic shock
(reviewed in (Burkle 2000). Similar results have been reported using chemical
inhibition of PARP-1.
PARP-1 is an early target for caspase-3 and -7 in apoptosis, being cleaved at the
DEVD motif in the nuclear location sequence (Soldani and Scovassi 2002) and
inactivated. The N-terminal p24 fragment retains its DNA binding ability without any
catalytic ability acting, in effect, as an inhibitor ofbase excision repair. There is
evidence that the C-terminal p89 fragment can interact with intact PARP-1 and thus
blocks intact enzyme homodimerisation which is essential for activity. Thus once the
apoptotic destruction of PARP-1 by caspases has commenced there is a rapid
inhibition of further DNA repair and the consequent energy consumption. This
observation is confirmed in experiments where uncleavable PARP-1 was transfected
into PARP-/- cells and apoptosis was delayed (Oliver, de la Rubia et al. 1998).
It would appear that early in apoptosis poly(ADP-ribosylation) contributes to
activation ofp53 and downstream effectors including the recruitment of AIF from the
mitochondria (Conde, Mark et al. 2001; Yu, Wang et al. 2002; Du, Zhang et al. 2003)
therefore also being involved in caspase-independent programmed cell death. The
caspase-dependent cleavage of PARP-1 during ATP-dependent apoptosis has a role in
channelling energy consumption into programmed cell death rather than DNA repair.
In summary PARP-1 activation participates in DNA repair and recovery at low levels
of DNA damage and over activation of the same enzyme appears to contribute to cell
death in high DNA damage states, the proposed interaction of these two processes is
shown diagrammatically in figure 1.6 (taken from (Bernstein, Bernstein et al. 2002).
Both the apparently conflicting roles for PARP-I in the cell are potentially targets for
drug modification in human disease states. These possible clinical uses and the
development of PARP-1 inhibitors will be discussed below.
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Figure 1.6 Diagrammatic representation of the interaction between ADP-ribosylation, energy use and
outcome after excessive DNA damage
1.6 Development ofPARP-1 inhibitors
PARP-1 inhibition is an attractive method for studying the significance of this enzyme
in biological systems. Many inhibitors have been designed around nicotinamide,
which is a by-product of PARP-mediated NAD+ cleavage, and is itself a weak PARP-
1 inhibitor. The first nicotinamide analogues were the benzamides. Inhibition of
PARP by 3-aminobenzamide (3-AB) was reported over two decades ago by Whish
with an inhibitory constant (K) of 1.8 ± 0.2 11M in L1210 cells (Purnell and Whish
1980). However to inhibit PARP sufficiently to retard DNA repair in intact cells
millimolar concentrations of 3-AB are needed. 3-AB is not a specific PARP
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inhibitor, having activity against mono (ADP-ribosyl) transferases and de novo purine
sythesis, and more specific and potent PARP inhibitors would be required both for
study of enzyme activity but also for any potential clinical applications. Considerable
effort has been put into finding specific PARP-1 inhibitors (reviewed in (Griffin,
Pemberton et al. 1995; Li and Zhang 2001; Southan and Szabo 2003).
The newer more potent PARP inhibitors have been designed based on interaction and
inhibition at the NAD+ binding site. Extensive studies of structure-activity
relationships revealed key desirable features (reviewed in (Griffin, Pemberton et al.
1995). It was proposed that a potent PARP inhibitor should have an unsubstituted
aromatic or polyaromatic heterocyclic structure; a carboxamide group restricted to the
anti-position; at least one amide proton for hydrogen bonding and a non-cleavable
bond at the equivalent of the 3'-position of 3-AB. X-ray crystallography of inhibitors
in the NAD+ binding site has complemented structure activity relationships and
allowed the identification of 3 critical hydrogen bonds.
Banasik screened more than 170 compounds available commercially as poly- and
mono(ADP-ribose) inhibitors. His group identified several potent inhibitors, e.g.
naphthalilides and dihydroxyisoquinolines, all ofwhich have the carbamoyl function
incorporated within a ring system (Banasik, Komura et al. 1992).
These advances allowed the second generation of PARP inhibitors to be developed,
the bicyclic lactams (PD128763 and NU1025) and benzimidazole-4-carboxamides
(NU1085), which showed much greater potency over 3-AB with ICsos in the
nanomolar range (reviewed in (Li and Zhang 2001), also figure 1.7).
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Figure 1.7 Small molecule inhibitors of PARP-1, including the molecule NU 1025 and NU 1085
identified during the Newcastle PARP inhibitor development programme. Year of discovery given
above, relative potency to 3-AB shown.
X-ray crystallography ofPD128763, NU1025, naphthaliamide and benzamide with
PARP-1 showed restriction of rotation of the carboxamide improved binding (Ruf, de
Murcia et al. 1998).
Part of the drive to develop potent, specific PARP inhibitors has been based on the
observations that inhibition of PARP can potentiate the cytotoxicity of anticancer
drugs. Durkacz et al first reported that ADP-ribosylation was involved in DNA
excision repair and that inhibition of the enzyme enhanced the cytotoxicity of
demethyl sulphate, a DNA alkylating agent, in 1980. At the end of this seminal paper
the authors suggested that this "potentiation of cell killing by alkylating agents and
PARP inhibitors may be of use in the treatment of human leukaemia" (Durkacz,
Omidiji et al. 1980).
There is now considerable academic and commercial interest in the development of
PARP inhibitors suitable for use in humans. Interest continues in the field of cancer
treatment, where inhibitor use would be envisaged in combination with cytotoxic
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agents to enhance the tumour response to chemotherapy or radiotherapy by preventing
repair of induced DNA damage. The in vitro observations that PARP-l inhibitors
potentiate the cytotoxicity of anti-cancer drugs and ionising radiation, and the fact that
in vivo PARP-l knock out mice show increased sensitivity to these agents has
stimulated the development of specific PARP-l inhibitors as potential chemo- and
radiosensitisers
However there is expanding interest in other clinical fields consequent on the
observation of the protective effects of PARP inhibition or the PARP knockout
mutation in cerebral ischaemia, endotoxic shock, inflammatory disorders and
reperfusion injury (reviewed in (Tentori, Portarena et al. 2002; Virag and Szabo
2002). The activation ofPARP-l and its putative role in necrotic cell death has led to
the development of PARP-l inhibitors to prevent such activation and decrease
resultant cell death. It has been suggested that such agents could be used as a
neuroprotective agent after ischaemic stroke and traumatic brain injury, could be
cardioprotective after myocardial infarction, and could be used in the treatment of
Alzheimer's disease and endotoxic shock (reviewed in (Tentori, Portarena et al. 2002)
- see figure 1.8.
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1.7 Development of AG014699
The Medicinal Chemistry Department and Drug Development Group, Cancer
Research Unit, University of Newcastle Upon Tyne has identified, using rational dru g
design, quinazolin-4-[3H]one (e.g. NU 1025 ) and benzimidazole-4-carboxami de(e.g.
NU 1085 ) derivati ves which are potent inh ibitors of PARP-1 (Griffin, Pemberton et al.
1995 ). NU 1025 and 1085 have been shown to potentiate the cytotoxicity of
alkylating agents, bleomycin (a free-radical producing glycopeptide which cause
ingle and double strand breaks) and ionising radiation in a murine leukaemia cell line
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(L1210) «Bowman, White et al. 1998); (Boulton, Pemberton et al. 1995) but not the
thymidylate synthase inhibitor nolatrexed or gemcitabine (a nucleoside analogue).
Potentiation of camptothecin (a topoisomerase I poison) but not etoposide (a
topoisomerase II poison) was reported in the same experimental system (Bowman,
Newell et al. 2001). Camptothecin forms both protein-associated and non-protein
associated single strand breaks which would bind and activate PARP-1. Etoposide is
associated with the formation ofprotein-associated double strand breaks which would
not be a stimulus to PARP-1. The enhancement of both temozolomide and topotecan
(a clinically active topoisomerase I poison) cytotoxicity has been confirmed in a panel
of human common tumour cell lines independent ofp53 status and tissue of origin
(Delaney, Wang et al. 2000).
Following the successful development ofpotent PARP-1 inhibitors in Newcastle a
collaboration was established with Agouron Pharmaceuticals (now part of Pfizer
GRD) to improve these agents and move them forwards to clinical trials (Canan
Koch, Thoresen et al. 2002; Skalitzky, Marakovits et al. 2003) as chemo-potentiating
agents. New compounds have been developed using x-ray crystal structure-based
design and structure activity relationships to improve both potency and solubility
(Skalitzky, Marakovits et al. 2003). Crystallographic analysis of one of the earlier
inhibitors (NU1085) bound in the PARP catalytic site (see figure 1.9) led to the
development of a new class of inhibitors, the tricyclic lactam indoles (Canan Koch,
Thoresen et al. 2002). These compounds are ~1OOOx more potent than 3-AB, Ki ::; 5
nm, and potentiate temozolomide and topotecan cytotoxicity at sub-micomolar
concentrations. In particular AG 14361 showed impressive in vitro activity, had
suitable pharmacokinetic properties and was a potent radio- and chemo-sensitiser in
vivo (Calabrese, Almassy et al. 2004).
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Figure 1.9
Figure 1.9 Co-crystal struct ure of NU 1085 and NA O+ binding site of chicken PARP-l
The clinical candidate, AG014699, and a range of back-up compounds were generated
and preclinical evaluation carried out both at Pfizer GRD (formulation and
toxicology) and in Newcastle (preclinical efficacy and pharmacodynamics). It was
proposed that the PARP-l inhibitor AGO 14699 (structure shown in figure 1.10) would
enter clinical trials early in 2003.
Figure 1.10
°
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Figure I. 10 Structure of AGO 14699
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A proposal for two phase I combination clinical trials, with temozolomide and
irinotecan respectively, was put to the New Agents Committee of Cancer Research
UK in 2001. The proposal was approved and these new agent trials will be run
through Cancer Research UK's Drug Development Office. The First-in-Human
clinical trial of the PARP-l inhibitor AGO 14699 will be in combination with
temozolomide.
The mechanism of action of temozolomide, its early clinical development and
evidence of the interaction with PARP-l are discussed below, completing the
introduction to this thesis. The further preclinical data pertinent to the protocol
development for the clinical trial of AG014699 and temozolomide will be discussed
in chapter 2.
1.8 Temozolomide
1.8.1 Chemistry and mechanism of action
Temozolomide (CCRG 81045; M&B 39831; NSC 362856; SCH 52365) is an
imidazotetrazine. It is one of a family of compounds synthesised by Stevens and
colleagues (Stevens, Hichman et al. 1987) which exhibited a broad spectrum of
activity against murine tumours. The lead compound, mitozolomide, entered clinical
trials but its further development was halted after severe and unpredictable
myelosuppression was reported (Blackledge, Roberts et al. 1989). Preclinical studies
with temozolomide showed good experimental antitumour activity with lower toxicity
which was schedule dependent (Stevens, Hichman et al. 1987). Temozolomide is an
orally available drug that is rapidly absorbed with 100% oral bioavailability, peak
plasma levels being achieved at 1.2 hours after oral dosing (Danson and Middleton
2001). In the plasma the drug undergoes spontaneous breakdown to the active
component, 5-(3-methyl) I-trizen-l-yl-imidazole-4-carboxamide (MTIC) at
physiological pH in aqueous solution (Stevens, Hichman et al. 1987). This is in
contrast to the original lead drug in this family, dacarbazine, which requires metabolic
activation in the liver with demethylation of the parent drug to release MTIC (figure
1.11).
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Figure 1.11 Structures of dacarbazine (DTIC) and temozolomide, and the active, DNA methylating
species, MTIC
MTIC is unstable and degrades into its methyldiazonium ion, a reactive methylating
compound. This acts as a major groove-directed DNA-alkylating agent, preferentially
binding to the middle guanine residue of a GGG sequence (Stupp, Gander et al. 2001).
Temozolomide generates methyl adducts, the predominate species being N7_
methyl guanine (70%), N3-methyladenine (9.2%) and 0 6-methylguanine (5%)
(Newlands, Stevens et al. 1997). It is the 0 6-methylguanine products, which although
in the minority, that appear to be responsible for the cytotoxicity oftemozolomide
(Tentori, Graziani et al. 1995; Hickman and Samson 1999). 0 6-methylguanine is not
lethal to cells per se but during DNA replication tends to mispair with thymine. This
mis-pairing is recognised on the daughter strand by the MMR pathway and the
thymine excised. However, unless the original 0 6-methylguanine lesion is repaired
by removal of the methyl adduct thymine is likely to be re-inserted. Repetitive futile
rounds of mismatch repair causes a state of chronic strand breaks and the MutS
branch of MMR signals G2/M cell cycle arrest and the initiation of apoptosis (Karran
and Hampson 1996; D'Atri, Tentori et al. 1998; Fink, Aebi et al. 1998).
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1.8.2 Repair of temozolomide induced DNA damage
1.8.2.1 N7-methylguanine and N3-methyladenine repair
The N-methylpurines formed are promptly repaired by the base excision repair
pathway. The modified base is excised by methylpurine glycosylase (MPG) resulting
in an abasic site. This initiates the BER repair pathway as discussed in section 1.2.1
with the close involvement ofPARP-l activation in this pathway (see section 1.4). It
is thought that unrepaired N7-methylguanine lesions are well tolerated, however the
N3-methyladenine adduct is mutagenic and cytotoxic if not rapidly repaired (Lawley
and Phillips 1996).
1.8.2.2 0 6-alkylguanine DNA-alkytransferase and MMR
Repair of 0 6-methylguanine lesions requires the activity of 0 6-alkylguanine-DNA
alkyltransferase (OGAT, ATase). ATase is the main component of the Direct Repair
Pathway, an efficient mechanism of DNA repair where the altered base is corrected
without removal or disruption of the phosphodiester backbone. Overexpression of
ATase in mammalian cells confers resistance to DNA alkylating agents (reviewed in
(Margison, Koref et al. 2002), and is a major factor in tumour resistance to alkylating
agents. Patients with brain tumours with low-ATase activity demonstrate a higher
response rate to DNA alkylating agents, carmustine (Belanich, Pastor et al. 1996) and
to temozolomide (Friedman, McLendon et al. 1998); however ATase levels have not
been found to be a predictor of response in melanoma patients (Middleton, Lunn et al.
1998) whereas patients with tumours staining positively for MMR proteins were more
likely to respond (Friedman, McLendon et al. 1998). The transfer of the methyl group
to ATase inactivates the enzyme and enzyme levels in peripheral blood lymphocytes
in patients treated with 5 days oftemozolomide show a progressive depletion (Lee,
Thatcher et al. 1994). It may be that the schedule dependency of temozolomide is
related to cumulative depletion. Attempts have been made to exploit this observation
by the development of inhibitors of ATase (PaTrin2) which improves the therapeutic
index of temozolomide in tumour xenografts (Middleton, Kelly et al. 2000) and is
currently in phase II trials.
27
In the absence of direct repair by ATase the mis-paired thymine is excised by the
mismatch repair system but leaving the 0 6-methylguanine in place and therefore
subsequent mispairing occurs during repair. It is thought that the repeated attempts to
repair this lesion generates double strand breaks and triggers apoptosis (Tentori,
Turriziani et al. 1999); figure 1.12 adapted from (Margison, Koref et al. 2002). The
hypersensitivity of ATase'" cells to DNA alkylating agents can be "rescued" by the
introduction of MMR deficiency (Karran and Bignami 1992), these double deficient
cells will tolerate high levels of 0 6-methylguanine without undergoing apoptosis.
MMR mutation in cell lines has been shown to confer resistance to temozolomide,
even in the presence of low ATase levels. In MMR proficient cells inhibition of
ATase with 0 6-benzyguanine increases sensitivity to temozolomide (Liu, Taverna et
al. 1999) but is ineffective in MMR-deficient cells.
Figure 1.12
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Figure 1.12 Repair of06-methylGuanine either by ATase or the consequences of MMR of the lesion,
S(1) and S(2) indicating the first and second rounds of replication following damage.
Tumour cell lines which are deficient in elements of the MMR pathway are resistant
to the cytotoxic effects of a number of DNA damaging agents (reviewed in (D'Atri,
Tentori et al. 1998). These authors studied MMR proficient and deficient cell lines
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and have shown that induction of p53 and signalling for apoptosis following
temozolomide treatment involves MMR.
1.8.3 Temozolomide and PARP-l inhibition
There is an increasing body of evidence that the inhibition of PARP-1 and consequent
deficiency in BER will increase the cytotoxicity of temozolomide. Inhibition of BER
will cause persistence of strand breaks caused by the more abundant N3_
methyladenine lesions in addition to the normally predominant cytotoxic lesion 0 6_
methylguanine. 3-methylpurine DNA glycosylase (MPG) catalyses the first step in
the repair ofN3-methyladenine, subsequent recruitment of the BER complex
including activated PARP-1 completing the repair.
Co-administration of potent PARP-1 inhibitors developed in Newcastle enhances the
cytotoxicity of temozolomide and the persistence of DNA single strand breaks in
L1210 cells (Boulton, Pemberton et al. 1995; Bowman, White et al. 1998), and in a
panel of other common tumour cell lines (Delaney, Wang et al. 2000) as discussed
above. These data have been confirmed in other studies.
Leukaemic cells resistant to temozolomide due to high ATase levels and MMR
deficiency were treated with the combination oftemozolomide and NU1025 (Tentori,
Turriziani et al. 1999). A three fold reduction in the growth inhibitory ICso
concentration for temozolomide was observed in the presence of the PARP-1 inhibitor
and increased rates of apoptosis in the treated group were detected by flow cytometry.
More pronounced effects were seen when the temozolomide and NU1025
administration was fractionated (Tentori, Portarena et al. 2001), the authors proposing
that this was due to the fact that more extensive DNA damage was introduced. These
experiments have been extended into in vivo situations and enhanced the survival of
mice bearing cranial lymphomas. The animals were treated with intra-peritoneal
temozolomide plus or minus intra-cerebral NU1025. The combination treatment
enhanced survival, particularly when the dose was fractionated, temozolomide alone
being ineffective (Tentori, Leonetti et al. 2002).
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Treatment of glioma cell lines with temozolomide ± 3-AB again demonstrated
increased cytotoxicity for the combination, with a reduction in the growth inhibitory
ICso for temozolomide (Tentori, Portarena et al. 2002). This enhancement was more
marked in glioma cells known to be deficient in MMR. Me-Lex (MeOS02(CH2h-
lexitropsin) is a methylating agent which selectively causes N3-methyladenine lesions.
These lesions are cytotoxic and repaired by BER. Increased sensitivity of activated
human PBLs to Me-Lex is caused by treatment with NU1025 (Tentori, Portarena et al.
2002).
Chemopotentiation of temozolomide has been demonstrated by the PARP-1 inhibitor
CEP-6800 both in tumour xenografts and cell lines. CEP-6800 is a 3-aminomethyl
carbazole imide which inhibits both PARP-1 and PARP-2 (Miknyoczki, Jones-Bolin
et al. 2003). Potentiation oftemozolomide, irinotecan and cisplatin has been observed
in their models. Increased DNA damage after temozolomide/PARP inhibitor
treatment was demonstrated using a COMET assay over 24 hours following
treatment, and PAR accumulation in combination treated xenografts was decreased
over control treated animals (temozolomide or irinotecan alone) at 4 hours after
dosing. Treatment ofU251MG glioblastoma xenografts with a combination ofCEP-
6800 (30 mg/kg) and temozolomide (34 mg/kg) caused complete regression of the
tumours by day 28. Similar potentiation of the activity of temozolomide has
subsequently been described in combination with AG14361 (Calabrese, Almassy et
al. 2004).
Studies on the combined effect of inhibiting ATase and PARP-1 have been performed
in leukaemic cell lines (Tentori, Orlando et al. 1997). Leukaemic cell clones deficient
in ATase were transfected to re-express the enzyme. These cells were originally
sensitive to temozolomide, re-introduction of ATase increased their resistance, and
this effect could be reversed with the ATase inhibitor 0 6-benzylguanine. Combined
treatment with temozolomide and a PARP inhibitor increased sensitivity to
temozolomide in both the ATase deficient and proficient cells. In cells which are
mismatch repair deficient, 0 6-methyl guanine lesions are tolerated; inhibition of PARP
and thus BER will cause N3-methyladenine to become the predominant cytotoxic
lesion.
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In a panel of human tumour cell lines temozolomide cytotoxicity was potentiated both
by 0
6
-benzylguanine and 3-AB treatment in MMR proficient cells, but only by 3-AB
in MMR deficient cell lines (Wedge, Porteus et al. 1996). Similarly colon cancer cell
lines which were mismatch repair deficient (RCTl16) or MMR wild type (SW480)
show differential sensitivity to temozolomide, treatment in combination with a PARP
inhibitor (PD128763) increased sensitivity to temozolomide in both the proficient and
deficient cell lines. Triplet treatment with temozolomide, PD128763 and 0 6_
benzylguanine was synergistic in the wild type cells, the addition of the ATase
inhibitor having no effect in the MMR deficient cells (Liu, Taverna et al. 1999).
These findings have been reproduced in paired cells lines, both MMR proficient and
deficient (Curtin, Wang et al. 2004). The effect of AG14361 on temozolomide-
induced growth inhibition was investigated in RCT-Ch3, A2780 and CP70-ch3
(MMR-proficient) and HCTl16, CP70 and CP70-ch2 (MMR-deficient) cell lines.
AG 14361 enhanced temozolomide activity in all the MMR-proficient cell lines, but
was more effective in MMR-deficient cells such that temozolomide resistance was
overcome. In the same paired cell lines inhibition of ATase by benzylguanine
enhanced the cytotoxicity oftemozolomide in the MMR-proficient cells only.
The potentiation of temozolomide by PARP inhibitors may be clinically important as
loss of mismatch repair occurs frequently in many common sporadic solid tumours
(small and non-small cell lung cancer, pancreatic, gastric, colorectal, ovarian,
endometrial, cervix and breast cancers) and in the majority of cases of hereditary non-
polyposis colon cancer (reviewed in (Tentori, Portarena et al. 2002).
1.8.4 Clinical use of temozolomide
A phase I trial of temozolomide, initially comparing both intravenous and oral
schedules, identified the maximum tolerated dose as 200 mg/mvday for 5 days of a 28
day cycle (Newlands, Blackledge et al. 1992). There was no significant difference in
plasma pharmacokinetics between oral and intravenous dosing and the oral route is
recommended. Maximum plasma levels were achieved 0.7 hours after dosing.
Toxicity included mild nausea compatible with oral dosing and dose dependent
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myelosuppression which was dose limiting. Responses were seen in melanoma and
malignant glioma encouraging further development. Patients with brain tumours are
usually excluded from phase I studies of novel anticancer agents because of concerns
relating to informed consent and the lack of penetration of drugs to the brain.
However, the preclinical observations that temozolomide crossed the blood brain
barrier in mice justified their inclusion in this trial.
Phase II studies have been conducted in malignant brain tumours (Bower, Newlands
et al. 1997; Yung, Prados et al. 1999; Brada, Hoang-Xuan et al. 2001; Harris,
Rosenthal et al. 2001) and metastatic melanoma ((Bleehen, Newlands et al. 1995), all
using a dose of200 mg/mvday for 5 days in a 28 day cycle. Reported response rates
of 8% with disease stabilisation in a further 43% ofpatients with glioblastoma
multiforme (GBM) at first relapse (Brada, Hoang-Xuan et al. 2001) and 35% in
patients with anaplastic astrocytoma are described. A randomised comparison of
dacarbazine and temozolomide in GBM found in favour of the latter with equivalent
response rates (5%), but improved median (7.3 v 5.8 months) and progression free
survival (21 v 8% at 6 months) for temozolomide. It is in this disease, with its poor
prognosis, that temozolomide is licensed and recommended for treatment in the
United Kingdom (NICE, 2001; (Dinnes, Cave et al. 2002).
Myelosuppression was the major adverse effect of temozolomide in all the studies in
brain tumours. 6-10% ofpatients developed CTC grade 3 or 4 thrombocytopaenia
and fewer than 5% developed significant neutropaenia or anaemia (Dinnes, Cave et al.
2002).
Phase II (Bleehen, Newlands et al. 1995) and phase III (Middleton, Grob et al. 2000)
studies of temozolomide have been performed in patients with metastatic melanoma.
The reported response rate in the phase II study was 24% with a median survival for
responders of 14.5 months (compared to 5.5 months overall). Severe
myelosuppression was observed in 9% subjects, otherwise toxicity rates were low.
The phase III randomised study of temozolomide v DTIC in metastatic malignant
melanoma did not show a significant difference is response rate between the two
treatment groups (13.5% v 12.1%). Once again the new agent was well tolerated with
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eTC grade 3 or thrombocytopaenia occurring in 11% of the temozolomide treated
group. The nadir occurred late in the 28 day cycles, at 20-21 days post treatment.
Temozolomide is licensed for use in malignant brain tumours in Europe. The
equivalence of the phase III trial in melanoma means that its uptake in this disease in
Europe has been small although world wide this is a major market for the drug.
There is, therefore, a potential clinical use for PARP inhibitor temozolomide
combinations. Potentiation of temozolomide cytotoxicity may improve its efficacy in
licensed indications or the change in emphasis of the cytotoxic lesion may alter the
range of sensitive human tumours.
1.9 Summary
The introduction to this thesis has attempted to cover the background to the
experimental work described herein. A brief summary of the proposed mechanisms
of DNA damage repair, in particular base excision repair, is given to explain the
rationale for the development of PARP-1 inhibitors as possible chemo- or radio-
potentiating agents. The development of the tricyclic lactam indoles is summarised.
A novel PARP-1 inhibitor in this class, AG014699, entered clinical trials in
combination with temozolomide in 2003.
The main points covered in the chapter are listed below
1. The action of many chemotherapeutic agents used in the treatment of
human tumours can be compromised by a variety of mechanisms,
including DNA repair.
2. Temozolomide is a DNA methylating agent in clinical use. The
predominant DNA lesions formed by temozolomide, 0 6-methylguanine,
N3-methyladenine and N7-methyladenine are repaired by ATase, MMR
(06) and BER (N3 and N7) respectively.
3. PARP-1 is an enzyme involved in BER and p53 mediated responses to
DNA damage.
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4. Potent inhibitors ofPARP-1 have been developed, leading to a clinical
candidate, AG014699, which is ;;:::1000x more potent than the early
inhibitors.
5. Tumour xenograft and cell line studies show that the antitumour activity
and cytotoxicity of temozolomide is enhanced by co-administration of a
PARP-1 inhibitor.
The next chapter will discuss the preclinical evaluation of AGO14699 and related
compounds in relation to the protocol design and development for the phase I study in
humans. Chapters 3-5 describe the laboratory experimental methods used and the
experiments undertaken to validate a suitable pharmacodynamic assay for use in the
clinical trial. Chapter 6 summarises a phase II study of temozolomide alone in
patients with malignant melanoma which provides clinical data to validate the
laboratory assays.
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Chapter 2
Protocol development of Phase I clinical protocol for first-in-human
use of a PARP-l inhibitor in combination with a cytotoxic agent
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2.1 Introduction
The role of PARP-1 in base excision repair and its potential in combination with
temozolomide has been discussed in chapter 1. As part of the Northern Institute for
Cancer Research Drug Development programme potent novel PARP-1 inhibitors have
been developed. One of these, AG014699, has been identified as the potential clinical
candidate and has moved forwards into a First-in-Human clinical trial. The phase I
clinical trial is based in the United Kingdom with Newcastle as the coordinating
centre. The other participating investigators and centres are Professor Harris and Dr
Middleton in Oxford and Professor Johnson and Dr Wilson in Belfast.
The initial proposal which was considered and accepted by the New Agents
Committee (NAC) of Cancer Research UK (formerly Cancer Research Campaign)
comprised two trials with AGO14447, one in combination with irinotecan, a
topoisomerase I inhibitor, and one with temozolomide. It is this latter trial that is
critical to the work described in this thesis, the trial with irinotecan is planned for a
later phase of the clinical development. The nomenclature of the compound for
clinical use was subsequently changed, AGO14699 is the phosphate salt of the parent
compound AGO14447 (8-Fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-
tetrahydro-azepino[5,4,3-cd]indol-6-1). During the clinical trial the drug is referred to
and prescribed as AG014699, however the compound measured in pharmacokinetic
studies in AGO14447.
The initial proposal to the New Agents Committee proposed the clinical development
of AG14361. At a late stage of the preclinical planning stage AG014447/AG014699
was discovered. This agent is more potent and more water soluble and was finalised
as the first clinical candidate. The late change in trial agent means that some of the
early pharmacodynamic assay development was done using AG14361 as the drug
reference. All final validation has been done using AGO14699. The chemical
structure of AGO14699 is shown in figure 1.10, this is a yellow solid, molecular
weight of 421.36. The compound is water soluble, and is stable for at least 30 days
either in the solid form or in solution in 50/0 dextrose (Pfizer, unpublished
observations). Crystallographic analysis of AG014447 bound to the inhibited target
enzyme revealed that the drug binds to the active site of PARP-1, forming 3 hydrogen
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bonds. The K; determined using 32p_NAD+ incorporation into polymer by purified
full-length human PARP, is 1.4 nM (unpublished AgouronlPfizer data). AG014699
inhibits oligonucleotide-stimulated PARP-l activity measured using a e2p] NAD+
incorporation assay in permeabilised SW620 cells (ICso= 24 nM). Analysis of the
time course of inhibition after exposure to 0.4 mM AG014699 showed >60%
inhibition of PARP-l up to 2 hours post-treatment confirming its tight binding and/or
cellular retention (Suzanne Kyle, personal communication).
A large part of this MD project has involved authorship of the first draft of the phase I
clinical trial protocol, and subsequent modifications and review in collaboration with
colleagues from the other centres involved, Cancer Research UK and Pfizer. The
toxicology summary of the protocol (section 1.2.4) was written by Professor Herbie
Newell and Sections 7.1.2.1 and 5.1, the pharmacokinetic processing of and
pharmaceutical information on AG014699 was written by Dr Poe Hsyu of Pfizer
GRD. The approved protocol is currently recruiting patients into part 1 of the trial.
In this chapter of the thesis the salient preclinical studies will be discussed and the
protocol design assessed in detail.
2.2 Preclinical efficacy study
During the preclinical assessment of AGO14699 a number of critical efficacy studies
were carried out in Newcastle. The design and results of these are summarised below
as these were instrumental in decisions made during the development of the phase I
trial protocol. The practical work for this efficacy study was performed by Chris
Calabrese, Suzanne Kyle, Huw Thomas and Mike Batey.
There were two arms to the studies: an efficacy arm and a PKlPD arm.
2.2.1 Efficacy
Groups of 5 CD-1 nude mice were inoculated subcutaneously with 1x107 SW620
colon cancer cells. The implanted tumours were allowed to develop; when they were
palpable (approx 4x4 mm, -day 10 after inoculation) treatment was started. The
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When the new clinical candidate AGO14699 was identified as the agent which would
be taken first into clinical trials the experiment described above was repeated using
this new inhibitor. Groups of 5 mice were again treated for 5 days with control
vehicle, temozolomide alone at a dose of68 mg/kg and 136 mg/kg oftemozolomide
in combination with 0.1 mg/kg, 1 mg/kg or 10 mg/kg AGO 14699. An additional
group of animals was treated with 10 mg/kg AGO 14699 alone to establish whether
this dose was toxic and/or efficacious as a single agent and as a control for
cannulation effects.
The results are shown in figure 2.2; temozolomide alone delayed tumour growth by
about 22 days (time to RTV4 in treatment group - time to RTV4 in control) whereas
AGO 14699 alone at the highest dose used had no effect on tumour growth compared
to control. Treatment with the combination of temozolomide 68 mg/kg with
AG014699 0.1 mg/kg caused a modest potentiation of the response to temozolomide.
A ten-fold increase in dose of inhibitor to 1 mg/kg caused xenograft cures, as had
been demonstrated previously with 15 mg/kg AG 14361. However, increasing the
dose of PARP-l inhibitor by another ten-fold in combination with temozolomide was
toxic and all animals had to be sacrificed. This dose of AGO 14699 alone was not
toxic.
Figure 2.2
Median RTV
_____ Control
----- 69910
_____ TM 68
_____ TM 136
_____ TM 68 + 699 0.1
_____ TM 68 + 699 1.0
_____ TM 68 + 699 10
12.5
10.0
~ 7.50::
c
ra
"C
Q)
5.0~
2.5
0.0
0 10 20 30
Day
40 50 60 70
Figure 2.2 Medi an RTV against time from treatment in grou ps of 5 nude mice bearing SW620 colon
canc er xenografts . Tr eatment of eac h group shown in figure legend.
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2.2.2 PK and PD
In the second phase of this pre-clinical efficacy study similar groups ofnude mice
were established but the animals sacrificed at intervals after treatment and blood and
tumour samples taken for pharmacokinetic and pharmacodynamic assessment.
Groups of 5 animals were implanted with 1 x 107 SW620 colorectal cancer cells.
Treatment was started when the tumours were larger than in the efficacy study to aid
sampling. No tumour was allowed to grow to greater than 10 mm diameter to avoid
problems with tumour necrosis causing inhomogeneity. Treatment with temozolomide
± AGO14699 was started approximately 15 days after implantation when the tumours
had reached 7 x 7 mm. The same combinations and doses of treatment were used,
although animals received a single dose only prior to sacrifice. Samples were taken at
0.5, 6 and 24 hours.
Animals were sacrificed by cervical dislocation and blood withdrawn immediately by
cardiac puncture for pharmacokinetic analysis. Whole blood was centrifuged to
obtain plasma and the concentration of AG014447 (the parent compound present in
the plasma) measured by HPLC. The tumour xenografts were removed and snap
frozen in liquid nitrogen prior to homogenisation and measurement of AGO 14447
concentration and PARP activity by e2p] NAD+ incorporation (assay described in
chapter 3).
Having confirmed the efficacy of AGO14699 in potentiating temozolomide this
PK/PD study had a critical influence on two aspects of the phase I trial design; the
definition of a PARP inhibitory dose (PID) and the recommended starting dose of
AG014699. The basis of these decisions will be discussed further below (section 2.4
and 2.5), the relevant PK/PD results are summarised below.
2.2.2.1 PKlPD at efficacious dose
Plasma and tumour levels of AG014447 were measured in 5 animals at each time
point after dosing. The times points chosen were 30 minutes, 6 hours and 24 hours
after intra-peritoneal injection of 1 mg/kg AG014699. The selection of the times was
based on previous preclinical evaluation of the pattern of PARP inhibition with
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similar inhibitors (Calabrese, Almassy et al. 2004) and also the clinical use of
temozolomide. The 30 minute time point was chosen to give a peak plasma level.
The 6 hour time point coincides with a time at which temozolomide would have
formed the maximum number of strand breaks (Danson and Middleton 2001), and
therefore demonstration of PARP inhibition at this time would provide support for the
proposal that PARP inhibition, and thus inhibition of BER, would be instrumental in
the potentiation of the cytotoxic drug. In clinical use temozolomide is given every 24
hours for 5 days and it would be envisaged that the PARP inhibitor would be given on
a similar schedule. The 24 hour time point gives an estimate of the AG014699
retention and PARP activity immediately prior to the planned re-dosing time.
The pharmacodynamic and pharmacokinetic results for animals dosed with 1 mg/kg
AG014699 is summarised in figure 2.3. This is the dose which maximally potentiated
temozolomide in SW620 xenografts. Plasma levels of AG014447 (yellow bars) were
between 110-120 ng/ml30 minutes after injection falling rapidly to <10 ng/ml at 6
hours and were undetectable at 24 hours. AG014447 levels in tumour (red bars) were
undetectable at 30 minutes, around 50 ng/g tissue at 6 hours with evidence of
retention in the tumour at 24 hours. This confirms the published data on AG14361
(Calabrese, Almassy et al. 2004).
PARP activity (blue bars), expressed as a percentage of the mean activity measured in
matched control tumours, was assessed by measuring the incorporation ofe2p] NAD+
into acid precipitated material. This assay is published (Boulton, Pemberton et al.
1995; Calabrese, Almassy et al. 2004) and discussed in detail in chapter 4.
Significant (>500/0) inhibition ofPARP activity was observed in tumours at 30
minutes, despite the drug levels being below the limit of detection at this time. At 6
hours the activity was 50% inhibited with a return towards baseline by 24 hours. The
relevance of all these results to the PARP phase I combination study will be discussed
below.
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Figure 2.3
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Figure 2.3 Plasma and tumour AG014447 levels (mean ± SD, n=5) left y axis 30 minutes, 6 and 24
hours after 1 mg/kg AG014699 i.p , tumour PARP acti vity as % control right y-axi s (mean ± SO, n=5).
2.2.2.2 PKlPD at toxic dose
An identical experiment was performed dosing animals with 10 mg/kg AG014699,
the dose of inhibitor which potentiated the toxicity of temozolomide to such an extent
that animals had to be sacrificed after 5 days dosing.
The results are shown graphically in figure 2.4. Plasma levels of AG014447 30
minutes after dosing were approximately 10-fold those seen in the previous
experiment (1500-2000 ng/ml cf 110-120 ng/ml) , and had fallen to ~ 50 ng/ml by 6
hours. Drug was still detectable in the plasma at 24 hours (1.5 ng/ml ). Tumour drug
levels were also higher ( ::::::200 ng/g tissue) and did not show a significant decline over
the 24 hours. PARP activity in the tumours was less that 10% of control values at
both 30 minutes and 6 hours after dosing; significant PARP inhibition (~80%) was
still found at 24 hours, the point at which re-dosing would occur during treatment.
The plasma levels of AG014447, the degre e ofPARP inhibition and leve l of toxicity
observed were all instrumental in the defining of the starting dose of AGO 14699 in
human trials and the defini tion of PK endpoints (see section 2.5).
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Figure 2.4
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Figure 2.4 Plasma and tumour AGOl4447 levels (mean ± SO, n=5) left y axis 30 minutes, 6 and 24
hours after I rng/kg AGOl4699 i.p , tumour PARP activity as % control right y-axis (mean ± SO, n=5).
2.3 Protocol development
2.3.1 Summary of protocol design
Any novel anti -cancer agent must be registered with one of the regulatory authorities
before it can enter into standard clinical treatment. Before registration is permitted a
programme of preclinical drug toxicity assessment and rigorous clinical trials must
take place. Preclinical repeated-dose toxicity studies of a defined duration, depending
on the proposed length of treatment of patients, are required in one rodent and one
non-rodent species by US and European regulations (Farrell, Leighton et al. 2003).
These studies should use similar schedules and duration to those planned in the Early
Clinical Trial. The results from the toxicity studies are used to predict possible
toxicity and to define starting dose.
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The trial outline proposed and approved in the NAC application was a phase I
combination study of AGO 14699 with temozolomide in patients with advanced solid
malignancies. Development of anti-cancer drugs, which may have serious and life
threatening toxicities, involves the treatment of patients rather than healthy
volunteers. This places a burden of careful study design on researchers to minimise
the chance of serious toxicity whilst avoiding treating large numbers of patients at a
sub-therapeutic dose.
Phase I clinical trials aim to determine the toxicity profile of new drugs or
combinations and establish acceptable doses for subsequent studies. It is hoped that
preliminary evidence of activity will also be seen, however the chances of this are
small given the disparate and resistant tumour types enrolled. The overall response
rate in phase I anticancer drug trials is reported as 4-6% (reviewed in Horng, Emanuel
et al. 2002). The specifics of trial design will vary between trials, depending on
whether the trial is a single agent phase I, a cytotoxic combination study or involves
one of the biological targeted therapies; however the general principles in study
design are similar. The starting dose is defined from the results of preclinical toxicity
studies. Cohorts of between 1-3 patients are treated at each dose level and toxicity
assessed, if no significant toxicity is observed the dose is increased by a previously
defined factor and a new cohort of patients recruited. When toxicity is observed the
cohort is expanded and subsequent dose escalation may be in smaller increments. In
combination studies the individual drugs may be escalated alternately or in sequence.
The maximum tolerated dose is thus defined. A variety of dose escalation schemes
exist including standard and modified Fibonacci, continued reassessment (O'Quigley,
Pepe et al. 1990), accelerated titration (Simon, Freidlin et al. 1997), and
pharmacologically guided dosing. All the schemes aim to minimise the numbers of
patients treated at low ineffective doses whilst safely defining dose limiting toxicity
(Rubinstein and Simon 2003).
The initial proposal for the first in human study of AGO14699 is summarised in the
protocol concept sheet below (figure 2.5) which was submitted as part of the early
negotiations over trial set-up before my involvement with the project. This is the
working template from which the protocol evolved and illustrates the starting point
from which the protocol was written. A number of changes have been made and these
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changes and the rationale for the starting dose and primary endpoint defmitions are
discussed below.
Figure 2.5
Protocol Concept Sheet
Phase 1/ Pharmacokinetic / Pharmacodynamic Study ofPARP Inhibitor (AGO14447)
in combination with temozolomide
Primary Objectives To determine a PARP-inhibitory dose of AGO 14447 using PK and PD
endpoints for PARP inhibition.
To determine the MTD oftemozolomide in combination with this PARP-
inhibitory dose
Secondary To evaluate the single-agent and combination pharmacokinetics of
Objectives AGO14447
To document any responses in melanoma patients included in the study.
Study Design Single-Agent AG014447 days 1-5. Combination AG014447 +
temozolomide day 15-19. PK studies at all dose levels.
Part 1: Open to all patients. Continues until PK studies indicate potentially
PARP-inhibitory levels.
Part 2: Melanoma patients only, obligatory post-treatment biopsy for
measurement of PARP inhibition.
Drugs Time 0 minutes: AG014447 by 30 minute iv infusion
Time 60 minutes: Temozolomide orally.
Dose Escalation AGO 14447. Starting dose determined from preclinical toxicology / PK /
PD studies. Final dose determined by clinical PKlPD studies. Escalation
in 50% dose increments.
Temozolomide: Starting dose 100, 126, 159,200 mg/m2 (50% of starting
and geometric increments).
3 patients per dose level.
~3 week follow up on all patients before escalation
Inclusion Criteria Part 1: Patients ~ 18 years of age with advanced cancer for which no
satisfactory treatment exists, PS 0-2, Standard anticancer Phase 1 Lab tests
Part 2: As Part 1, but also must have malignant melanoma with at least
two lesions and consent to post-treatment biopsy.
Exclusion Criteria Brain metastasis
Serious intercurrent disease
Statistical Design Consider use of 2-drug modified continual reassessment method
Pharmacodynamic PARP activity in leucocytes
correlates PARP activity in tumour biopsies (Part 2)
PARP protein level in biopsies (Part 2)
Pharmacokinetics Both agents
Toxicity History and physical examination before each dose
Evaluation Full blood count, biochemistry, liver function and toxicity assessments
weekly
Efficacy Responses in assessable patients using RECIST criteria.
Evaluation Apoptosis measurements in biopsies
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Following a prolonged period of drafting and discussion of the trial design the final
format of the agreed clinical trial is summarised as follows. Treatment under part 1 of
the protocol commenced in June 2003.
The First-in-Human trial is an open-label, non-randomised, dose escalation phase I
combination study in two parts, escalating first the dose of AGO14699 then that of
temozolomide. A Modified Fibonacci scheme is being used to increase the dose of
the inhibitor, with the subsequent dose escalation of temozolomide being based upon
the clinical use of temozolomide, the available tablet sizes and thus increasing
towards the established maximum tolerated dose of temozolomide alone in equal
increments. The dosing strategy including the proposal for test "single agent" dose is
discussed in the following sections.
2.3.2 Dosing plan for the two parts of the study
Part 1 - Fixed dose temozolomide, escalating dose of AG014699
Patients with advanced solid malignancies of any type for whom no standard therapy
exists and who are of a reasonable performance status, physically and on blood
indices, are being recruited to this part of the study. Patients receive one half the
standard dose of temozolomide throughout this part of the trial, i.e. 1Oumg/m''. The
PARP-1 inhibitor is given by intravenous infusion one hour before temozolomide
dosing. Treatment started at a low, safe dose of AGO 14699 with cohorts of 3 patients.
Dose escalation of AGO14699 has been initially been by dose doubling. If any grade 2
toxicity is seen according to Common Toxicity Criteria (CTC version 3.0),
subsequent dose increments will be smaller (30% or less), a modified Fibonacci dose
escalation. This part of the trial will be complete when a PARP-1 inhibitory dose
(PID) of AG014699 is reached, and not on the basis of observed toxicity unless this is
severe and unexpected. The basis of this decision is discussed further below.
Phannacokinetic and pharmacodynamic samples are being taken on the first cycle in
every patient.
Part 2 - Fixed dose AG014699, escalating dose of temozolomide
Patients with advanced metastatic malignant melanoma will be recruited to part 2 of
the trial. These patients will be asked to have a biopsy of a melanoma lesion before
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and after dosing with the combination so that the degree of DNA damage (strand
break number) can be assessed and also tumour AG014699 pharmacokinetics and
phamacodynamics can be measured. The starting doses of this part will be
Temozolomide 100 mg/m' and the PARP-1 inhibitory dose of AG014699. The dose
of AGO14699 will be fixed throughout this stage of the study and the dose of
temozolomide escalated until dose-limiting toxicity is seen, a lower dose level will
then be investigated to define the maximum tolerated dose of the combination. It is
envisaged that the doses oftemozolomide investigated would be 100 mg/rrr', 125
mg/rrr', 150 mg/rrr', 175 mg/m'' and up to 200 mg/rrr' depending on toxicity observed.
Pharmacokinetic and pharmacodynamic samples will once again be taken on the first
cycle in every patient. A maximum tolerated dose (MTD) will be established and this
cohort of patients expanded to at least 6 to further evaluate toxicity and allow some
indication of response.
2.3.3 Single agent dosing with AG014699 prior to cycle 1
In the initial protocol concept it was proposed that patients would receive 5 daily
doses of AG014699 on days 1-5 of cycle one, with treatment with the combination
starting on day 15 of this cycle and the total length of the first cycle being six weeks.
All subsequent cycles would be four weeks in length, without this single agent
treatment.
The reason for this schedule was to obtain single agent PARP-1 inhibitor PK data and
to look for potential toxicity of the novel agent. A PARP-1 inhibitor would not be
expected to be active against cancer cells on its own; the rationale for its action
depends on enhancing DNA damage caused by other agents. It would be ethically
difficult to carry out a dose-finding trial of the single agent alone in a population of
patients with limited life-expectancy in whom quality of life is paramount, given that
administration would be of no therapeutic benefit.
During the process of writing the phase I trial protocol the specific plan for 5 test
doses was discussed further and amended for a number of reasons. There was
concern over the delay before patients received combination therapy as the 5 day test
dosing then one week wash out period meant that there was a two week delay from
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entry into the trial and receipt of temozolomide and AGO14699. Preclinical
toxicology studies did not observe significant toxicity with AGO14699 alone at doses
predicted for clinical use apart from some local irritation at the injection sites in
smaller animal species, all toxicity appeared to be related to exacerbation of the side
effects of temozolomide in the combination studies. It was felt that a more
appropriate design would be for patients to receive one single agent AGO 14699 dose,
then PK and PD data in humans could be obtained and an assessment made for any
possible unexpected single agent toxicity.
The final study design involves patients receiving a single dose of AG014699 seven
days (range 11-6 days) prior to starting the combination therapy on cycle one only.
This dosing day is designated "day -7" ( or -6 etc) allowing cycle one of combination
treatment to start on day 1 and all cycles therefore being 28 days long with re-
treatment on day 29. In the event of any dose limiting toxicity being observed,
defined in the protocol in section 2.2.2.1, the cohort of patients would be expanded to
six. This expanded cohort of patients will receive 5 single doses of AGO14699 on
days -14 to -10 of their first cycle to enable assessment of whether the observed
toxicity is due to the novel agent or the combination with temozolomide. The
minimum of 6 days between single agent treatment and starting combination is
sufficient to allow processing of the PK samples and issuing of the results from the
CRO (Contract Research Organisation) before combination dosing. PD assessment of
the degree of PARP inhibition is also possible in this time frame. This allows
investigators the possibility of discussing any unexpected handling of the drug before
embarking on the combination, a fact which may be particularly important once
toxicity has been observed in other patients in the cohort.
2.3.4 Study objectives and endpoints
The primary and secondary objectives of the study as proposed in the protocol
concept sheet were expanded during the protocol development and the additional
endpoints are listed below. It proved necessary to define clinical study endpoints for
both part 1 and part 2 of the trial. The definition in the protocol is given below and
the rationale for completion ofpart 1 of the study based on PD endpoints discussed in
section 2.4
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Additional Primary Objectives:
• to determine and establish the toxicity profile of the above combination and to
identify the dose limiting toxicity (DLT)
• to select doses of AGO14699 and temozolomide for combination use in phase
II evaluation
Additional Secondary Objectives:
• to investigate pharmacokinetics of temozolomide when given in combination
with AGO14699 and possible interactions
Clinical study end points:
Part 1
A primary endpoint of the trial is to establish a PARP inhibitory dose (PID) of
AGO14699 in adult patients using pharmacokinetic and pharmacodynamic parameters
measured in patients' blood. Development and validation of the PD assay was
ongoing during protocol drafting. Whilst it was acknowledged that, ideally, PD data
would be used to define PID an alternative PK endpoint was also defined in the
protocol. In the absence of significant toxicity, the primary PK end point will be the
dose that results in a plasma concentration of AGO14699 that exceeds by a factor of
10 the level that maximally potentiated the antitumour activity of temozolomide at 6
hours in mice (ie, 10 x 10 ng/mL= 100 ng/mL). Ifpharmacodynamic data suggest a
plateau in inhibition at a concentration lower than this, escalation may be stopped. If
toxicity is observed, clinical effects will be used to guide dosing.
Part 2
The endpoint in part 2 will be dose limiting toxicity (DLT) of the combination of
temozolomide and AG014699, based on drug-related adverse events graded according
to the NCI Common Toxicity Criteria (CTC) Version 3.0, occurring during the first
cycle of treatment. DLT will have been reached when 2 patients at a given dose level
(with up to 6 treated at that level) have experienced drug-related DLT. The maximum
tolerated dose (MTD) will be defined as a dose below that eliciting DLT. (Standard
definitions for dose limiting toxicity in phase I trials).
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2.4 Preclinical toxicology and starting dose
Before entering patient trials investigational cancer drugs are subject to pre-clinical
toxicology studies. These are aimed at screening for unexpected adverse toxicity and
also projecting a human starting dose. Classically, two toxicology studies would be
performed, one in a rodent species and one in non-rodents (Farrell, Leighton et al.
2003). The rodent study identifies a dose in mg/m' which produces severe toxicity in
10% of animals (STD lO or LD lO) . The second study should confirm that this dose
does not cause severe toxicity in the non-rodent species. The starting dose for a phase
I study in humans would normally be one-tenth of this LD lO or one-third of the toxic
dose level (TDL) in the larger animal species (reviewed in Mahmood 2003). An
alternative approach when estimating starting doses in a combination study is to
define the MTD of the combination and use one-tenth of the MTD in the most
sensitive species as the starting dose in the human study. The aim in all situations is
to start at a safe dose of a novel agent or combination but to minimise the potential for
starting at an inappropriately low dose and hence avoid treating large numbers of
patients with ineffective doses.
Single agent toxicity studies of AG014699 were performed in rats and beagle dogs.
Doses of 5, 15 and 75 mg/kg/day for 5 days were given to groups of20 male and
female rats (32, 97 and 484 mg/rrr' respectively). At doses over 15 mg/kg/day bone
marrow hypocellularity was observed with a most marked decrease in erythroid
precursors. Minimal to moderate myocardial degeneration was observed in rats
treated at the highest dose of AG014699, similar lesions were observed in dogs at 50
mg/kg in acute and multi-dose range finding studies. The concern about potential
cadiac toxicity led to the definitive single agent study being repeated in beagle dogs
utilising dose of 15, 25 and 40 mg/kg/day for 5 days. The cardiac lesions were not
reproducible in this definitive study although ECG abnormalities were observed.
Animals developed a persistent sinus tachycardia or an atrioventricular nodal rhythm.
AGOl4699 was acutely emetogenic in dogs at doses over 15 mg/kg/day.
These single agent toxicity studies used doses of AG014699 significantly above the
starting dose predicted from the combination studies. It was felt that it was unlikely
that combination dosing in humans would reach the equivalent doses and that toxicity
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from AG014699 alone was not likely. However, in response to the suggestion of
potential cardiac toxicity a new exclusion criterion of "patients with active or unstable
cardiac disease or myocardial infarction within 6 months, and patients with left
ventricular ejection fraction below the institutional limit of normal, determined by
multiple gated acquisition (MUGA) scan or echocardiogram" was introduced. All
patients will have an Echocardiogram or MUGA scan prior to entry and this will be
repeated after 4 cycle of treatment. All patients will also have serial ECGs before and
after the test dose and during treatment on cycle 1 of the combination. The ECG will
be repeated and compared to baseline before the beginning of each subsequent
treatment cycle.
Pre-clinical pharmacokinetic studies in mice, rats, dogs and monkeys indicated that
AGO14699 had a moderate to rapid clearance and a large volume of distribution. The
half-life ranged from 2.1 to 5.2 hours in the species studied. Combination
pharmacokinetic studies with temozolomide did not demonstrate a significant
pharmacokinetic interaction. Studies of elimination of radiolabelled [14C] AGO 14699
in bile-duct cannulated rats documented 49%, 31% and 17% recovery from urine,
bile and faeces respectively, with a mean cumulative recovery of 98%. The short
half-life and rapid clearance of AG014699 support the decision to dose daily
immediately prior to temozolomide. Temozolomide is very rapidly absorbed,
reaching peak plasma concentration at 1.2 hours after dosing (Newlands, Stevens et
al. 1997; Danson and Middleton 2001). In a phase I combination trial of an
established drug (temozolomide) and a novel agent which will be used for the first
time in humans it was felt that temozolomide should be given after AG014699. The
main rationale for this was that if unexpected, unpredictable acute toxicity was
observed with the novel agent management of this would not be complicated by prior
administration of a cytotoxic drug.
The proposed starting dose of AGO 14699 in combination with temozolomide was
determined by analysis of the animal toxicity and pharmacokinetics in mice, rats, and
dogs. These pre-clinical toxicology studies were performed by CTBR (Quebec,
Canada) on behalf of Pfizer GRD. An initial range finding study in rats was
performed where groups of 10 male animals were dosed with temozolomide 15
mg/kg/day for 5 days in combination with a range of AG014699 doses from 0.02 to
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2.1 mg/kg/day. Assuming a weight of200 g (Body surface area, BSA 0.031 m2) these
doses were equivalent to 100 mg/rrr' temozolomide, the proposed starting dose in the
human trial, and up to 13.5 mg/m' AG014699. No clinical toxicity or lethality was
observed at the highest dose in this range finding experiment.
An AGO14699 + temozolomide combination toxicity study was undertaken,
evaluating low- mid- and high-dose AG014699 + Temo. The same dose of
temozolomide (15 mg/kg/day x 5 days) was used as above. Low-dose AG014699 was
set at the non-toxic 2.1 mg/kg/day dose of AG014699 used in the range finding study.
The mid- and high-dose combinations were based on the same dose of temozolomide
and a half-log escalation of the AG014699 dose. Two groups of 10 male and 10
female animals were treated for 5 days, one group being sacrificed on day 6 and one
on day 29. The doses investigated are summarised in table 2.1.
Table 2.1
Treatment Temozolomide AG014699
mg/kg/day mg/mvday mg/kg/day mg/m2/day
Vehicle control 15 97 0 0
Temo only 15 97 0 0
Low-dose + temo 15 97 2.1 13.5
Mid-dose + temo 15 97 6.6 42.5
High-dose + temo 15 97 21 135.5
The toxicity observed in these animal studies was essentially a potentiation of the
expected toxicity of temozolomide, with reduction in blood indices, reduced food
consumption and loss ofbody mass and gastrointestinal side effects. These were
more marked in the high-dose AG014699 group with lethality in 3/20 animals soon
after completion of treatment. The MTD from this study was felt to be the mid-dose
of AG014699, 42.5 mg/m'. The starting dose based on one-tenth of the MTD of
AG014699 given in combination with temozolomide in rats would be 4 mg/nr'.
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However, experiments performed in the drug development laboratory in Newcastle in
parallel to the preclinical toxicology carried out by Pfizer internal operatives, have
shown that the equivalent of 3 mg/rrr' in mice produced significant PARP-l inhibition
and potentiation of the anti tumour activity of temozolomide. Full toxicology studies
could not be performed in this species because of problems related to tail vein
injection sites. The small volumes of drug required for treatment of mice meant that
infusions of AG014699 were acidic and hypertonic and caused tail vein necrosis.
This problem was not observed in the larger animal species. After prolonged
discussion with Pfizer collaborators it was decided to opt for a lower starting dose.
This was partly for safety reasons since potentiation of activity could also mean
potentiation of toxicity and the concern was that starting at 4 mg/nr' might risk
significant toxicity at the first dose level. A ten-fold increase in the dose of
AG014699 from the curative dose (1 mg/kg, 3 mg/nr') to 10 mgJkg (equivalent to 30
mg/m/) in combination with temozolomide was so toxic that the animals had to be
killed. The same dose of the individual drugs was not toxic (figure 2.4).
In addition, it was felt that there was a danger that no gradation in PARP-l inhibition
between escalations of AGO14699 would be observed if the starting dose caused
significant PARP-l inhibition. This would then introduce the question as to whether
we should reduce the inhibitor, and also might mean that the PARP inhibitory dose
(PID) was defined at an excessive dose of AG014699. This could have future
implications for the use of the drug and drug costs if it were subsequently proven that
a similar level of inhibition could be achieved with a lower dose.
After discussion of all the pre-clinical toxicity data and comparison of doses with
those used in the mouse efficacy study the starting dose of AGO14699 was set at 1
mg/m", one fortieth of the MTD of the combination in rats, with infusion one hour
before the administration of temozolomide.
2.5 Definition of pharmacodynamic endpoints
The primary endpoint of part 1 of the first in human PARP inhibitor trial is to
determine a PARP inhibitory dose of AGO14699 using pharmacokinetic (PK) and
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pharmacodynamic end points for PARP inhibition. It would be hoped to define this
dose using a measure ofPARP inhibition in the patient's peripheral blood
lymphocytes (PBLs) rather than relying on pharmacokinetic data and extrapolation
from animal PD and efficacy studies. The major laboratory work undertaken during
this MD project has been development and evaluation of PARP activity assays which
can be used to measure the degree of PARP inhibition achieved in patients. This
work is described in chapters 4 and 5.
AG014699 has been designed to act as a potentiator of cytotoxic agents and therefore
the dosing strategy will be different in a phase I trial compared to that undertaken
with a new cytotoxic drug. Classically, in phase I trials the dose of the new agent is
escalated until toxicity is seen. For AG014699 to be effective the dose needs to cause
inhibition of the PARP-1 enzyme in human cells. Preclinical toxicology data has
shown that in the animal species tested there was no significant toxicity associated
with dosing with AG014699 alone unless doses far higher than those needed to inhibit
PARP-1 and potentiate temozolomide were given. The most likely potential cause of
toxicity in part 1 of the study is therefore an increase in the toxic effects of
temozolomide.
The decision to complete this phase of the study will be based on achieving a PARP-1
inhibitory dose of AG014699, i.e. a proof ofprincipal that the action of AG014699 is
indeed inhibition of PARP-1. A PARP-1 inhibitory dose has been defined in the
protocol as that dose at which PARP-1 activity in peripheral blood lymphocytes is
reduced to 50% ofbaseline and there is a plateau in the degree of inhibition achieved
between 2 PARP escalations. This definition is based on the SW620 xenograft
efficacy experiment described above (figure 2.3). At a dose of AG014699 which
significantly potentiated temozolomide, PARP-1 was inhibited by approximately 50%
in the tumours at 6 hours after dosing. It was felt that at least this degree of inhibition
should be achieved in humans before it could be said that AGO 14699 was being given
at adequate doses. The 6-hour time point also coincides with the point of maximum
strand breaks after temozolomide and therefore PARP-1 inhibition at this time is
important. 50% inhibition was felt to be a minimum requirement; if a greater degree
of inhibition can be achieved in the absence of toxicity this would be accepted. The
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aim of this part of the study would be to obtain the maximum non-toxic inhibition
which is sustained over the period when temozolomide is causing DNA strand breaks.
Should it prove difficult to define a suitable dose of AG014699 using the proposed
pharmacodynamic endpoint a pharmacokinetic primary endpoint has been defined in
the protocol so that escalation can be stopped and part 1 of the trial concluded. The
rationale for defining a "fall back" position is two fold. The protocol was written
during development of the PD assays and it was accepted that it might not be possible
to validate a suitable PD assay and an alternative strategy was needed. Even with a
suitable assay it was felt that if doses such as these were being reached without
demonstration of significant PARP-l inhibition it would suggest that AGO14699 was
not sufficiently potent and an alternative clinical candidate should be explored rather
than continued escalation.
Part I of the trial involves escalation of the starting dose of 1 mg/rn' using a modified
Fibonacci scheme. It was initially proposed to the NAC that a continual reassessment
method would be used. This method was described by O'Quigley (O'Quigley, Pepe et
al. 1990) and aims to base dose escalation by prediction of toxicity using data from all
patients previously treated and not to base escalation decisions on the preceding
cohort only. The aim is to more accurately predict and avoid severe toxicity and
reduce the number ofpatients treated at a low, potentially ineffective dose. Following
extensive discussion it was decided that for the first part of the study a more classical
phase I trial design, with escalation of AGO14699 in combination with a fixed dose of
temozolomide would be used. The aim of this part of the study was to demonstrate
that AG014699 could be safely administered to patients and that PARP-l was
inhibited by the drug. In preclinical studies AGO14699 potentiated the toxicities
associated with temozolomide administration. For this reason in the first part of the
trial it was decided to fix the dose of temozolomide at 100 mg/m' (half the normal
adult dose) until significant PARP inhibition is achieved. Toxicity will only be seen
if AGO14699 has an unexpected toxicity on its own in humans or if it successfully
potentiates half-dose temozolomide to cause significant myelosupression.
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2.6 Precursor study rationale and links with PARP inhibitor study
Critical to the successful conduct of the phase I PARP inhibitor/temozolomide
combination protocol discussed above was the development of a pharmacodynamic
assay that could measure PARP-l activity and hence the degree ofPARP inhibition in
both human tumour biopsies and also in human peripheral blood lymphocytes (PBLs)
as a surrogate for target tissue inhibition. The methodology, development and
validation of two such assays is described in chapters 3, 4 and 5. In addition, a
precursor study was proposed prior to the phase I study to provide supporting data for
the First-in-Human PARP inhibition combination study. This precursor study is
described in detail in chapter 6 and the results presented therein, the rationale for it is
summarised below.
The major justification for this precursor study was to provide control data for the
effect oftemozolomide alone on the endpoints to be measured in the First-in-Human
study so that it could be ascertained which effects were due to the addition of
AGO14699 rather than temozolomide alone. The proposed precursor study would
treat 12 patients with advanced malignant melanoma with full dose temozolomide
(200 mg/mvday for 5 days every 4 weeks) and on the first cycle blood and tumour
biopsy samples would be taken for analysis of PARP activity and DNA damage. The
proposal had a number ofpotential benefits for the first in human trial.
1. It provided additional validation for the proposed pharmacodynamic assay
2. There are no data in the literature on the effect of cytotoxic agents, in
particular temozolomide, on PARP activity. Although treatment would
not be expected to affect PARP activity, this is not proven.
3. It was proposed that the COMET assay will be used during the precursor
study to evaluate the number of strand breaks produced by standard doses
of temozolomide in PBL and tumour samples. This would allow direct
comparison with the number of breaks caused by temozolomide in
combination with the PARP inhibitor and provide control data to support
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the proof of principle that PARP-l inhibition potentiated the action of
temozolomide by causing DNA damage to persist following the inhibition
ofBER.
4. Analysis of changes in ATase levels and N7-methyl adenine and N3-methyl
guanine formation after temozolomide would again provide control data to
be used in analysis of any similar results from the combination study.
5. The conduct of a precursor study in the same three clinical centres prior to
embarking on a First-in-Human study with complex sampling and
processing schedules has the advantage of allowing any operational
"hiccups" be identified prior to the main study.
2.7 Conclusion
This chapter describes the key preclinical experiments and toxicology which were
critical to the design of the first in-human phase I study of AG014699 and
temozolomide. This protocol was submitted to the northern MREC (multi-centre
research ethics committee) in January 2003 and approved with minor alterations to the
patient information sheets and consent forms only. Enrollment into the study
commenced in June 2003 in Newcastle, Oxford and Belfast, with the validated
pharmacodynamic assay being performed in Newcastle within NICR.
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Chapter 3
Laboratory Methods
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The materials used and standard laboratory techniques are described below. For the
pharmacodynamic assays developed during this MD thesis the final assay protocol
only is described in this methods section. Any variation/evolution of the assay
technique is given in the appropriate section.
3.1 Materials
3.1.1 General laboratory chemicals
All chemicals were obtained from Sigma (Poole, Dorset, UK) unless stated otherwise.
Dulbecco's phosphate buffer saline was prepared from tablets produced by Gibco
(Paisley, UK). Sucrose, sodium hydroxide and potassium chloride were supplied by
BDH (Lutterworth, UK) and digitonin by Boehringer Mannheim (Roche Diagnostics,
Lewes, UK). In addition a BCA protein assay kit (Pierce, Perbio Science, Rockford,
IL, USA) containing BCA albumin standard, BCA protein assay reagent A and BCA
protein assay reagent B was used for protein concentration determination. Milk
powder was obtained from Marvel Premier Brands UK Ltd (Spalding, UK), and ECL
Western Blot Detection kits from Amersham (Little Chalfont, UK). AG014699 and
AG14361 were supplied by Pfizer GRD (La Jolla, USA).
3.1.2 Tissue culture reagents
Cells were maintained in RPMI 1640 medium (Sigma) supplemented with 10% foetal
calf serum (Invitrogen, Glasgow,UK) and 1 Ulml Penicillin-streptomycin solution
(Sigma), in a Hereus incubator (Fischer Scientific, Manchester, UK) maintained at
37°C in a humidified atmosphere of 5% CO2 in air. Cell handling was performed
under sterile conditions in a Class II tissue culture cabinet. Sterile tissue culture
plasticware was obtained through Fischer Scientific (Manchester, UK). L1210 cells
used were routinely cultured in NICR, originally obtained from ATCC (American
Type Culture Collection, Manassas, VA).
3.1.3 Clinical supplies
Nycorned" Lymphoprep was obtained from Axis-Shield (Oslo, Norway) and EDTA
and Lithium heparin pre-prepared blood collection tubes from BD Vacutainer
(Plymouth, UK).
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3.1.4 Radiochemicals
e2p] NAD+ was supplied by Amersham (370 MBq/ml, 10 mCijml) and Wallac
Optiphase HiSafe2 by Perkin Elmer (Loughborough, UK)
3.1.5 Antibodies
The 10H mouse monoclonalprimary antibody was generously supplied by Professor
Alexander Burkle, the Goat anti-mouse secondary antibody (HRP-conjugated) was
obtained from DAKO (Ely, UK).
3.1.6 Other reagents
Oligonucleotide was initially synthesised by Dr J Lunec, (NICR), subsequent supplies
were obtained from Invitrogen. Purified PAR polymer was obtained from BIOMOL
Research Lab (Plymouth Meeting, PA, USA).
3.2 Tissue culture and preparation of Quality Control samples
3.2.1 Methods
All experiments to establish and validate a suitable quality control (QC) standard for
the pharmacodynamic assays were performed using the murine leukaemia cell line
L1210. This cell line grows reliably in tissue culture under standard conditions with a
cell doubling time of 10-12 hours and has been used extensively in the investigation
of the cellular effect of PARP inhibitors. Cells were grown as a suspension to a
density of approximately 6x105/ml at harvesting to ensure they were in the exponential
growth phase. Allowing the cell density in the suspension to increase causes some cells
to enter GO. During experiments to establish and validate the assays cells were grown in
a total volume of 50-100 ml, when bulk preparation of QC samples for frozen storage
was required cells were grown in a final volume ofup to 500 ml.
Whenever fresh L1210 standards were required on the day of assay cell density was
counted using a haemocytometer and sufficient medium harvested to obtain the required
number of cells. The cell suspension was spun at room temperature at 1500 rpm for 10
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minutes to obtain a cell pellet. The pellet was resuspended in 20 ml phosphate buffered
saline (PBS), and re-centrifuged as above at 4°C to obtain a washed cell pellet. This was
stored on ice prior to use for up to one hour.
3.2.2 Preparation of QC samples for the e2p]NAD+ incorporation PARP activity
assay
QC standards for freezing were prepared as follows. The cell suspension was cultured in
large flasks so multiple aliquots of contemporaneous cells could be obtained. After
counting the suspension at harvesting appropriate volumes to obtain approximately 12 x
106 cells were separately centrifuged as above. The pellets obtained were resuspended in
1 ml of RPMI culture medium supplemented with 10% foetal calf serum and 100/0
DMSO and transferred to a screw capped cryotube (Nunc, Roskilde, Denmark) for
storage and frozen at -80°C. Samples were labelled with the approximate cell number,
date of storage and laboratory book reference so that the length of storage of any given
QC samples could always be ascertained. When required for assay an aliquot was
defrosted as rapidly as possible, transferred to a 30 ml Universal container and 20 ml ice
cold PBS added. After mixing the sample was centrifuged at 1500 rpm for 5 minutes at
4°C, this wash being repeated before the pellet was held on ice for up to one hour prior to
performing the assay.
3.2.3 Preparation of QC samples for immunoblot assay
QC samples for the immunoblot assay were harvested from exponentially growing
L1210 cells (cell density ~ 6x105Iml as discussed above). The cell suspension was
aliquoted such that lxl06 cells were obtained in each individual sample, the medium
spun off as above and the sample resuspended in 1 ml of medium plus 10% DMSO and
10% foetal calf serum. These samples were placed in cryovials and frozen at -80°C.
Similar documentation of the samples with date, number of cell and lab book reference
ensured tracking of the sample use. When required for assay an aliquot was defrosted as
rapidly as possible, transferred to a 30 ml Universal container and 20 ml ice cold PBS
added. After mixing the sample was centrifuged at 1500 rpm for 5 minutes at 4°C, this
wash being repeated before the pellet was held on ice for up to one hour prior to
performing the assay.
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3.3 Lymphopreparation of human PBMCs
All procedures were carried out wearing a suitable laboratory coat and protective
gloves. All needles were disposed of into an appropriate clinical waste container, any
solutions requiring disposal were diluted with excess bleach solution prior to washing
away with excess water.
A 5 ml whole blood sample was collected into a pre-prepared Lithium Heparin or
EDTA blood tube and mixed gently to ensure anticoagulation. The sampled blood
was held on ice and processed as soon as practical, usually within minutes of
collection. The blood was diluted 1:1 with PBS and than layered over 8-10 ml of
lymphoprep in a 30 ml disposable Universal tube. The lymphopreparation was
carried out at room temperature in order to maximise the peripheral blood
mononuclear cell harvest through the Ficoll gradient.
Care was taken to avoid any mixing of the blood and lymphoprep prior to
centrifugation. The samples were centrifuged at 800xG for 15 minutes in a swing-out
rotor refrigerated centrifuge at 16°C. The centrifuge brake was taken off to avoid
disturbance of the PBMC layer during the deceleration process.
The leukocyte band, visible at the interface between plasma and the lymphoprep, was
harvested with a glass Pasteur pipette and put into a fresh 30 ml Universal tube. 20 ml
ice-cold PBS was added to the lymphocyte suspension and the cells pelleted by
centrifugation at 4°C. A second identical wash was performed to obtain a PBMC
pellet free of Lymphoprep.
When the cells were required for an immediate assay the cell pellet was held on ice
for up to one hour prior to assay. PBMCs prepared for storage were resuspended in
500 J.lI of pre-chilled RPMI plus 10% foetal calf serum + 10% DMSO. This aliquot
was transferred to a labelled screw capped Eppendorf tube and frozen. Samples were
stored at -80°C for up to 15 weeks.
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3.4 Preparation of tissue/tumour homogenates
3.4.1 Collection and storage of tumour samples
Patients with metastatic malignant melanoma who had biopsiable disease were
eligible for the TemoCOMET clinical trial described later in this thesis. The trial was
approved by The Local Ethics Research Committeee (LREC) and informed consent
obtained from all patients before any trial specific procedures were performed. Small
biopsies were obtained under local anaesthesia from metastatic lesions in these
consenting patients, before and at one time point after receiving a dose of
temozolomide.
The biopsies were collected from the operating theatre in a sterile container and
placed immediately on ice. Within 30 minutes they were snap frozen in liquid
nitrogen and stored at -80°C until homogenised for analysis
During the development of both the e2p]NAD+incorporation and immunoblot PARP
assay mouse liver was used as a surrogate tissue to establish the assay technique and
to validate some elements of the process. Livers were obtained from control/untreated
mice sacrificed as part of other on-going research in the Drug Development
Laboratory, maintained on ice until snap freezing in liquid nitrogen and storing as
described above.
3.4.2 Homogenisation of Tissue
All samples were prepared in an isotonic buffer made as described in section 3.5.1
below. For the e2p]NAD+ incorporation assay only 25 III of 100 mM dithiothreitol
(DTT) was added to each 1 ml isotonic buffer (final concentration = 2.5 mM)
immediately prior to use.
Frozen tumour or liver was defrosted on ice and the wet weight documented. For
weights over 100 mg the tissue was homogenised using a Pro 2000 (pro Scientific Inc,
Monroe, CT, USA) in 3 volumes (l mg > 1 III solution) of isotonic buffer, giving a
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homogenate with an overall dilution of 1 in 4). Where smaller samples had been
obtained they were homogenised in 99 or 999 volumes, giving final dilutions of 1 in
100 and 1 in 1000 respectively.
The homogenate was kept on ice throughout the process, homogenisation was
performed in 10 second bursts to prevent undue warming of the sample. Unless for
assay on the day of homogenis ation samples the homogenates were re-frozen to -80°C
and stored at this temperature until use. Prior to assay the samples were further
diluted with isotonic buffer where necessary to a final dilution of 1 in 40 (e2p] NAD+
incorporation assay) or 1 in 1000 (immunoblot assay).
3.5 e2p]NAD+ incorporation PARP activity assay in Peripheral blood
lymphocytes (PBLs)
3.5.1 Stock solution preparation and storage
Stock solutions were prepared and stored for up to 3 months for the following
reagents:
Isotonic buffer (7 mM Hepes, 26 mM KCI, 0.1 mM dextran, 0.4 mM EGTA, 0.5 mM
MgCh, 45 mM sucrose dissolved in 200 ml distilled water, pH adjusted to 7.8) was
stored at 4°C and supplemented with 25 ul/ml 100 mM DTT stock immediately prior
to use (final concentration = 2.5 mM).
DTT 100 mM stock (154 mg in 10 ml distilled water) was stored at -20°C in 500 III
aliquots and defrosted when required.
Digitonin stock solution (0.15 mg/ml in water) for cell permeabilisation was stored at
4°C for up to 3 months.
Oligonucleotide was prepared from pellets of a pallindromic sequence
(CGGAATTCCG) synthesised by Dr J Lunec, Molecular Biology, NICR were stored
at -20°C. Stock oligonucleotide solution was prepared by dissolving the pellet in 500
JlI of 10 mM Tris/EDTA (pH to 7.8) and pipperting vigorously to ensure fully
dissolved. The solution was heated to 60°C in a water bath and cooled at 1°C per
minute to ensure correct reannealing. 9.5 ml Tris/EDTA buffer was added once cool to
obtain 10 ml stock. A dilution of 1/50 of the DNA solution was made and the optical
density read at 260 nm. 1 OD unit is equivalent to a concentration of 50 ug DNA/ml,
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hence the concentration of the stock solution was calculated. The stock solution was
diluted with further Tris/EDTA buffer to a final concentration of 200 ug/ml. 500 JlI
aliquots were stored at -20°C in screw top microtubes and thawed prior to the assay
procedure.
10% TCAINaPPi solution and 1% TCAINaPPi solution were prepared and could be
stored at room temperature until used as "stop" and washing solutions respectively at
the latter stages of the assay. These solutions were stable for 3 months under these
storage conditions.
NAD+ stock 600 JlM was prepared fresh on the day of assay. Aliquots of 4.5 mg
NAD+ were stored at -20°C under anhydrous conditions and an aliquot was dissolved
in 1 ml of distilled water on the day of use. 10 JlI of the NAD+ solution was made up
to 1 ml and the optical density measured at 260 nm. The molar extinction coefficient
of NAD+ is 18, thus the molarity of the stock solution was calculated using the
equation {(aD reading x 100)/18}. An appropriate dilution was made to obtain 4 ml of
600 JlM stock. 3-5 JlI ofe2p] NAD+ were added to this immediately prior to reaction.
3.5.2 Assay procedure
The principle of this assay involves the measurement of incorporation into acid
precipitable matter of 32p ADP-ribose from a e2p] NAD+ substrate by PARP-l, which
has been maximally stimulated by a blunt ended oligonucleotide. Although there is a
family of PARP enzymes which also could incorporate 32p ADP-ribose into polymers
PARP-2 is the only other PARP known to be activated by DNA breaks. PARP-2 is
not stimulated by blunt ended DNA double strand ends (G. de Murcia, personal
communication) and so this assay is specific for PARP-l. The majority of the e2p]
NAD+ incorporated into protein during the reaction will be as poly(ADPribose) and
thus gives an indirect measure of enzyme activity when maximally stimulated in the
presence of oligonucleotide, or basal activity in its absence.
e2p] NAD+ incorporation PARP activity assays were performed using either human
peripheral blood lymphocytes or mouse L1210 cells. Any frozen cell preparation was
defrosted rapidly at room temperature and washed twice in ice cold PBS, as described
above, so that the freezing medium containing DMSO was removed.
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The prepared cell pellets were resuspended in 0.15 mg/ml digitonin stock to a density
of 3x10
7
cells per ml for 5 minutes to permeabilise the cells. 9 volumes of ice-cold
isotonic buffer were added and the sample stored on ice until assayed. No samples were
held on ice for longer than one hour before assay incubation.
A 10 JlI sample of each cell suspension was diluted 1:1 with Trypan Blue and the
number ofpermeabilised cells per ml counted on a haemocytometer for each suspension.
This accurate counting allowed correction of results obtained to counts per million cells
and allowed comparison between samples. Use of Trypan blue also allows the extent of
cell permeabilisation by digitonin to be assessed, this should be >90% with the above
method.
The assay was performed in a water bath warmed to 26°C and set to agitate at 70
oscillations per minute. The reaction tubes were set up as in the table below (table 3.1)
and allowed to come up to temperature before addition of the cell samples. In addition,
the cell suspensions were warmed in the water bath for 7 minutes prior to reaction to
ensure the process occurred at 26°C.
Table 3.1
Reagent TO + oligo - oligo Final
concentration
Oligonucleotide (200 5 JlI 5 JlI 2.5 ug/rnl
ug/ml)
e2p] 600 JlM NAD+ 50 JlI 50 JlI 50 JlI 75 JlM
stock
Water 45 JlI 45 JlI 50 JlI
Running total 100 III 100 III 100 III
Cell suspension 300 JlI 300 JlI 300 JlI :::::106 cells/tube
(:::::3x107/ml)
Reaction Total 400 III 400 III 400 III
Each cell suspension was assayed in triplicate for the TO, + and - oligonucleotide
samples. 2 ml ice cold 10% TCA + 100/0 NaPPi was added to the TO tubes prior to
addition of permeabilised cells to correct for non-specific binding of radio-label to the
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filter. Oligonucleotide is omitted in one set of samples to measure basal PARP activity in
comparison to total stimulatable activity. The permeabilised cell suspension was
vortexed briefly and the reaction started by adding 300 ~l (approx. lx IO'cells) of this to
each reaction tube. After exactly 6 minutes the enzymatic reaction was stopped by
adding 2 ml of ice cold 10% TCA + 10% NaPPi and vortexing. The tubes were then kept
on ice for at least one hour prior to filtration to allow precipitation of cellular
macromolecules including poly(ADP-ribosylated) proteins ..
Following precipitation on ice samples were filtered through a Millipore-12 funnel
manifold (Bedford, Mass, USA) attached to a vacuum. The glass microfibre filters
(Whatman Int Ltd, Maidstone, UK) were soaked in 10% TCA + 10% NaPPi and
placed rough side up on the filtration apparatus and the contents of individual assay tubes
vortexed, then added to an individual funnel on the filtration apparatus. Each tube was
washed 2x with 4 ml l % TCA + 1% NaPPi, and washings added to the funnel after
vortexing. The filters were aspirated with gentle suction, and 4 further 4 ml washes of
1% TCA + 1% NaPPi drawn through each filter. Following air drying of the filter
papers they were added to individual scintillation vials, 10 ml scintillant was added to
each vial and the vials prepared in racks for counting. Triplicate standard vials were set
up of scintillant plus 5 ~l of 32p 600 ~M NAD+. This adds 3000 pmoles ofNAD+ to the
standard vial and allows calculation ofDPM per pmol NAD+. Vials were counted on a
Wallac ~-counter (perkin Elmer Life Sciences, Loughborough, UK) for 2 minutes and
results displayed as "disintegrations per minute" (DPM).
DPM for each sample + or - oligo were corrected by background (TO) subtraction. The
values DPM per pmol NAD+ calculated from the standard vials allowed conversion to
pmol NAD+ per assay tube. The number of permeabilised cells added to each reaction
tube was calculated from the number of Trypan Blue-staining cells per ml of cell
suspension. From these reference values it was possible the express the mean
experimental values in terms of pMol NAD+ per million cells incorporated into
polymer following maximal PARP-1 activation.
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3.6 e2p ] NAD+ incorporation PARP activity assay in Tumour/Tissue
Homogenate
3.6.1 Stock Solutions and Storage
The stock solutions used to perform a e2p] NAD+ incorporation PARP activity assay
in homogenised tissue are the same as those described above in section 3.5.1
3.6.2 Assay procedure
The stored tissue or tumour homogenate (section 3.4.2) was defrosted on ice and a
further dilution made with isotonic buffer to obtain an overall 1 in 40 dilution. The
assay was performed in a water bath warmed to 26°C and set to agitate at 70 oscillations
per minute. The reaction tubes were set up as in the table below (table 3.2) and allowed
to come up to temperature before addition of the homogenate. In addition, the
homogenates were warmed in the water bath for 7 minutes prior to reaction to ensure the
process occurred at 26°C.
Table 3.2
Reagent TO Reaction Final
concentration
jLp 600 IlM NAD+ 50 III 50 III 751lM
stock
Water 50 III 50 III
Running total 100,.11 100 JlI
Homogenate (1 in 40) 300 III 300 III
Reaction Total 400 JlI 400 JlI
It is not necessary to add oligonucleotide to these reactions as homogenisation introduces
sufficient DNA strand breaks to maximally stimulate PARP (S. Kyle, personal
communication). Each homogenate was assayed in triplicate for the TO and reaction
samples. 2 ml ice cold 10% TCA + 100/0 NaPPi was added to the TO tubes prior to
addition of homogenate to correct for non-specific binding of radio-label to the filter.
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The homogenate was vortexed briefly and the reaction started by adding 300 JlI to each
reaction tube. After exactly 6 minutes the enzymatic reaction was stopped by adding 2
ml of ice cold 10% TCA + 10% NaPPi and vortexing. The tube was then kept on ice for
at least one hour prior to filtration to allow protein precipitation.
Following at least l-hour cooling on ice samples were filtered through a Millipore
filtration manifold and the radioactivity determined and converted to pmol NAD+ by
reference to 32p NAD+ standards as described in section 3.5.2.
During the cooling phase the remaining homogenate was centrifuged at 800 xG for 5
minutes at 4°C. The supernatant was withdrawn and a Pierce protein assay
performed. The supernatant could be stored frozen at -20°C and the protein assay
performed at a later date without compromising accuracy. The protein assay was
performed as per the Pierce protocol. Bovine serum albumin standards were set up
over the range 1.2 mg/ml - 0.2 mg/ml from a 2 mg/ml stock. 1 in 5 and I in 10
dilutions of the reacted homogenate were made. 10 JlI of these unknown sample
dilutions were loaded in quadruplicate onto a 96-well micro-titre plate, incubated in
200 JlI of the freshly mixed BCA protein reaction mix (1 volume reagent B with 20
volumes reagent A) at 37°C for 30 minutes. The protein concentration in the
homogenate was read using a Titertek Multiscan MCC/340 plate reader (Thermo Life
Sciences, Basingstoke, UK). The protein concentration in the homogenate was
calculated from the mean concentrations for both the I in 5 and I in 10 dilutions. All
further dilutions and standards were made up in isotonic buffer without DTT added.
Addition of DTT interferes with the protein assay.
The amount of protein added to the reaction tubes was calculated from the protein
concentrations measured above. From these reference values it was possible the
express the mean experimental values in terms ofpmol NAD+ per mg protein
incorporated into polymer by maximal PARP-I (and PARP-2) activation.
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3.7 Immunoblot assay for measuring PAR formation as a measure of PARP-l
activity in peripheral blood lymphocytes and cell suspensions
The principle of this assay depends on the specific binding of a mouse monoclonal
antibody to the ADP-ribose polymer, a secondary anti-mouse antibody coupled to horse
radish peroxidase (HRP) amplifies the signal which is detected when luminol in the ECL
reagent is broken down by the HRP to give off light. The light emission, which is
proportional to the amount of antigen (PAR), is measured by chemiluminescence
detection.
3.7.1 Stock Solutions
Stock solutions were prepared and stored for up to 3 months for the following
reagents:
10 mM TrislEDTA was prepared by adding 0.121 g Tris and 0.292 g EDTA to 90 ml
distilled water. This was buffered to pH 7.8 with 1M NaOH and the volume made up
to 100 m!. The solution was transferred to a labelled bottle and stored at room
ternperature.
Isotonic buffer was prepared as in section 3.5.1. The solution was labelled as per the
Standard Operating Procedure and stored at 4°C for 3 months at most. DTT was not
added to the isotonic buffer prior to use.
Reaction buffer was also made in advance by adding 1.12 g Tris.HCI (100 mM) and
2.4 g MgCh (120 mM) to 90 ml of distilled water. This was again buffered to pH 7.8
with 1 M NaOH and made up to a 100 ml fmal volume with distilled water. This
solution was stored at 4°C and was considered stable for up to 3 months.
7 mM NAD+ stock solution was made up fresh on the day of experiment. Solid
NAD+ was stored desiccated in pre-weighed aliquots at -20°C. 500 JlI of distilled
water was added to an aliquot of approximately 2.5 mg NAD+. The concentration was
calculated from the optical density as described in section 3.5.1 and the stock diluted
with distilled water to obtain a 7 mM solution.
Stop solution for the assay was prepared from AGO 14699 stock solution stored in -
20°C freezer as 10 mM stock in DMSO. This stock was diluted 1 in 800 in PBS to
provide a final concentration of 12.5 JlM AGO 14699 by adding 25 JlI stock to 20 ml
PBS on the day of reaction. This solution was kept on ice until used.
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Oligonucleotide pellets of a pallindromic sequence (CGGAATTCCG) were obtained
directly from Invitrogen and stored in -20°C freezer. A Stock solution of 200 ug/ml
was prepared from the oligonucleotide pellets as described in section 3.5.1.
Digitonin (0.15 mg/ml) was prepared as in section 3.5.1.
PBS-MT was made by adding 5 g milk powder and 50 III Tween 20 to 100 ml PBS.
This solution can be stored overnight at 4°C. PBS-T was similarly prepared by adding
50 III Tween 20 to 100 ml PBS
10% TCAl2% NaPPi solution was prepared from 100 g TCA and 20 g NaPPi
dissolved in 900 ml distilled water. After stirring to dissolve all crystals the final volume
was made up to 1000 ml with distilled water. This solution is stable for 3 months at
room temperature.
3.7.2 Preparation of PAR standards
Purified PAR was supplied by BIOMOL Research Laboratories as a branched and
linear polymer, average chain length 25 ADP-ribose monomers (range 3-300). It is
supplied as 100 III of a 10 ug/ml solution. 1 ug is equivalent to 2000 pmol ADP-
ribose monomer. The polymer must be stored frozen at -80°C, and repeated freeze-
thaw cycles avoided.
On receipt of the PAR polymer it was placed at 4°C until aliquoting on the day of
receipt, if the stock needed to be left overnight before aliquoting it was placed in a -
80°C freezer. The supplied stock was stored as 4 III aliquots in Eppendorftubes.
These were kept frozen at -80°C and defrosted at room temperature on the day of
reaction. The aliquoted sample was diluted 1 in 80 with sterile water (adding 316 III
water) to give a new stock solution with 25 pmol of ADP-ribose monomer per 100 III
of solution. This solution was serially diluted according to the table (table 3.3) below
in Eppendorf tubes, providing enough standard for two blots. 100 III of each dilution
was added to 300 III PBS and the total volume (400 Ill) loaded into an individual well
completing one row of the manifold to provide a standard curve, range 0-25 pmol
monomer.
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Table 3.3
Final concentration Volume of preceding Volume of sterile water
dilution
25 pmol Undiluted stock
5 pmol 50 III 200 III
1 pmol 50 III 200 III
0.2 pmol 50 III 200 III
0.04 pmol 50 III 200 III
opmol oIII 250 III
3.7.3 Assay Procedure
PARP activity was assessed and the immunoblot assay validated using both human
peripheral blood lymphocytes and mouse L1210 cells. The method below describes
the assay as finally validated. Any variation to the procedure which was used during
individual experiments whist the assay was being developed will be described in the
relevant results sections in this thesis.
Any frozen cell preparation was defrosted rapidly at room temperature and washed
twice in ice cold PBS, as described above, so that the freezing medium containing
DMSO was removed. The prepared cell pellets for assay were resuspended in 0.15
mglml digitonin stock to a density of approximately 1-2 x l 06 cells per ml for 5 minutes
to permeabilise the cells. 9 volumes of ice-cold isotonic buffer were added and the
sample stored on ice until assayed. A 6 JlI aliquot of the cell suspension was withdawn
after vortexing, mixed with an equal volume ofTrypan Blue and the cell density counted
using a haemocytometer. The cell suspension was diluted if necessary with isotonic
buffer to achieve appropriate cell density for reaction (2.44xl0 5/ml, (range 2-
1Oxl05/ml)).
No samples were held on ice for longer than one hour before assay incubation. The
assay was performed in a water bath warmed to 26°C and set to agitate at 70 oscillations
per minute. The reaction tubes were set up as described in the table below (table 3.4),
note the volume of reaction buffer to be added to make a final reaction volume of 100 III
was calculated knowing the cell suspension volume containing the required cell number.
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However reaction buffer was added before the cell suspension. Once prepared the tubes
were allowed to come up to temperature before addition of the cell samples. In addition,
the cell suspensions were warmed in the water bath for 7 minutes prior to reaction to
ensure the process occurred at 26°C.
L1210 QC samples were analysed with each batch of clinical samples to provide quality
control. These were prepared as described in section 3.2.3, and prior to each assay one
aliquot defrosted and permeabilised for assay as above. Triplicate samples were reacted
and analysed. These cells have greater stimulatable PARP activity so between 5,000-
10,000 were loaded to ensure a reading within the limits of the standard curve.
Table 3.4
Reagent + oligo Final concentration
Oligonucleotide 5 III lOllg/ml
7mMNAD+ 5 III 350 11M
Running total 10 J.11
Cell suspension 40-60 III
Reaction buffer To make volume to 100 III
Reaction Total 100 J.11
Stop Solution 400 III 10 !1M
Final volume 500 J.11
Each sample was assayed in triplicate. The permeabilised cell suspension was
vortexed briefly and the reaction started by adding the appropriate volume as
calculated above to give10,000-20,000 PBMCs or 5,000-10,000 L1210 cells to each
reaction tube. The permeabilised cell suspension was replaced on ice. The reaction
was stopped exactly 6 minutes after addition of cells by adding 400 III of ice cold 12.5
11M AG014699 (final concentration 10 11M) and vortexing. The vortexed tube was
placed on ice and completed reaction loaded onto the blotting membrane within 1
hour. Each cell suspension being analysed for PARP-l activity was recounted using a
haemocytometer and the cell density in the reaction mixture calculated. Control (TO)
cell samples (for cell specific background), were prepared in triplicate for each patient or
L1210 QC sample. A volume ofunreacted cells (from the remaining diluted cell
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suspension) identical to that used in the reaction mixture was added to 400 ul PBS. This
preparation was loaded onto the blot alongside the reaction specimen to give an estimate
of the endogenous PAR levels within the cells.
A specific 6x4 array 24-well manifold has been designed which attaches to the base
plate of a standard 96-well dot-blot manifold (BRL, Life Technologies Inc,
Gaithersburg, MD). This allows loading of a larger volume of reaction solution, with
approximately 1 cm diameter wells.
Hybond N membrane (Amersham, Little Chalfont, UK) and filter paper (Whatmann,
Maidstone, UK) were soaked in PBS and the dot blot manifold set up with the
membrane lying on two layers of filter paper. The PAR standards were loaded across
the top row of the 6 wells. Each reaction mixture was vortexed and loaded into wells
alongside the appropriate TO samples. The manifold was aspirated with gentle
suction, and washed with 400 J.lI 100/0 TCA 2% sodium pyrophosphate, re-aspirated,
then a further wash with 800 J.lI 70% ethanol performed.
The membrane was trimmed, marked in the top right hand comer and rinsed twice in
PBS before blocking for 1 hour with PBS-MT. Overnight incubation with the primary
antibody (diluted 1 in 500 in PBS-MT) at 4°C was followed by 2 washes in PBS-T and
then incubation in secondary antibody (1 in 1000 in PBS-MT) for 1 hour at room
temperature. The incubated membrane was washed frequently with PBS over the
course of one hour then exposed for one minute with ECL reaction solution.
The exposed membrane was placed on the tray within the Fuji LAS3000 UV
Illuminator (Raytek, Sheffield, UK) and the chemiluminesence during a 5 minute
exposure measured using the imaging software (Fuji LAS Image version 1.1, Raytek).
The acquired image was analysed using Aida Image Analyser, version 3.28.001, and
results expressed in LAU/mm2. Three background areas on the exposed blot were
measured and the mean of the background signal from the membrane subtracted from
all results. The PAR polymer standard curve was analysed using a one site binding
non-linear regression model and unknowns read off the standard curve so generated.
Results were then expressed in terms of number of cells loaded and standardised to a
given number of cells (usually 20,000).
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3.8 Immunoblot assay for measuring PAR formation as a measure of PARP
activity in homogenised tumour/tissue
3.8.1 Stock solutions
The stock solutions used to perform an immunoblot PARP activity assay in
homogenised tissue are the same as those described above in section 3.7.1
3.8.2 Assay Procedure
Where quality control (QC) standards were required L1210 mouse cells were used.
These cells were grown, stored and prepared for assay as described above (section 3.2)
and the assay reaction and blot loading performed as described in section 3.7.2.
PAR standards were prepared and used in an identical way to that described in section
3.7.2. The assay procedure described below is that validated for use in the PARPi
clinical trial. Once again any deviations from the assay procedure for an individual
experiment will be described in the relevant section of the results.
Homogenised tumour or normal tissue was either used fresh (within 1 hour of
homogenisation, being held on ice during this period) or defrosted on ice if stored at -
80°C as described in section 3.4.2. A further dilution was made with isotonic buffer
to obtain an overall 1 in 1000 dilution. The assay was performed in a water bath
warmed to 26°C and set to agitate at 70 oscillations per minute. The reaction tubes were
set up as in the table below (table 3.5) and allowed to come up to temperature before
addition of the homogenate. In addition, the homogenates were warmed in the water
bath for 7 minutes prior to reaction to ensure the process occurred at 26°C.
Table 3.5
Reagent Reaction tube Final concentration
7mMNAD+ 5 JlI 350 JlM
Reaction buffer 45 JlI
I
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Running total 50,...1
Homogenate 50 JlI I in 2,000
Reaction Total 100,...1
12.5 JlM 699 400 JlI 10 JlM
Final volume 500,...1
Each sample was assayed in triplicate. The homogenate was vortexed briefly and 50
JlI added to each reaction tube to start the reaction. The remaining homogenate was
replaced on ice. The reaction was stopped exactly 6 minutes after addition of
homogenate by adding 400 JlI of ice cold 12.5 JlM AGO 14699 (final concentration 10
JlM) and vortexing. The reaction tube was placed on ice and entire contents loaded
onto the blotting membrane within 1 hour of reaction. Control (TO) cell samples (for
cell specific background), were prepared in triplicate for each patient or QC sample. An
identical volume (50 ul) of homogenate (from the remaining 1 in 1000 dilution of
homogenate) was added to 400 JlI PBS. This was loaded onto the blot alongside the
reaction specimen. The same manifold, membrane and procedure used to assess PARP
activity in lymphocytes was used for this experiment. PAR standards and QC samples
were made up and loaded as described in sections 3.7.2 and 3.7.3
After loading of all samples the remaining 1 in 1000 tissue/tumour homogenate was
centrifuged at 800 xG for 5 minutes at 4°C to remove any particulate matter that might
interfere with the Pierce protein assay. The supernatant was withdrawn and a Pierce
protein assay performed as per the Pierce protocol. If the protein assay was deferred
the supernatant was stored frozen at -20°C. At least 200 JlI of supernatant was stored
so that a repeat assay could be performed if necessary. Bovine serum albumin
standards were set up over the range 0.250 mg/ml- 0 mg/ml from a 2 mg/ml stock. A
lower standard curve was required and the assay run according to the "enhanced"
protocol because of the high dilution of the homogenate necessary to ensure that the
assay fell within the immunoblot polymer validated standard curve. 25 JlI of these
unknown supernatants were loaded in quadruplicate onto a 96-well micro-titre plate,
incubated in 200 JlI of the freshly mixed BCA protein reaction mix (1 volume reagent
B with 20 volumes reagent A) at 37°C for 30 minutes. The protein concentration in
the homogenate was read using a Titertek Multiscan MCC/340 plate reader.
76
The chemiluminescence measured was analysed as described in section 3.7.3, the
results were expressed in terms of pmol PAR formed per mg protein loaded.
3.9 Statistical analyses
All clinical results are analysed using descriptive statistics. All other statistical
analyses have been performed using the standard statistical analyses with the Graph
pad Prism Version 3.03.
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Chapter 4
Validation of e2p ] NAD+ incorporation assay for PARP
activity in clinical samples
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4.1 Introduction
Pivotal to the design of the First-in-Human trial of a PARP inhibitor was
establishment and validation of a robust laboratory assay which measured the relative
activity of human PARP-1 before and after treatment with the inhibitor so that a
comparison of the degree of inhibition achieved could be made. The decision to
move from part 1 (AG014699 escalation) to part 2 (temozolomide escalation) is
dependent on achieving a PID (in the absence of toxicity).
An assay for PARP-1 activity in permeabilised cells has been developed in the Drug
Development Laboratory, Cancer Research Unit, University of Newcastle and
published in peer reviewed literature (Boulton, Pemberton et al. 1995). The principle
of the assay relies on the fact that PARP-1 is constitutively expressed in cells and is
stimulated by addition ofblunt ended oligonucleotide (Grube, Kupper et al. 1991).
The assay measures incorporation of [32p] ADP ribose into acid-precipitatable ADP-
ribosylated cellular proteins in a given number of cells provided with a e2p] NAD+
substrate by radiochemical scintillography. The degree of PARP-1 inhibition can be
determined on post-treatment samples by reference to pre-treatment controls.
This e2p]NAD+ incorporation radiolabel PARP-1 activity assay has been described
using established tumour cell lines as a permeabilised cell suspension and also
homogenised human tumour xenografts (Calabrese, Almassy et al. 2004), but its use
with human peripheral blood lymphocytes had not been investigated or validated. In
the context of a clinical trial in human subjects it is possible to take multiple blood
samples but practically more difficult to obtain repeated tumour tissue samples. It is
therefore essential for the design of part 1 of the trial to document the degree and
duration of PARP-l inhibition achieved at the different doses of AGO 14699 in blood
cells.
In addition to the adaptation of the assay for use with a new cell preparation, it was
necessary to establish a reliable standard cell sample that could be run with every
clinical trial assay to provide quality control and establish individual test run
acceptance criteria for the assay. Assays used in clinical trials must comply with ICH
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GCP guidelines, and should also be validated to as close to ICH GLP guidelines as is
practical in an academic laboratory.
In the last two decades there has been the emergence of quantitative macromolecule-
detecting technologies which allow pharmacodynamic endpoints to be used far more
widely in clinical trials. Use of the data generated by these assays for drug
registration with the regulatory authorities has brought to the forefront the difficulty
of minimising the variability ofbiological assays and of validating them for
regulatory purposes. International Workshops were held in 1990 and 2000, sponsored
by the American Association of Pharmaceutical Scientists (AAPS), to address these
issues and summary reports issued for guidance (Shah, Midha et al. 1992; Miller,
Bowsher et al. 2001). In addition, the U.S Food and Drug Administration (FDA) has
issued a guidance document (2001) and Handbooks of ICH Good Clinical Practice
and ICH Good Laboratory Practice provide further advice (1996).
Validation of a pharmacodynamic (PD) bioassay is accepted to be a difficult issue
(Shah, Midha et al. 1992; 2001; Miller, Bowsher et al. 2001), given the intrinsic
variability ofbiological samples. Additionally the difficulty of obtaining multiple
samples from a patient/human population means that much of the assay development
and validation needs to be performed using surrogate biological preparations. Shah
and colleagues suggest that when attempting to establish and validate a PD assay that
the pharmacodynamic effect should be related to the actual therapeutic endpoint of the
activity of the drug. The workshop report (1990) suggests 3 phases ofbioanytical
method validation which are shown in table 4.1. Not all the steps in pre-study
evaluation will be applicable to a given assay but the model provides a useful guide
for examining an assay for use in a clinical trial.
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Table 4.1
Phase of bioanalytical method validation
1 - Bioanalytical Method Establishment
2 - Pre-study Validation a) Specificity
b) Calibration Model
c) Precision, accuracy, recovery
d) Quality Control samples
e) Stability
f) Acceptance Criteria
3 - In-study Validation
This chapter describes the pre-study validation of an existing bioanalytical method,
including establishing a human blood cell preparation technique which provided cells
suitable for use in the radiolabel PARP activity assay. The ability to measure PARP
inhibition with a potent PARP inhibitor (AG14361) was evaluated in these cells. In
addition, quality control (QC) standards were established to be run with each
individual assay so that acceptance criteria could be defined as well as enabling inter-
assay comparison. The sample handling and storage conditions were investigated to
establish whether frozen storage of samples produced any deterioration in the activity
of the PARP-l enzyme or any loss of inhibition. Similar experiments were performed
to validate use of the assay to measure PARP activity in frozen homogenised tumour
samples.
4.2 Measurement of PARP activity in human peripheral blood lymphocytes
4.2.1 Lymphopreparation and permeabilisation
4.2.1.1 Lymphopreparation
Separation of the different blood cell populations from whole blood was performed by
centrifugation through a liquid gradient. Prepared gradients are available
commercially and different cell populations can be separated. Nycomed Lymphoprep
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was used for all experiments to separate mononuclear cells from erythrocytes,
platelets and polymorphonuclear cells. The e2p] NAD+ incorporation PARP activity
assay was performed using peripheral blood lymphocytes only (PBLs) and the method
used described in chapter 3 section 3.3.
Lymphoprep'P' (Ficoll-Isopaque) is a commercially produced sterile solution
containing 9.1% (w/v) sodium diatrizoate and 5.7% (w/v) polysaccharide. It has a
density of 1.077 ± 0.001 g/ml and an osmolality of280 ± 15 mOsm. The solution
allows one step centrifugation to separate mononuclear blood cells from erythrocytes
and granulocytes (neutrophils) and was first described by Boyum (Boyum 1968). The
solution aggregates the erythocytes, increasing their sedimentation rate and with
appropriate centrifugation conditions a layer of mononuclear white blood cells (PBLs)
collects at the interface between the diluted plasma, and the ficoll-isopaque.
When designing an assay that would be used on serial blood samples taken from a
patient consideration needs to be given to the total volume of blood that can safely be
withdrawn without adversely affecting the patient's well being. It was decided
therefore that any assay developed could not depend on impractically large numbers
of cells being available to produce reliable results. Clinical trial sample analysis
would be performed on the cells harvested from 5 ml of whole blood.
The normal range for total white blood count in human blood is 4-11 x 109 per litre.
Approximately 70% of these cells will be neutrophils, and 200/0 PBLs.
Lymphopreparation of 5 ml blood typically gives a total harvest of 5.6 ± 3.5 x 106
cells (mean ± SD of 26 samples prepared over 2 days from healthy volunteers), an
estimated extraction of75% of the available cells.
The possibility of increasing the cell harvest by including polymorphomononuclear
cells was investigated. There were some concerns over this since it is reported in the
literature that some highly differentiated tissues do not express PARP-l, namely
gastrointestinal epithelial cells, neutrophils and epidermal cells (Chatterjee and Berger
1998), and stable cell populations do show lower enzyme levels than rapidly dividing
cells (Prof A Burkle, personal communication). A consistent finding over repeated
assessment of PBLs in parallel with L1210 control cells was that the mature blood
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cells have lower inducible PARP-1 activity than an immortalised cell line. It was
decided to investigate whether inclusion of polymorphs would alter the measured
PARP-1 activity in nucleated blood cells.
Separation ofboth PBLs and granulocytes can be achieved using Polymorphprepr»
Axis-Shield (Oslo, Norway), a solution of 13.8% (w/v) sodium diatrizoate and 8.0%
(w/v) Dextran 500. It has a density of 1.113 ± 0.001 g/ml and an osmolality of 445 ±
15 mOsm. This solution is more hypertonic than "Lymphoprep", causing shrinkage
and faster sedimentation of erythrocytes. Two lymphocyte bands are formed and
polymorphonuclear cells can be harvested along with PBLs. The number of cells
harvested from 5 ml whole blood by this method was greatly improved, an average of
26 x 106 cells were obtained allowing loading of the required one million cells.
However, as would be predicted from the published data this led to even lower levels
of PARP-1 activity /106 cells being measured in the permeabilised white cells, since
the additional cells had low or negligible PARP-1 activity. The measured value was
10.3 ± 0.9 pmol NAD+ incorporated per million cells, 8% of the matched L1210
control value compared to approximately 30 pmol NAD+ (24%) incorporated per
million cells for pure PBL samples (see table 4.2). The absolute counts were low
meaning that there was greater potential for noise in the system as there was a less
clear differentiation between background (TO) samples and the reaction scintillation
counts. This is presumably due to the dilution of the signal from polymer in cells
expressing PARP-l because of the high proportion of cells without enzyme activity.
It was concluded that PBLs only would be used to develop the assay. This decision
meant that the number of PBLs harvested from the 5 ml sample of blood could be a
limiting factor in assay development.
4.2.1.2 Permeabilisation
To ensure the most accurate measure of maximum stimulatable PARP-l activity in
clinical samples it was felt important that cell handling times were kept to a minimum
so that the potential for loss of activity was reduced or, indeed, any inhibition of the
enzyme was not lost. Cells can be permeabilised by 30-minute ice-cold hypotonic
shock (Boulton et al 1995) or by a 5-minute exposure to 0.15 mg/rnl digitonin
(Calabrese et al, 2004) prior to transfer to isotonic buffer. Digitonin permeabilisation
would reduce cell handling time and therefore potentially be the preferred method.
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To ensure both assays gave comparable data L12l0 cells and PBLs were assayed by
both methods.
L120l cells were cultured and harvested as described in section 3.2, permeabilised
either with hypotonic buffer (9nM Hepes pH 7.8, 4.5% Dextran, 4.5 mM MgCl2, and
5 mM DTT) for 30 minutes or with digitonin (0.15 mg/ml water) for 5 minutes, or
with both hypotonic and digitonin solutions for 30 minutes. After the
permeabilisation time 9 volumes of isotonic buffer was added. The cells
permeabilised with digitonin alone were held on ice until those prepared by hypotonic
shock were available and all cell preparations assayed simultaneously. The results are
shown in figure 4.1, PARP activity is expressed in terms of the radioactivity (DPM)
per million cells. The data shown is the mean and standard deviation of triplicate
samples, and this preliminary experiment suggested that there was no difference
between the two permeabilisation techniques. (These experiments were performed
with the able assistance of Suzanne Kyle)
Figure 4.1
PARP activity in L1210 cells permeabilised by cold hypotonic shock or digitonin
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Figure 4.1 DPM for triplicate samples ofL1210 cells permeabilised either with hypotonic buffer
(HYPO), digitonin (DIG!) or both (HYPO + DIGI) with (+oligo) and without (- oligo) stimulation with
oligonucleotide. Mean +SD, n=3
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Further investigation of the affects of the two penneabilisation techniques was
performed using both L1210 cells and human PBLs. Following penneabilisation 6 III
aliquots of the cell suspension were stained with 6 III Trypan Blue and not only the
cell density in the preparation but also the percentage of cells which were
penneabilised was assessed using light microscopy and a haemocytometer. Both
penneabilisation techniques consistently produced >95% penneabilisation of the
cells.
Summary data from repeated assays on different days is shown in table 4.2,
demonstrating that there is no significant difference between the maximally
stimulated PARP-1 activity following penneabilisation by hypotonic shock or
digitonin in either L1210 cells (p= 0.91) or human PBLs (p=0.90). The degree of
PARP-1 activity is expressed in terms of pmol NAD+ incorporated into polymer per
million permeabi1ised cells in the reaction time.
Table 4.2
PARP activity (pmol NAD/106 cells/6 min)
Hypotonic shock Digitonin
L1210 121±73(4) 124 ± 48 (16)
PBls 34±10(2) 31 ± 13 (8)
Data are mean ± SD WIththe number of assays given m parenthesis, (p values calculated usmg
Students T test, unpaired, 2-tailed).
In order to determine if the penneabilisation technique affected the measurement of
PARP inhibition fresh PBLs were obtained from whole blood in a healthy volunteer
by lymphopreparation, the washed cells being resuspended in isotonic buffer and
separated into 2 portions. One sample of cells was exposed to 0.4 JlM AG14361 prior
to penneabilisation. AG 14361 is a potent PARP-1 inhibitor and PARP-1 activity is
suppressed to <10% normal with this concentration (Calabrese, Almassy et al. 2004).
The inhibited and control PBL suspensions were then again divided into 2 aliquots,
the cells pelleted by centrifugation and separate aliquots penneabilised either by
hypotonic shock or with digitonin. The results are shown in figure 4.2. Mean and
85
standard error of triplicate samples is given, results again expressed as pmol NAD+
incorporated per million cells. There was no evidence that use of digitonin rather than
hypotonic shock affected the result, and the presence of the PARP-l inhibitor meant
that PARP activity was undetectable in either preparation. Further data from repeated
experiments on different days comparing the two permeabilisation techniques is
summarised in table 4.2 as discussed above.
Figure 4.2
PARP activity in PBLs permeabilised by
cold hypotonic shock or digitonin
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Figure 4.2 PARP activity in PBLS measured with 2 different penneabilisation techniques. Mean +
SEM, n=3.
On the basis of these combined results it was decided that changing permeabilisation
technique to the shorter exposure to digitonin would not affect the result of the assay.
Digitonin permeabilisation had the advantage of shortening the cell handling time
before determination of PARP activity hence reducing the potential deterioration of
the enzyme with time in isolated cell preparations. It also decreased the risk of
cumulative DNA damage due to cell handling.
All subsequent experiments and the validation of the assay have used the digitonin
permeabilisation technique.
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4.2.2 Demonstration of PARP inhibition in human PBLs
The clinical trial primary endpoint in part 1 of the temozolomide/PARPi trial is the
demonstration of PARP inhibition in PBLs from patients treated with AGO 14699. It
was necessary to demonstrate that PARP-1 could be inhibited in these cells and that
this inhibition could be measured prior to embarking on full validation of the
proposed assay.
To this end whole blood from healthy volunteers was incubated with varying
concentrations of AGO14699 at 37°C for 20 minutes. In parallel, PBLs from healthy
volunteer blood were prepared first and then exposed to the drug as a cell suspension
in tissue culture medium. AGO14699 was dissolved and diluted in DMSO to 100x the
final concentration so that the final concentration of DMSO in any incubation did not
exceed 1%. Following an incubation period of 20 minutes the drug was removed by
washing and the cells prepared, permeabilised and assayed for PARP activity. The
results are shown in figure 4.3, data are from triplicate samples giving mean and
SEM. Inhibition of the PARP-1 activity was observed when whole blood was
incubated in a known concentration of AG014699 prior to lymphopreparation (the
most similar situation to that to be experienced in patients) and also when the inhibitor
was added to a suspension of washed isolated PBLs. In both cases the inhibitor was
washed off before permeabilisation, indicating that the inhibitor can permeate the
PBL cell membrane.
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Figure 4.3
Inhibition of PARP activity in PBls with 699
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Figure 4.3 Inhibition ofPARP-l in PBLs. Mean +SEM, n=3. prelympho = incubation with inhibitor
prior to lymphopreparation, post-lympho = incubation with inhibitor after preparation of PBLs. 50 and
100 nM refer to the concentration of AG014699.
4.3 Establishment of quality control samples
The aim of this project was to establish a validated pharmacodynamic assay for use in
an early clinical trial. As discussed in the introduction to this chapter identification of
the standard biological matrix which can act as a quality control for each assay
containing unknown samples is a critical step in any such validation (Shah, Midha et
al. 1992; Miller, Bowsher et al. 2001). In practical terms it was also important that
validation of the assay could be carried out using a surrogate but validated cell type
rather than repeatedly drawing blood from the healthy volunteer population.
It was decided to assess the mouse leukaemia cell line (L1210) for QC function.
PARP-1 activity in fresh exponentially growing L1210 cells, permeabilised with
digitonin, was measured as described above. Summary data from serial experiments
carried out on separate days is given in table 4.3. PARP activity is expressed as pmol
NAD+ incorporated per million cells. The number of repeated assays on separate days
using freshly prepared ezp] NAD+ stock in shown in column 2. The range of values
obtained is shown in column 4. The result for each individual assay is the mean of
triplicate or quadruplicate samples.
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Table 4.3
n pmol NAD+/106 CV (%) Range
cells (mean ± SD)
Fresh 20 124 ± 51 41.4 50-200
Ll2l0
Fresh 10 32 ± 12 37.3 16-55
PBLs
% Control
PBL as % 5 25 ± 8 32.6 18-37
Ll2l0
control
Comparison of the maximal PARP-1 activity obtained from repeated PBL samples is
also shown in table 4.3. The PBL result is also expressed as a percentage of the
matched L1210 control assayed on the same day. This confirms the reports that
maximal PARP-1 activity is lower in this "mature" cell population when compared to
immortalised cells, the results being in the range of 20-30°,/0 the mean L1210 value.
When a linear regression analysis was performed on 6 pairs of matched PBL and
L1210 samples, assayed in parallel? = 0.89 suggesting that a significant relationship
exists between the values and it is justified to use L1210 cells as a QC comparator for
the PBL result.
4.4 Validation of sample storage and handling techniques
The preliminary experiments reported above demonstrated that PARP activity and
inhibition of PARP-1 could be measured in human PBLs. However during the course
of the clinical trial patient samples will be obtained over a period of 12 days on cycle
I of treatment for pharmacodynamic assessment. It is planned that sample will be
taken on day -7 when the PARP-1 inhibitor is given alone and on days I and 4 when
given with temozolomide. Samples will be taken prior to treatment, at the end of the
infusion (TO), 4-6 hours post infusion, and at 24 hours. Immediate assay of each of
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these samples would not be practical and would also mean that any inter-assay
variation could affect comparison of results within one patient.
In addition, performing the study at three Cancer Research UK centres means that
storage and shipping of sample to Newcastle for PARP-1 assays is necessary.
Therefore, lymphocytes prepared at the other centres will need to be frozen and
shipped to the laboratory. It was essential to establish that the PARP enzyme activity
is stable with freezing over time. In addition it was necessary to establish that the
level of PARP inhibition in the fresh samples did not deteriorate with freezing and
storing at -80°C for prolonged periods so that there could be confidence that the
PARP-1 activity measured in patient samples after storage was a true reflection of the
inhibition of PARP-1 activity in PBLs at the time of sampling.
Initial experiments to investigate the effects of storage were performed with L1210
cells. These cells gave reproducible PARP activity results and it was planned to use
them as QC samples. Use as QC samples would be simplified if frozen aliquots of
these cells could be used in serial assays; therefore it was necessary to confirm
enzyme stability after freezing in these cells. In addition, the initial experiments to
investigate the preservation of PARP-1 inhibition with freezing were performed using
L1210 cells because of the difficulty of obtaining large numbers of PBLs.
4.4.1 PARP-l activity in fresh versus frozen L12l0 cells
L1210 cells were grown in 200 ml of medium as described in the methods (section
3.2). The cells were harvested in the exponential growth phase, washed and counted.
One sample of cells was analysed fresh on the day of harvesting and multiple aliquots
were frozen in medium + 10% DMSO. The original cell culture was maintained in a
healthy growth phase in the incubator for the duration of the experiment. At regular
intervals one of the frozen samples was rapidly thawed, washed in buffer and assayed
according to the standard operating procedure. At the same time a sample of freshly
harvested cells from the growing stock was also analysed so that results could be
expressed in terms of a fresh enzyme control assayed in the same sample run.
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The results are presented in figure 4.4 and table 4.4. Figure 4.4 shows the mean
PARP-l activity measured in triplicate defrosted samples expressed a percentage of
the mean activity from triplicate samples of the matched fresh sample. It
demonstrates that the enzyme activity is stable with storage in this manner. These
paired samples were stored over a range of 1 to 15 weeks with no evidence of
deterioration in maximally stimulated enzyme activity.
Figure 4.4 Data from paired L1210 cell samples, fresh and frozen assayed in triplicate on the same day.
Results displayed as control data expressed as a percentage of the fresh control value assayed on that
day
Repeated assays of frozen L1210 cells gave a mean PARP activity of 119±52 pmol
NAD+/l06 cells (mean±SD, n=12 with a range of 40-185, CV(%) 43).
Although there is considerable variation between individual assays the mean (and
standard deviation) PARP-1 activity of frozen samples was very similar to that
obtained with fresh samples. For all clinical trial assays batched frozen L1210 cells
are used and one sample run as QC with every clinical assay. This allows comparison
to be made between assays by comparing the relative values with respect to the QC
results. To ensure that there is consistency between batches ofL1210 QC cells
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samples were prepared in bulk batches and stored in the designated -80°C freezer. A
new batch is prepared once there are 6 samples only available and at least 2 assays run
using the old and new batch of QC samples in parallel so direct comparison between
assays remains possible. The projected recruitment time for the PARPi trial means
that banking sufficient QC samples to cover the entire 2 year period would mean that
samples would be used outwith the time frame assessed above for stability of the
PARP enzyme with freezing.
4.4.2 Preservation of PARP-l inhibition with frozen storage
Although the PARP-1 enzyme function when maximally stimulated with
oligonucleotide is preserved with frozen storage for up to 3 months it was also
necessary to establish whether there was a deterioration in the degree of inhibition
when the inhibited cells were stored for a period prior to analysis.
Exponentially growing L1210 cells (6x10s cells/ml, total volume 250 ml) were
exposed to either O.4/LM AG014361 (20 ul of 40 /LM stock AG014361 in DMSO
diluted in 1980 ul medium, final DMSO concentration 10/0) or in medium plus 1%
DMsO (control samples) for 20 minutes at 37°C, the cells were pelleted out of this
solution by centrifugation, washed in PBS and one aliquot assayed for PARP activity.
The rest of the samples were frozen in aliquots of 15 x 106 cells for subsequent
tandem assay of inhibited/control cells.
Paired samples were defrosted and analysed over a 14 week period. The results are
shown in figure 4.5. Data are expressed as the % ofPARP-1 inhibition demonstrated
in the frozen sample compared to its own control sample which had been frozen for
the same length of time. Values for PARP-1 activity are derived from triplicate
samples. There was no evidence of a loss of the degree of inhibition of the enzyme
over this period of storage.
92
Figure 4.5
Maintenance of PARP inhibition with O.4~M AG14361
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Figure 4.5 Preservation of inhibition with frozen storage. Mean of triplicate samples expressed as %
matched uninhibited control
The same experimental design was used to set up a series of L1210 cell samples
inhibited with different concentrations (10 nM, 50 nM, 100 nM) of AG014699, the
clinical trial candidate. These samples were frozen and serially analysed as described
above. The practical work for this experiment was ably performed by Suzanne Kyle.
The results are shown in figure 4.6 once again there was no evidence in a
deterioration of the degree of inhibition with time.
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Figure 4.6
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Figure 4.6 Graph showing the degree of PARP -I inhibition caused by a given concentrat ion of
AG0 14699 . Data are expressed as a percentage of the control (DMSO incubation only prior to
freez ing) LI 210 samp les assayed on the same day, PARP -I activit y being measured in pmol AO+
incorporated per million cells.
4.4.3 Comparison of frozen storage temperature
In the experiment described above stored samples had been frozen by placing in a
freezer maintained at -80°C. It is more common in clinical facilities to have -20°C
storage available, particularly because of the constraints of space and the requirement
for more sophisticated monitoring and back-up facilities if -80°C storage is used.
An experiment was designed to assess what storage temperature was necessary for the
integrity of the clinical sample s. L1210 cells were grown in tissue culture in the usual
manner. The harvested cells were divided into 4 portions. These were incubated in
medium containing 10 nM, 50 nM, 100 nM AGO 14699 or 1% DMSO as a control for
20 minutes. The inhibitor solution was washed off and the sample divided into 3.
One aliquot was processed for immediate radiolabel PARP assay, and the others
resuspended in medium + 10% DMSO for freezing. One of these was placed in the -
80°C freezer as previously and the other in the -20°C freezer.
The two frozen samples were defrosted and analysed after 10 days at this temperature.
The results are shown below in figure 4.7 and figure 4.8. Figure 4.7 shows the data
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expressed as mean and SD of triplicate values in pmol AD+incorporated per million
cells. It can be seen that freezing and storage at -20°C does not preserve the samples
adequately, the standard deviation in the results is much larger than with fresh
samples or those frozen at -80°C and the degree of inhibition has not been preserved.
Figure 4.7
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Figure 4.7 Comparison of the preservation ofPARP inhibition at different storage tempe ratures. Mean
+ SO, n=3.
When the means from the above data with the inhibited samples is expressed as a
percentage of their own control value comparison can be made between the assays on
the fresh cells performed 10 days earlier with those of the frozen samples. The
pattern of inhibition measured is very similar in the fresh and -80°C frozen samples
but more variable when frozen at -20°C (figure 4.8).
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Figure 4.8 Comparison of effect of storage temperatures on inhibition of PARP-I . Mean data from
figure 4.7 expressed as % own control value
It was concluded that freezing and storing at -20°C did not adequately preserve the
samples. Despite the resource implications it was recommended that samples should
be placed directly into storage at -80°C, and kept at this temperature until transfer to
the analysis site.
4.4.4 Enzyme stability in PBLs
The feasibility of freezing prepared PBLs for a period of days, then defrosting and
measuring PARP activity was investigated in the follo wing manner. Blood from a
healthy volunteer was drawn, PBLs harvested and one aliquot assayed and the other
frozen in medium + 10% DMSO at - 80°C for one week. At the point of thawing
further blood was obtained from the same volunteer and from an additional source.
The two fresh samples were analysed at the same time as the thawed sample and the
appropriate L 1210 control cells. Three measurements were obtained from the same
individual and assayed in triplicate; fresh week 1 = 8.7 pmol NAD+/l 06 cells, fresh
week 2 = 16.0 pmol NAD+/l06 and frozen wee k 2 12.7 pmol NAD+/l06 . These data
demonstrated the inherent variability of a biol ogica l assay, and emphasises the
difficulty of comparing between assays. However expressing the measured PARP -l
activity in PBLs in terms of the QC sample run in the same assay appeared to sugge t
that there had not been a significant deterioration in the PBL enzyme function over 1
week of storage (values of 14%, 14% and 11 % of matched QC ample re pecti ely) .
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The practicalities of the clinical trial necessitate frozen storage of blood samples,
therefore further experiments were carried out to establish the stability of the PARP-1
enzyme with more prolonged storage and also the stability of enzyme inhibition.
These experiments were carried out using L1210 cells and are described in sections
4.4.1-4.4.3 above, partly to strengthen the validity of using these as the QC samples
but also because of the practical problems in obtaining large volumes of blood to
prepare multiple frozen aliquots of PBLs from one source.
4.4.5 Temporal fluctuation in PBL PARP activity
The experiments described above had shown that PARP-1 activity can be measured in
human PBLs using the radiolabel PARP activity assay and that this assay might be
adaptable for use as a clinical trial pharmacodynamic assay. During the clinical study
blood samples are withdrawn from the patient for PD assay over a 24 hour period on
three separate days, initially on the test dosing day where AGO14699 is given alone,
then on days 1 and 4 of the combination treatment to determine the degree of PARP
inhibition achieved and any cumulative inhibition. All the samples from a 24 period
are analysed together so that results can be expressed using the baseline sample as the
control.
For this strategy to be appropriate it was necessary to establish whether there was a
temporal variation in PBL PARP-1 activity. 5 ml whole blood samples were
withdrawn from a group of healthy volunteers at TO and either 4 or 24 hours later to
correspond with the patient sampling times. PBLs were obtained by
lymphopreparation and frozen in medium + 10% DMSO. The samples were
subsequently defrosted and all analysed in one assay run so that comparison of the
absolute values was possible.
All the data obtained were close to the mean PARP activity measured in human PBLs
and within the range given in table 4.3 (see figure 4.9).
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Figure 4.9 Mean + SO over paired PBL samples. N= 15 for baseline, n=7 at 4 hour s, n=8 at 24 hours.
For a closer evaluation of temporal variation only the data from samples where there
was an adequate (> 1 x 106Iml) harvest of PBLs was considered. There was no
evidence for a variation with sampling time in the value obtained for maximally
stimulated PARP activity in human PBLs in normal volunteers (figure 4. 10, mean and
standard deviation of triplicate measurements).
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Figure 4. 10 Individual results from human PBL assa y, mean + SO of triplicate measurements
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The results of this experiment did not suggest there was a clear variation in the
maximally stimulated PARP-1 activity in human PBLs over a 24 hour period.
However there was a great variation in the number of PBLs separated from the 5 ml
blood samples, in subjects where few cells were obtained this led to an unacceptably
large standard deviation in the results.
4.4.6 Assessment of enzyme integrity after transportation of samples
The First-in-Human trial is based at three clinical centres; all the PARP-1 activity
pharmacodynamic assays are being performed in the NICR, Newcastle. PBL samples
obtained in the different clinical centres will be transported overnight on dry ice (solid
C02, sublimation point at -78.5°C) to the NICR for analysis. It was therefore
important to establish whether treatment of the samples in such a manner would cause
deterioration in the samples.
Ll210 cells were grown to a suitable cell density in suspension. Cells were harvested,
washed and frozen in medium + 10% DMSO at -80°C. A sample of the freshly
growing cells was passaged and allowed to continue to divide for one further day.
After freezing two aliquots of the stored QC samples were packaged as for transport
in a polystyrene container filled with solid C02, left overnight on the bench top to
mimic the transport conditions of the samples. These samples was analysed in
parallel with a fresh L1210 sample and one which had remained in storage at -80°C.
Results are shown in table 4.4, PARP-1 activity being expressed in terms of pmol
NAD+ incorporated per million cells; mean, standard deviation and coefficient of
variation (%) from quadruplicate samples.
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Table 4.4
pmol NAD+/lOb cells CV (%)
(mean±SD)
Frozen L1210 54 ± 13 24.1
Fresh L1210 84 ± 13 15.2
Transport 79±26 32.7
condition L1210
(1)
Transport 67±4 6.5
condition L1210
(2)
There was no a significant deterioration in the measured PARP-1 activity with the
planned transport conditions. The samples will be considered adequately stored if
they arrive at the receiving centre still frozen and with solid COz in contact with the
vials, maintaining the temperature below -20°C.
4.5 Assay validation for use with human tumour samples
Tumour biopsies from patients with metastatic malignant melanoma will be taken
during the second part of the study and PARP-1 activity and inhibition will be
assessed in these samples. The published ezp] NAD+ incorporation PARP-1 assay is
already established to be able to measure PARP activity in tissue homogenates.
Therefore, in terms of validating the assay for the clinical trial the issues to resolved
were confirmation that freezing and storage of the tissue did not affect the measured
PARP activity, validation of the change to the assay methodology (omission of
oligonucleotide) and demonstration that PARP inhibition with AGO14699 could be
measured in tissue homogenates.
There is great practical and ethical difficulty in obtaining multiple samples from a
patient/human population. This paucity of samples is a particular problem when
small tissue biopsies are being analysed. Therefore, of necessity, assay development
and validation work must be done using surrogate tissues. All experiments have
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either been carried out using homogenised mouse liver as a readily available tissue,
and because in patients the liver is a common site of metastatic disease and hence a
potential source of samples or using human tumour xenografts in nude mice. The
close homology of PARP-1 between species makes this an acceptable manoeuvre.
4.5.1 Confirmation of activation in the absence of added oligonucleotide
When PARP-1 activity is measured in permeabilised cells a blunt-ended
oligonucleotide is added to the reaction to maximally stimulate PARP-1 by providing
multiple blunt ended strand breaks. Mechanical homogenisation of tumour samples
or visceral tissue to dissociate the cells causes sufficient DNA breakage to maximally
stimulate PARP-1 (M. Batey, MSc thesis). Maintaining the sample on ice during and
after homogenisation prevents polymer formation utilising endogenous NAD+ on
these introduced DNA strand breaks.
Whether addition of oligonucleotide was required to ensure maximal stimulation of
PARP-1 was investigated by incubating samples from the same homogenised liver
sample in the presence or absence of 5 III oligonucleotide. The results are expressed
in terms ofNAD+ incorporated per mg protein added, mean and standard deviation of
quadruplicate samples. Addition of oligonucleotide to these preparations (figure 4.11)
did not further enhance the measured PARP activity and is, therefore, unnecessary.
Figure 4.11
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Figure 4.11 Effect of adding oligonucleotide to homogenised tissue. Mean + SO, n=3. PARP activity
expressed as pmol NAO+ incorporated per mg protein
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4.5.2 Affect of freezing and storage of tissue samples
During part 2 of the clinical trial small tumour samples will be obtained from patients
under local anaesthesia and snap frozen in liquid nitrogen immediately after biopsy
with no further processing at this stage. Samples will be stored at -80°C. They will
be transferred to the assay laboratory frozen from the clinical centres. It has been
shown above that PARP-l enzyme activity and inhibition is preserved with freezing
in cell preparations. As part of the assay validation process it was necessary to
demonstrate that snap freezing and storage of tissue over time does not cause
deterioration in enzyme function.
Each liver was divided into 2, one portion processed immediately and the other snap
frozen for 1-8 weeks at -80°C prior the homogenisation and assay as described in
sections 3.4.2 and 3.6. The PARP activity (pmol/mg protein) was compared. These
paired data are shown in figure 4.12 (mean and standard deviation of triplicate
results), there was not a significant deterioration in the samples with freezing and
storage. This means that snap freezing of tumour biopsies, with subsequent frozen
transport to the laboratory is feasible in the clinical setting.
Figure 4.12
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Figure 4.12 Stored tissue results (mean + standard deviation) paired with freshly analysed sample of
same liver. No significant deterioration with storage time
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4.5.3 PARP inhibition with AG014699 in tissue
PARP-I inhibition by AGOI4699, the clinical candidate, has been demonstrated in
cell culture suspensions (LI2IO cells) and in isolated human PBLs in the sections
above. During the preclinical development and evaluation of the proposed clinical
candidate nude mice bearing human tumour xenografts (SW620 human colon cancer
cell tumours) were treated with a single intra-peritoneal dose of AGOI4699 dissolved
in sterile water. The dosages used were 0.1 mg/kg, 1 mg/kg and 10 mg/kg. Vehicle
was injected as a control. The mice were sacrificed 30 minutes later and the tumours
removed and snap frozen.
These samples were subsequently homogenised and assayed as described in section
3.7. The results are shown in figure 4.13 confirming that inhibition ofPARP-I within
the tumour can be demonstrated and that the degree of inhibition can be measured
with the described assay. The practical work for this experiment was performed by
Suzanne Kyle.
Figure 4.13
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Figure 4.13 Demonstration of inhibition of tumour PARP-1 Data derived from the mean of three
tumours analysed in triplicate, mean and standard deviation shown.
In summary, it was demonstrated that the assay could be adapted for use with frozen
homogenised tissue and that enzyme inhibition could be demonstrated. This PARP
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activity assay can therefore be used to measure the degree of PARP inhibition
achieved in the clinical trial tumour samples.
4.6 Intra-assay validity
As part of the validation procedure the intra-assay precision was investigated. This
was done to establish two facts, did analysis of the same sample give the same result
when done at the beginning and the end of the assay and what were the lower limits
for cell numbers analysed for accurate PARP activity determination?
Ll210 cells were harvested and permeabilised for the assay in the standard way. A
cell suspension density of 3 x 106 cells per ml was obtained. This solution was
serially diluted with isotonic buffer to obtain samples such that 0.75 x 106,0.66 X 106,
0.5 X 106, 0.33 X 106 cells would be added to the reaction tube rather than the protocol
stipulated 1 x 106. Six replicates of these suspensions were analysed in one assay run.
The results are summarised in table 4.5. As the cell number added to the reaction
tubes decreases the variation in the replicates increases, demonstrated by the increase
in observed standard deviation. This increase was also observed when analysing PBL
samples. Their intrinsically lower PARP activity meant that any additional variation
due to low cell numbers might compromise detection of PARP inhibition by
AGO 14699. For the purposes of assay validation it is felt that the range of values for
added cells over which the assay is reliable is 0.6-1.0 x 106•
Table 4.5
Cell density pmolNAD+ pmol NAD+/I0 6
incorporated cells
1.0 135 ± 10 135 ± 10
0.75 108 ± 5 144 ± 6
0.66 85 ± 7 144 ± 10
0.5 63 ±20 127 ± 41
0.33 45 ±4 138 ± 11
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4.7 Discussion
The work described above explains the steps taken to develop and then validate a
pharmacodynamic assay for potential use during the PARPi trial. These data were
also used to produce a full validation report for use of the radiolabel PARP activity
assay with human PBLs and a supplementary validation report for its use with tumour
samples. These validation reports have been reviewed and accepted by the Quality
Control section of Cancer Research UK and by Pfizer GRD.
Most published material on method validation and ICR guidelines (1996) refer to the
validation of analytical procedures, largely based around chromatographic methods.
For these procedures it is clearly possible to be much more precise than when
validating a bio-assay. The ICR guidelines list five key characteristics of an assay
which need to the demonstrated and defined; specificity, linearity, range, accuracy
and precision. FDA Guidance (2001) defines the fundamental parameters for
bioanalytical validation as being accuracy, precision, selectivity, sensitivity,
reproducibility and stability.
The principles to be used for establishing a valid method are defined in the 1990
AAPS International Workshop report (Shah, Midha et al. 1992) as being
a) Production of a specific detailed description and protocol of the
method (Standard Operating Procedure)
b) Investigation of each step in the method to determine the extent that
external variables may affect the estimation of the result
c) Validation of the method for the intended use
d) Wherever possible validation should be performed using the same
biological matrix as the intended samples
e) Within and between run accuracy should be demonstrated to allow
accuracy and precision to be assessed
f) For assays where a standard curve is included the range of the curve,
relationship between response and concentration and lower limit of
quantification must be defined
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The conference report acknowledges the difficulty of applying all these principles to a
biological assay and states that "the pharmacodynamic effect measured for
bioequivalence studies should be related to the actual pharmacologic (therapeutic) end
point of the activity of the drug".
Therefore, when validating an assay based on a biological system such as enzyme
activity it is acknowledged to be much more difficult to produce detailed and exact
validation of data. Huber (Huber 1998) states that compound analysis a precision of
better than 1% relative standard deviation is easily achieved whereas for biological
samples the precision is likely to be between 10-16%.
The pharmacodynamic effect which is measured by the [32p] NAD+ incorporation
PARP activity assay is the number of pmol NAD+ incorporated into acid precipitable
macromolecules by PARP-1 in the 6 minute reaction period. Addition of the
permeabilised cells to a plentiful supply of the enzyme substrate (NAD+) and a
powerful enzyme activator (oligonucleotide) means that NAD+ incorporation into
poly(ADP-ribose) is the major reaction product that can be precipitated by TCA. The
assay has been designed to assess inhibition of PARP-1activity by AGO14699 by
measuring a reduction in the ability to form this reaction product. It would seem,
therefore, that the radiolabel assay does fulfil this validation requirement.
Detailed Standard Operating Procedures have been produced for both the assay using
PBLs as the experimental matrix and that using homogenised tumours. Validation
has focused on the intended clinical use of the assay and wherever practical the
method has been validated using the biological matrix of the intended unknown
samples. The influence of external factors on the validity of assay results has been
investigated by studying the effects of storage and transport of the samples on both
enzyme activity but also the maintenance of inhibition.
The steps taken to address intra and inter assay variability whilst adapting the PARP
activity assay for use for analysis of clinical trial samples have included the definition
of quality control samples to be run with each assay. Within the SOP QC acceptance
limits for an assay are defined based on the multiple replicates analysed. This
provides confidence that a given assay run has produced valid readings for the
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unknown values if the QC samples lie in the expected range (118.9 ± 51.6 pmol
NAD+ per million cells).
Throughout the development and validation of this PARP-1 assay for use in the
clinical trial it became apparent that the low cell recovery from whole blood
compromised the assay results. Studies on intra-assay reproducibility described
above using L1210 cells, which have higher basal levels ofPARP-1 activity than
PBLs, showed the assay was less robust and variability increased as cell numbers
were reduced. This problem would be expected to be more marked when analysing
cells with a lower basal enzyme activity. It has been shown that inclusion of
polymorphonuclear cells would not improve the situation.
One option to increase the number of cells it is possible to add to each reaction tube is
to decrease the number of replicates within an assay, but there was concern over
reducing this to fewer than 3. During the clinical trial blood will be taken from
patients for pharmacokinetic analysis of AGO 14699 and temozolomide, and for two
pharmacodynamic assays, the PARP activity assay and also COMET analysis for
DNA strand breaks. Increasing the volume of blood drawn from the patient would
obviously increase the absolute number of cells harvested but could significantly
impact on the patient's wellbeing. This was, therefore, not considered an option to
improve assay reproducibility.
Another option would be to omit the "- oligo" triplicate set of reaction tubes, thus
reducing by 33% the number of cells needed. The "-oligo" samples give a measure of
background PARP-1 activity in the permeabilised cell population, however decisions
in the trial will be made based on the degree of inhibition measured when PARP-1 is
maximally stimulated. Omission of these replicates would still leave a requirement
for a minimum of 3.6 x 106 cells to perform the assay, leaving no scope for assay
repetition if the QC indicated an invalid run. A poor cell harvest would make
obtaining a reliable result difficult. Patients recruited into phase I anticancer drug
trials have failed standard therapy for their tumour and many have had significant
previous cytotoxic treatment and have low bone marrow reserve and blood counts at
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the bottom of the normal range. The possibility of the low PBL harvest is greater in
the phase I trial population that when drawing blood samples from healthy volunteers.
Therefore despite the successful and accepted validation of the [32p] NAD+
incorporation PARP activity assay there remained significant concerns that in clinical
practice it might prove less robust. Chapter 5 describes the work undertaken to set up
and validate an alternative assay based upon an immunological method using far
fewer cells.
108
Chapter 5
Development and Validation of Immunoblot PARP activity
assay
109
5.1 Introduction
The extensive scientific interest in and diverse potential clinical uses of PARP-1
inhibitors (discussed in chapter 1) means a number of authors have described assays
which attempt to measure PARP-1 activity or inhibition. Earlier assays relied upon
radio-labelled substrate (Aboul-Ela, Jacobson et al. 1988; Boulton, Pemberton et al.
1995) or purification ofpoly(ADP-ribose) by complex chromatography (reviewed in
(Shah, Poirier et al. 1995). De Murcia's group reported an ELISA based screening
assay (Decker, Miranda et al. 1999) and more recently a non-radioactive biotinylated
NAD assay has been described (Brown and Marala 2002) which is suitable for use
with high-throughput screening (HTS) of PARP inhibitors. Dillon and colleagues
reported a 3H-NAD+FlashPlate scintillation proximity assay which again can be used
for HTS since it can be adapted for use with a 384-well plate format (Dillon, Smith et
al. 2003).
The development of monoclonal antibodies has produced a widely used tool in both
scientific research and clinical practice, with a multitude of commercially available
products and assays. The rapid emergence over the previous decade of quantitative
macromolecule detecting assays, including immunoassays, was identified in the 2000
AAPS Validation Workshop, and the issues surrounding their validation included as a
key goal in the conference (Miller, Bowsher et al. 2001).
The possibility of using a monoclonal antibody against poly(ADP-ribose) (PAR) to
detect polymer formation and thus enzyme activity with Western Blotting was first
described in 1995 (Shah, Kaufmann et al. 1995). Whilst exploring potential
alternative PARP activity assays which would allow smaller biological samples
advice and help was sought from Professor Alex Burkle. His laboratory studies
PARP-1 and its relationship to ageing. In 1999 they published a report of a
"quantitative nonisotopic immuno-dot-blot method" which allows assessment of
cellular poly(ADP-ribosylation) capacity (Pfieffer, Brabeck et al. 1999). This assay
exposed permeabilised cells to oligonucleotide and a reaction buffer containing
NAD+. The formation of PAR under these circumstances was stopped after the fixed
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period by the addition of an excess of ice-cold 3-aminobenzamide. The permeabilised
cells were then blotted onto a nitrocellulose membrane, fixed and exposed to a
primary monoclonal antibody which binds to PAR. An RRP-conjugated secondary
antibody was used to detect the bound primary and the chemiluminescence signal
detected and quantified. Pfieffer et al reported that intensity of the chemiluminescent
signal was a function of the cell number loaded and that PARP-l inhibition with 3-
aminobenzamide could be demonstrated.
The primary antibody used in the assay described above in the lOR anti-PAR
antibody was generated by Dr M Miwa from a mouse hybridoma cell line
(Kawamitsu, Hoshino et al. 1984). The antibody binds to a linear structure of the
ADP-ribose polymer which is greater than 15-20 ADP-ribose monomers in length,
ethanol precipitation of antibody-bound polymer suggested that lOR binds to almost
all molecular sizes of polymer generated from rat liver PARP (Kawamitsu, Hoshino et
al. 1984). Antibody binding to polymer is inhibited by 20% by the presence of excess
monomer suggesting some cross-reaction with the monomer subunit. Species cross-
reactivity is reported for human, mouse, rat, bovine and monkey poly(ADP-ribose)
(Shah, Kaufmann et al. 1995). These authors also report a "simple activity-Western
blot technique" which can detect polymerase activity in cultured cells by virtue of
detection of the reaction product. The lOR antibody is commercially available from
Alexis Biochemicals at >95% purity but in all the experiments reported below has
been generously supplied by Professor A Burkle. In the early experiments much
advice and assistance was given by Professor Burkle, his colleague Dr Pfieffer and by
Dr Paul Jowsey (NICR).
It was decided that the quantitative immuno-dot-blot method might be a suitable assay
for modification and validation as an alternative pharmacodynamic assay in the
clinical PARP inhibitor trial. The published method demonstrated linear
chemiluminescence detection for up to 120,000 cells loaded, above this cell number
there was saturation of the signal. Reliable signal detection in the linear range was
demonstrated for 15,000-30,000 cells. These experiments used IARC 273 cells, a
Epstien-Barr immortalised human B-Iymphoblastoid cell line. Clearly far fewer cells
were needed than the 6 x 105 cells for a reliable radiolabel PARP activity assay.
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5.2 Poly(ADP-ribose) detection in L1210 and PBL cell preparations
Preliminary experiments were carried out to assess whether the established QC cells
(L1210) and human PBLs could be reacted, blotted onto a membrane and polymer
detected. These initial experiments were performed using a standard 96-well
manifold rather than the custom-made 24 well manifold designed by Professor
Burkle.
Early experiments were performed using the isotonic buffer and permeabilisation
buffer described in the published method (Pfieffer, Brabeck et al. 1999). However it
was found that the long permeabilisation incubation and further centrifugation
required in this method significantly contributed to the background on the
immunoblot (see section 5.4). The method which is described in detail in chapter 3 is
the final validated protocol being used in the clinical trial. This method uses the same
isotonic buffer as in the e2p] NAD+ incorporation PARP activity assay, with the
omission ofDTT and a short permeabilisation with digitonin. In addition NAD+ was
prepared fresh on the day of each experiment and added to the reaction buffer to
ensure that there was no degradation of this substrate with storage and that it was
present in excess in the reaction, the concentration of oligonucleotide in the final
reaction has also been reduced compared to the published assay (Pfieffer, Brabeck et
al. 1999). These changes are also discussed in section 5.4.
5 ml of whole blood was taken from healthy volunteers and PBLs obtained by
lyphopreparation. Either the whole blood prior the lymphopreparation or the washed
PBLs were exposed to 100 nM AG014699 (1% DMSO only added to controls) for 15
minutes at 37°C. Whole blood was lymphopreped, the cells were permeabilised with
the published permeabilisation buffer (10 mM Tris-HCL pH 7.8,1 mM EDTA, 4 mM
MgCh, 30 mM 2-mercaptoethanol supplemented with 0.015% (w/v) digitonin), then
reacted in the presence of oligonucleotide and NAD+ for 6 minutes. The reaction was
stopped by the addition of 400 III ice cold 6.25 11M AG014361 and placing on ice.
The cell density in the reaction was counted. The dot-blot 96 well manifold was set
up, a suitable sized piece of filter paper and Hybond-N membrane were rehydrated in
PBS then clamped into the manifold. 5000, 10000 and 20,000 cells from the reaction
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mixture (diluted in PBS to a final volume of 50 ul) were loaded into the wells , fixed
and exposed to primary and secondary antibody as described in section 3.4.
After exposure to ECL for 1 minute the blot was exposed to film to see if PAR could
be detected in human PBLs with lOR and whether inhibition with AG014699 was
detectable. This experiment was repeated three times , a sample visual blot is shown
below (figure 5.1). Triplicate samples of different cell numbers have been loaded, it
can be seen that there is an increase in the amount of chemiluminescence detected as
the cell number increases, and that this is reduced in the presence of the inhibitor.
Figure 5.1
Cell number
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Figure 5.1 Scanned film showing detection of PAR in PBLs , in the presence or absence of 100 nM
AG014699. Cell number loaded shown beside.
A similar experiment was performed using L 1210 cells. This was done in parall el
with a e2p] NAD+ incorporation PARP assay as part of the investigation into whether
enzyme inhibition was preserved with frozen storage (section 4.4.2 , figure 4.6) .
L 1210 cells were exposed to 0, 10, 50 and 100 nM AGO 14699 for 15 minutes at 37°C,
the inhibitor removed and samples frozen in medium + 10% DMSO. At the 8 week
time point a small aliquot of the defrosted sampl e was remo ved prior to the [32p]
NAD + incorporation assay. This was wash ed, permeabilised and reacted as de cribed
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above. Varying cell numbers were again loaded onto the 96-well dot-blot manifold
and exposed to primary and secondary antibody.
The results are shown in figure 5.2. The se correspond to the 8 week data on fiaure
b
4.6. The increase in chemiluminescence with cell number and decrease with
increasing concentration of inhibitor are evident, the change with inhibitor was most
obvious when only 1000 or 2000 cells were loaded.
Figure 5.2
Figure 5.2 Scanned film showing detection of PAR in Ll21 0 cells inhibited with varying concentration
of AGO 14699 (shown across top of film), cell number on RHS.
Having verified that the technique worked with human PBLs and the proposed QC
cell line additional work was undertaken to establish the quantification of these
matrices using the digital chemiluminescence detector. The original report for the
technique used a customised 24 well manifold with a blotting area of >100 mm",
allowing loading of a larger volume of cells. Pfieffer and colleagues reported that
permeabilised cells tended to cluster and the larger loading area allowed averaging of
this clustering effect.
Initiall y a 24-well mani fold was borrowed from Professor Burkle 's group;
subsequently one was made in 18 mm Perspex by Forge House Group , Darlington
(figure 5.3). The chemiluminescence detection apparatus initiall y used wa a Fuji
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LAS 1000 in Professor Burkle ' s laboratory, later we purchased the LAS 3000 model
which was used in later experiments and all clinica l trial work. The image detected
was digitised then interpreted using the Aida Image Analyser, version 3.28.001
software package. An example of the output obta ined and defined as source data for
the clinical trial is shown below (figure 5.4). The final numerical output is described
as "densitometry", the camera detection unit takes a digital picture of the
chemiluminescence from the exposed blot, this digital picture is imported into the
Aida software as a grey scale image and the densities measured from this image.
Figure 5.3
Figure 5.4
2D Densitometry
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Figure 5.4 Example of output from Aida software following exposure of Fuji LAS 1000. Serial
dilution of QC cells, loading pattern being (left to right) 100,000, 50,000, 25,000, 12,500 in triplicate.
4 background areas also measured, see text.
The problem of clustering of cells and pooling of chemiluminesce nce was observed in
early experiments. This was overcome by usin g two pieces of filter paper as a base to
the Hybond-N membrane so that a tighter sea l was obtained, and also by diluting
small volume samples up to 400 ).11 with PB S prio r to loading.
Serial dilution of both LI2IO cells and human PBLs confirmed that the
chemiluminescence detected was proportional to the cell number loaded, a linear
relationship obs erved up to 100,000 LI 2I Ocells and 50,000 PBLs (figure 5.5). Data
are mean and standard deviation of triplicate samples. Pfieffer et al (1999) report
similar results with the same detection system, with a linear relation hip up to
120,000 IARe 273 ce lls. The upgrade to the Fuji LA 3000 y tern meant that th
arbitrary densitom etry units were increa ed 50 fold becau e of the increa d
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sensitivity of the machine. All clinical trial samples are being analysed on the more
sensitive machine. It must also be noted that the data in the graphs in figure 5.5 were
analysed on two separate blots, using the Fuji LAS 1000 analyser. Given the multiple
variables in any biological assay it is not possible to compare directly between assays
in terms of absolute LAD readings. The purpose of these two separate experiments
was to demonstrate the linear relationship between cell number and
chemiluminescence detected. Whenever PBLs and Ll210 cells were analysed on the
same blot it is clear that the maximally stimulatable PARP activity in Ll210 cells is
higher than that in PBLs confirming the findings with the radiolabel assay. When the
QC samples from serial patient samples were compared, corrected to LAD per 20,000
cells PBLs given a reading about 27% of the concomitantly analysed Ll210 QC
sample.
Figure 5.5
Relationship between
densitometry and cells loaded
75000 75000
2.5 5.0 7.5 10.0 12.5
Cell number x104
o-l--=---.---.----,----r----,
0.0
>.
~ NE 50000E Eo _
~::J
~ ~ 25000
2.5 5.0 7.5 10.0 12.5
Cell number x104
o-+L------.--,---,------,----,
0.0
~-G:)NE 50000E Eo _
~::J
~ :5~ - 25000
Figure 5.5 Means and standard deviation of triplicate samples ofa serial dilution ofLl210 cells
(LHS) and PBLs (RHS).
These experiments suggested that the method was adaptable as a pharmacodynamic
assay using far fewer cells and therefore more suitable for repeated blood sampling
procedures. Further investigation was necessary however to establish a standard
curve to allow quantification of the polymer formed, to investigate the nature of any
background staining and to validate the assay to include QC samples.
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5.3 Identification and characterisation of a poly(ADP-ribose) standard curve
In order to apply the immunoblot to clinical trial samples from sequentially treated
patients it is necessary to be able to compare between assays performed on different
days. The use of QC samples in parallel with the clinical samples allows
demonstration that the individual assay had given a valid result and the validation of
L1210 cells as QC samples for this assay is described below. It was also considered
desirable that an absolute numerical value could be given to the maximally
stimulatable PARP activity in the PBLs in terms of the amount of polymer formed to
allow such inter-patient comparison. The validated e2p] NAD+ incorporation assay
expresses results in terms ofpmol NAD+ incorporated per million cells allowing
comparison of different assays. It was hoped to establish a similar method of relating
the measured chemiluminescence to an absolute amount of substance.
Standard curves from antibody detection of in vitro synthesised polymer have been
reported (Affar, Duriez et al. 1998) showing a linear relationship between the detected
chemiluminescence and the amount of polymer loaded. They reported the reliable
detection of as little a 1 fmol ADP-ribose equivalent polymer using a digital imaging
system.
A similar method has been applied to the quantification of this assay. Purified
poly(ADP-ribose) polymer is available commercially from BIOMOL Research
Laboratories. The polymer consists of branched and linear polymer with an average
chain length of25 ADP-ribose monomers (range 3-100). The concentration of the
polymer is expressed in pmol ADP-ribose monomer equivalent and is supplied as a 10
,ug/ml solution. l,ug is equivalent to 2000 pmol ADP-ribose monomer. The product
information sheet states that the product contains <0.1% ADP-ribose, and is
completely degraded by poly (ADP-ribose) glycohydrolase (PARG).
A standard curve which included 6 values was generated, initially over the range 1-50
pmol monomer equivalent. It was suggested (Shah, Midha et al. 1992) that between
five and eight concentrations will define a standard curve in many biological assays.
The amounts of PAR loaded as each point on the standard curve were based partly on
an estimate of the amount of polymer that would be formed by 100,000 maximally
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stimulated PBLs if the mean amount ofNAD+ incorporated into one million PBLs is
24.5 pmol NAD+ as determined using the e2p] incorporation assay but also utilising a
range that allowed several standard curves to be obtained from one batch of
commercially produced PAR which is supplied in 100 ul aliquots
It is generally accepted that repeated freeze thaw cycles of the purified PAR polymer
should be avoided to preserve its integrity. Therefore a standard curve was designed
such that all polymers had two freeze thaw cycles only. On receipt of a new batch of
polymer it was aliquoted appropriately and refrozen. When required an aliquot was
defrosted and serially diluted on the day of experiment. Due to the limitations on
number of wells on the blot apparatus one standard curve was set up for each blot of
patient samples, and the number of standards limited to 6 as discussed above. This
occupied one complete row on the 6 by 4 manifold. For trial samples all the samples
from one patient in one complete 24 hour sampling period were loaded onto one blot.
Purified polymer was diluted to obtain a solution containing 50 pmol monomer
equivalent in 100 ~l solution in sterile water. This was serially diluted and a standard
curve loaded with the values 50, 25, 12.5, 6.25, 3.125, 1 pmol monomer equivalent.
These standards were loaded onto a membrane which was processed according to the
SOP. The chemiluminescence signal detected was proportional to the amount of
polymer loaded. To further investigate the relationship between chemiluminescence
and [PAR] and to determine whether the standard curve could be used to both read off
unknown results in terms of polymer formed, and then to compare these values with
those from assays performed on different days the data from serial blots processed on
different experimental days were compared. All standard curves were set up and
loaded as described above. Comparison of single standard curves from immunoblots
developed on separate days shows that there was a good correlation with the
densitometry reading obtained indicating that the polymer is stable when aliquoted
and stored as described above and gives reproducible results (figure 5.6). The best fit
for the data generated from the standard curve is non-linear. Statistical analysis was
performed by non-linear regression using a one-site binding model, which is reported
as best modelling the binding of receptor to ligand, in this case secondary antibody to
the 10H primary antibody bound to its polymer binding site. The equation used to
calculate the non-linear curve fit (one site binding) is Y=(Bmax . X)/[I<J+X]. Where X
119
is the concentration of PAR, Y is the luminescence detected following exposure of the
bound secondary antibody to EeL. Bmax is the maximum chemiluminescence, the
point where the gradient of the standard curve becomes zero with all PAR present
bound to antibody complexes. K, is the equilibrium dissociation constant, the
concentration of PAR at which half is bound to antibody complex at equilibrium.
Figure 5.6
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Figure 5.6 Means and standard errors of 11 repeats of PAR standard curve, each standard being run in a
separate assay (Note: all data from cell dilution experiments and initial work on the standard curve
used a Fuji LAS 1000 digital camera. All subsequent experiments were performed with the more
sensitive upgraded Fuji LAS3000, there is a consequent change in the range of the digitised output
(LAU/mm2) with the scale on the y-axis being much larger).
Regression analysis of the standard curve generated over the range 1-50 pmol PAR
suggested that the portion between 1 and 25 pmol was linear. There appeared to be a
saturation of the antibody binding and chemiluminescence signal between 25 and 50
pmol. This was not due to the limit of detection of the digital camera; comparison of
the densitometry values shown on the y-axis in figures 5.6 and 5.5 shows that more
intense signals can be detected and there was not a saturation of detection with
increasing cell number. The plateau effect on the standard curve may be due to the
mechanism of antibody binding to polymer.
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Initial analysis of patient PBL samples after treatment with a PARP inhibitor showed
that significant PARP inhibition was caused even with low doses of the drug. Dose
escalation decisions will be made based on the degree ofPARP inhibition caused'
,
therefore defining the lower limit of quantification was felt to be important. The
range of the standard curve was therefore extended to include a "blank" or no polymer
well to define the point where the standard curve cuts the y-axis, chemiluminescence
signal equivalent to this being due to noise/background, The dilutions were altered so
that most standards were at the lower end of the scale, the new standard curve being
over the range 0-25 pmol monomer equivalent, with data points at 0, 0.04, 0.2, 1,5
and 25. The same equation for best fit describes this curve.
Figure 5.7 gives the mean and standard error of 10 separate standard curves set up
using this new protocol. These were the standard curves used to derive the PAR
values measured from PBLs during the TemoCOMET study (see chapter 6). Each
individual standard curve had a coefficient of regression (r2) of 0.95 or greater. When
the data was pooled together ~ = 1.000, confirming that when analysed using a one-
site biding non-linear regression model there was a good relationship between the
concentration of PAR and measured densitometry on different days.
Figure 5.7
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Figure 5.7 Pooled data from 10 individual standard curves run with patient samples during
analysis of samples from TemoCOMET study. Mean and SEM.
121
There is a background chemiluminescence detected by the camera from the
Hybond-N membrane itself. When the data was analysed 4 readings were taken
of this background and the mean of these reading subtracted from the
chemiluminescence detected from the area of each well of the manifold. To
establish the lower limit of detection, the PAR standard was diluted further and
compared with the blank standard well (400 III PBS) in two independent
experiments. The practical work for these two experiments was carried out by Dr
Chris Jones. Firstly the 5 replicate PAR samples of concentrations 0, 0.01 and
0.05 pmol PAR were blotted onto a membrane and analysed. The limit of
detection was found to lie somewhere between 0.01 and 0.05, there was no
significantly detectable difference between 0.01 and 0 (p=0.225, unpaired t-test,
figure 5.8).
To further define the lower limit of detection 5 replicate samples over the range 0
pmol to 0.04 pmol in 10 fmol steps were loaded onto one blot and analysed in the
usual way. The results are shown in figure 5.9 where it can be seen that polymer
levels of fmol amounts can be distinguished from zero. Statistical analysis of the
groups using one-way ANOYA to establish whether the mean values of the
groups are statistically different gives p=<O.OI when comparing either all 5
groups or the three lowest groups, showing that the chemiluminescence detected
for these low standards can be distinguished from zero. It was felt, on the basis of
these two experiments, that one could be confident that the chemiluminescence
from 0.02 pmol PAR could be reliably distinguished from zero.
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Figure 5.8 Mean and SEM of quintuplet samples of polymer, the difference between 0.01 pmol
PAR and 0 is not significant (p=0.225, unpaired t test).
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Figure 5.9 Densitometry readings from quintuplet samples, mean plus SEM shown.
Having established a standard curve which allowed the translation of
chemiluminescence detected from the unknown samples into an amount of PAR
polymer present it was necessary to establish how many human PBLs and L121 0 QC
cells needed to be loaded to detect a signal within the standard curve range. QC
samples were loaded to demonstrate that a given blot has given a valid or "expected"
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result. The amount of polymer formed within these cells when maximally stimulated
for 6 minutes should be within the standard curve.
Likewise the baseline blood sample taken prior to the PARP inhibitor infusion should
give the maximum value for that set of patient samples. This value should also lie
below the upper limit of the standard curve to avoid extrapolation being needed.
Serial dilution of volunteer PBLs or frozen L1210 cells and also the initial clinical
samples studied using this assay (from the TemoCOMET study, chapter 6) suggest
that between 5,000-10,000 L1210 cells will give values in the required range (mean
PAR per 5000 L1210 cells= 22.2 ± 5.6 pmol, CV(%) = 25%, n=6) and that between
10,000 to 20,000 PBLs (mean PAR = 15.4 pmoIIlO,OOO cells, range 5.6-20.0, n=6)
should be loaded onto the blot.
5.4 Modifications to the assay protocol during validation experiments
The aim of the PARP activity determination within the clinical trial setting is to
measure PARP inhibition following treatment with AGO14699. This measure is
obtained by quantifying the amount of polymer formed after a 6 minute period of
maximal enzyme stimulation with oligonucleotide. However, the primary antibody
against PAR, 10H, will bind to any polymer present within the permeabilised cell, not
discriminating between that formed during the reaction period and that present due to
existing DNA strand breaks. The existing polymer could potentially contribute to the
signal when PBLs are obtained from patients who have received chemotherapy and
consequent DNA damage. The effect of this endogenous polymer formation on
existing strand breaks, whether caused by chemotherapy or cell handling was
demonstrated in an experiment where a direct comparison was made between the
radiolabel PARP activity assay and the immunoblot.
Exponentially growing L1210 cells were harvested, washed and then exposed to 0 nM
(DMSO only), 10 nM, 50 nM and 100 nM AG014699 for 15 minutes at 37°C. The
cells were then washed, permeabilised and assayed for PARP activity using both the
e2p] NAD+ incorporation and immunoblot assay. It was observed that, although there
was a similar pattern of inhibition, the two curves were parallel, with that from the
immunoblot lying above (figure 5.10). On the immunoblot samples were loaded
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which had been "spiked" with an identical number of unreacted but penneabilised
cells to give a measure of this endogenous PAR. When the mean of this background
(non-stimulated) polymer signal was subtracted the two curves to come close together
and gave very similar ICso values. (13.2 cf 12.7 nM)
• Dot blot
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Figure 5.10
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Figure 5.10 PARP activity as %control for parallel [32p] NAD+ incorporation and immunoblot of
LI2l0 cells inhibited with AG014699. % calculated from mean of triplicate samples.
The assay methodology was changed to include "TO" i.e. unreacted samples so that
the contribution of this endogenous polymer could be evaluated and excluded from
the measure of enzyme activity for all clinical samples. The TO samples loaded were
taken from the permeabilised cell suspension held on ice, and same number of cells
loaded into the TO wells as were placed in the reaction samples. Triplicate TO
samples were loaded from each cell suspension and the mean chemiluminescence
detected from these subtracted from the reaction samples before calculation of PAR
levels.
The initial description of the PARP immunoblot used an isotonic buffer containing 2-
mercaptoethanol, and the permeabilisation step involved supplementation of this
buffer with digitonin, incubation for 1 minute then a 10 minute centrifugation step at
ODe. Two problems were encountered when analysing either L121 0 or PBLs with this
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method. Firstly the degree ofpermeabilisation was variable and could be as low as
200/0, and secondly there was a high background staining in the TO cells. It was found
that samples prepared using the same isotonic buffer as described in the e2p] :\"AD+
incorporation PARP assay and utilising 0.15 mg/ml digitonin penneabilisation
method showed ~1000/0 permeabilisation and background TO staining was much
lower. It is presumed fewer DNA strand breaks are introduced during cell handling
with the removal of the prolonged O°C centrifugation step. The assay method was
changed to adopt digitonin permeabilisation and to use the alternative isotonic buffer.
The other significant adaptation to the assay method was reduction in the
concentration of oligonucleotide in the reaction. In the published immunoblot PARP
activity assay the concentration of oligonucleotide in the final reaction volume was 50
ug/ml (or 1.95 mM). The amount present in the e2p] NAD+ incorporation assay was
much lower (2.5 ug/ml) and an experiment was undertaken to investigate whether
decreasing the amount of oligonucleotide in the reaction mixture would affect the
amount of polymer produced.
Frozen QC cells were defrosted, washed and permeabilised with digitonin. The
reaction tubes were set up with a range of oligonucleotide concentrations added to the
tubes in a final reaction volume of 100 ul in isotonic buffer. 5000 penneabilised
L1210 cells were added to each reaction tube, the reaction carried out for 6 minutes
before stopping with excess inhibitor. The contents of the tubes were loaded onto a
membrane and immunoblotted in the usual way. The results (mean and standard
deviation, n=3) are shown in figure 5.11. There was no suggestion that reducing the
amount of oligonucleotide present compromises PARP-1 ability to form polymer.
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Figure 5.11 Relationship between densitometry and concentration of oligonucleotide in reaction.
Mean + SO, n=3.
Pfieffer and colleagues (Pfieffer, Brabeck et al. 1999) described the prototype assay
using a reaction buffer which contained 1 mM NAD+. This buffer was made in
advance and stored over a number of weeks at 4°C (Dr Ragen Pfieffer, personal
communication). When planning to establish an assay that was to be validated to
GLP-like standards and produce data that could be used for regulatory purposes there
were concerns about the stability ofNAD+ in this solution. To be able to measure
maximal PARP-1 activity the reaction solution must contain NAD+ at a concentration
which is at or near the Km for the enzyme. The protocol was modified to that
described in section 3.6 so that NAD+ was made up fresh on the day of reaction from
frozen anhydrous stocks, the molarity calculated from the optical density and
sufficient added so that the final concentration in the reaction mix was 350 ~M. Use
of a 7 mM NAD+ stock allowed as little as 5 ul to be added to the reaction mix,
giving a greater flexibility on the volumes of cell suspension that could be added,
keeping the final volume at 100 Ill. This was particularly useful if a low cell harvest
was obtained and the permeabilised cell suspension more dilute than anticipated.
The reaction phase of the assay was carried out in a water bath at 26°C. The reaction
solution containing oligonucleotide, NAD+ and reaction buffer was allowed to come
to this temperature to ensure optimal reaction conditions. Permeabilised cells were
held on ice throughout the assay to prevent autolysis. Since the cell suspension
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represents 40% of the reaction mix cells were routinely pre-warmed to 26°C for 7
minutes prior to addition so as not to cool the reaction. There was concern that the
pre-warming might contribute to an increased background chemiluminescence from
pre- formed polymer.
This potential effect was investigated using Ll210 cells. Frozen L1210 cells from the
prepared QC stocks were defrosted, washed and permeabilised. The permeabilised
cells were counted and cell suspension diluted such that 10,000 cells would be added
to the reaction in a volume of 40 ul, Triplicate reaction tubes were set up containing
oligonucleotide, NAD+ and reaction buffer to a total volume of 60 /-ll or isotonic
buffer only as a control. All tubes were warmed to 26°C. One aliquot of
permeabilised cells was held on ice until addition to the reaction volume or isotonic
control, and one portion of cells was pre-warmed for 7 minutes prior to addition to the
reaction to allow temperature equilibration.
The immunoblot was loaded with control cells which had been held on ice throughout
the experiment (TO) and the 4 different experimental preparations, ice cold cells-
blank reaction, ice cold cells - full reaction mix, pre-warmed cells - blank reaction,
pre-warmed cells - full reaction mix. The results are shown in table 5.1. There were
three findings, firstly there was minimal PAR formation due to endogenous ADP-
ribosylation at existing strand breaks when cells were maintained on ice. Secondly
that pre-warming of the cells is essential if a true measure of maximal PARP-1
activity is required. There was a 25% reduction in the maximally stimulated value
when pre-warming was omitted. Finally the pre-warming step did not increase the
endogenous PAR per se (pre-warm isotonic control).
Table 5.1
Cells Reaction mixture Densitometry (LAV/mmz) per
10,000 cells
Ice cold TO 156±131 !
IIce cold Isotonic only 353±485
I
.Ice cold Full reaction mix 11..J.61±990
I
Pre-warm Isotonic only 84±137 I
Pre-warm Full reaction mix
i
15161±561
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The result found in this experiment was confirmed by Dr Chris Jones using both
freshly grown and frozen stocks ofL1210 cells, no difference being observed between
the fresh or frozen samples. Therefore, in frozen samples too, pre-warming does not
have a major impact on the endogenous PAR formation. Pre-warming of cell
suspensions is essential as loading of ice cold cells results in a 25-40% reduction in
PAR formation compared to pre-warmed cells.
The results of all the experiments described in this section were all taken into account
during the evolution of the final validated standard operating procedure for the
immunoblot PARP activity assay.
5.5 Immunoblotting for tumour/tissue samples
In part 2 of the trial tumour biopsies will be taken before and after AGO 14699
administration not only to determine PARP inhibition of the target tissue but also to
determine any correlation with PARP inhibition in PBLs from the same patient. Any
pharmacodynamic assay therefore needs to be feasible using both experimental
matrices, PBLs and homogenised tissue.
Studies were undertaken to investigate whether the immunoblot technique could be
used to detect PAR formed by a tumour/tissue homogenate, and to establish the
dilution of the homogenate required so that the chemiluminescence detected would lie
within the standard curve.
The experimental protocol was used as described in section 3.8. 50 ul of homogenate
were added to 5 ~l 7 mM NAD+ and 45 ul reaction buffer in all experiments.
Oligonucleotide was not necessary in the reaction as explained above (section 4.5.1 ).
The principle of the assay is the same as for the determination of PARP activity in
permeabilised cells in that it measures the amount of polymer formed in a fixed period
by the PARP enzyme in the homogenate in the presence of added substrate (NAO+).
The reaction is stopped with excess AGO 14699 and the product detected as described
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in section 5.2. Pre-existing polymer, formed in response to DNA damage in the
presence of endogenous NAD+, is corrected for by the subtraction of the measured
chemiluminescence from an identical volume of un-reacted homogenate (TO). The
data is expressed in terms ofpmol monomers ofADP-ribose detected in polymer per
mg protein added to the reaction.
All experiments undertaken to establish and investigate the use of the immunoblot
with homogenised tissue were performed using homogenised mouse liver as a
surrogate sample. It was not ethical or possible to get tumour biopsies to perform this
validation work. The established quality control (QC) standards (L1210 cells) will be
run with each assay so that individual test run acceptance criteria can be defined as
well as enabling inter-assay comparison.
Mouse liver was snap frozen in liquid nitrogen and maintained at -80°C until
homogenisation. This mimics the treatment of tumour samples. When thawed prior
to homogenisation the wet weight was determined and the specimen homogenised in
3 volumes of isotonic buffer giving an initial dilution of 1 in 4. This preparation was
serially diluted to obtain 1 in 100, 1 in 1,000 and 1 in 10,000 dilutions. These were
incubated with reaction buffer as described above and blotted. Triplicate samples
were loaded, including triplicate TO (unreacted homogenate) from each dilution. As
can be seen in table 5.2, there was a high background chemiluminescence signal
measured in the TO samples as expected. This is due to endogenous polymer
formation due to DNA damage induced by the homogenisation procedure. This
background signal could be kept to a minimum by ensuring that, except during the
pre-warm phase and reaction phase of the assay all tissue homogenate was kept on ice
to prevent enzyme activity (personal observation, data not shown).
Subtraction of the TO endogenous staining gives a clearer picture of the amount of
additional polymer that can be made by the enzyme in the presence ofNAD+ at the
dilutions investigated (column 3, table 5.2). There did not appear to be a linear
relationship between the dilution of homogenate and chemiluminescence signal over
this range of dilutions, suggesting that there may be saturation of the signal at higher
concentrations.
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Table 5.2
Homogenate Densitometry (LA /mm' xI0 5)
dilution Endogenous PAR Total PAR PAR formed
during reaction
I
1:100 10.22 18.18 7.96 I
1:1, 000 3.22 6.53 3.31
1:10,000 0.15 0.32 0.17
To establish the optimum dilution of homogenate, such that PAR forma tion fell
within the range of the standard curve, serial dilutions of frozen mouse liver
homogenate were reacted as described abo ve and the standard PAR polymer curve
loaded onto the blot. 1 in 100 , 1 in 1,000 and 1 in 2,000 dilu tions were et up. The
mean PAR formed (after subtraction of background) was measured and i shov n
below (figure 5.12)
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Figure 5.12 Mean + SEM of triplicate readings of serially diluted homogenised Ii er.
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liver (1230 pmol NAD+/mg protein cf 39.0 pmol NAD+/mg protein), this was also
observed with xenografts analysed with the immunoblot (Chris Jones, personal
communication). Preliminary results from the TemoCOMET study (data in table 5.-+.
trial discussed in chapter 6) had suggested the measured PARP-l activity was
significantly higher in human tumour samples than in normal tissue when compared
on a per mg protein loaded basis. It was therefore felt safer to opt for a higher
dilution rather than to risk all baseline samples being without the range of the standard
curve.
Table 5.3
Preparation Mean PAR ± SEM (pmol)
Mouse liver 1 in 100 8.37 ± 0.59
Mouse liver 1 in 1000 0.3 ± 0.04
Mouse liver 1 in 2000 0.16 ± 0.02
Table 5.4
Summarised results from individual tumours/livers analysed by the different PARP-I assays.
n=number livers/tumours studied, each measured in triplicate.
Liver Tumour
Mean±SD Mean±SD
Radiolabel assay (pmol NAD+/mg 39 ± 9 (n=9) 1229 ± 26 (n=3)
protein)
Immunoblot (pmol PARlmg protein) 26 ± N/A (n=l) 828 ± 599 (n=9)
. .
Previous experiments using the [32p] NAD+ incorporation PARP activity assay had
established that PARP-l enzyme activity within tissue cells was stable with frozen
storage, and also that PARP inhibition was maintained with storage (see sections -+.5.3
and 4.5.2). It was felt unnecessary to repeat these studies with the immunoblot assay.
As part of the parallel laboratory studies, which are being performed along side the
PARP inhibitor clinical study, nude mice bearing SW620 human colon cancer
xenografts were treated with a single intra-peritoneal injection of AG014699 and
sacrificed at various times after doses. Groups of 3 mice were treated. Xenograft
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homogenates from these mice were diluted to 1 in 1000 or 1 in 2000 and an
immunoblot performed as per the protocol. It was clearly possible to measure the
degree ofPARP inhibition in these samples, which varied with dose (figure 5.13).
These data are generously supplied by Dr Chris Jones.
Figure 5.13
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Figure 5.13 PARP activity expressed as a % that measured in matched controls in SW620 xenografts
treated with AG014699. Mean + SEM of three tumours, each measured in triplicate
Having established that the immunoblot could be used as a PARP-1 activity assay in
both human PBLs and tissue samples further experiments were undertaken to
elucidate the nature of the antibody binding. These are described below.
5.6 Investigation of the nature of 10H antibody binding/chemiluminescence
detection
10H is a monoclonal antibody which is reported to bind to poly(ADP-ribose) polymer
15-20 ADP-ribose monomers in length. The published characterisation of the
antibody has been discussed in section 5.1. The objective whilst developing this
assay has been to accurately and reliably obtain a measure of PARP-1 activity in the
presence or absence of inhibitor. The measure of activity is quantified by allowing the
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enzyme to synthesise polymer in a maximally stimulated state for a defined period of
time.
There will be some polymer present in cells, particularly if there is any DNA damage
(either due to cytotoxic drug or cell handling procedures). The TO samples loaded in
triplicate for each cell suspension allow for any antibody binding and detection of this
background polymer to be excluded from the quantitative assay results.
The contribution of non-specific binding of the either the primary or secondary
antibody to the membrane or the some component within the cells loaded to the
chemiluminescence detected was investigated. Any non-specific binding will be a
possible cause of inaccuracy in quantification of unknowns. The potential
contribution of the secondary antibody to this was investigated by setting up two
identical blots by loading L12l0 cells which had been inhibited with AG014699 and a
standard curve. One blot was incubated in primary antibody over 48 hours whilst the
other was stored in PBS. The blots were then returned to the same container for the
secondary antibody incubation and washes. After staining with EeL there was no
detectable pattern of staining coinciding with the location of the manifold on the
secondary only blot.
By carefully lining up the marked areas of the identical blots it was possible to
compare the digitally measured chemiluminescence from 5 wells on the intact blot
where the signal was strongest (those loaded with L12l0 cells) with the same areas on
the secondary only blot. Despite being certain that these would be areas where there
were cells present, indicated by the dense chemiluminescence on the complete blot,
there was very little detection from the secondary-only blot. It was calculated that for
these wells any contribution to the densitometry reading over and above background
from non-specific signal due to secondary antibody was 0.18± 0.03% (mean ± SD,
n=5) .
The signal detected from background areas (areas not loaded with cells) was very
similar for both blots described above and represents luminescent pixels detected
from the nitrocellulose membrane. The low background densitometry suggests that
non-specific binding of either antibody to the nitrocellulose membrane is low. To
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correct for any such binding the mean of three background areas is automatically
subtracted from all densitometry readings. With the evolution in assay methodology
during the validation process and despite the introduction of the more sensitive Fuji
LAS 3000 this background detected remains a small contribution to the overall
densitometry. When the mean background figure for 12 successive experiments was
compared to the chemiluminescence detected from 12.5 pmol PAR the background
contribution to the chemiluminescence was in the order of 6%.
The nature of the TO background signal, i.e. endogenous polymer, was examined by
adding a known number (100,000) ofpermeabilised cells to each standard. Antibody
binding to a known amount of polymer was compared in the presence or absence of
these cells. The chemiluminescence measured in the spiked standards was higher
than that from the control standards but the correlation between chemiluminescence
and concentration of PAR was unchanged (table 5.5, r2=0.95 and 0.96, non-linear
regression one site binding). This suggested that the primary/secondary antibody
complex detected by EeL in the cells was binding to a consistent feature in those cells
which was the same antibody interaction as the known standard, i.e. the polymer.
Table 5.5
LAD xlO5
[PAR] standard Standard alone Standard + cells Cells alone
(pmol)
1.5 0.03 0.7 0.7
3.125 0.1 1.2 1.2
6.25 0.3 1.7 1.4
12.5 0.6 1.8 1.3
25 0.9 2.6 1.7
50 0.9 2.4 1.5
The specific background binding of the primary antibody to any existing polymer
(endogenous, i.e. TO samples) was further investigated by exposing permeabilised
fresh L1210 cells to purified PARG enzyme (2 mll/ul) in the presence and absence of
excess PARP inhibitor. Purified PARG was obtained from BIOMOL research
laboratories Inc (catalogue N° SE-179, Lot ~ P6321). 2.5 JlM AGO 1..+699 or an
135
equivalent 0.25% DMSO alone as control was added to aliquots of 100,000
permeabilised LI2l0 cells on ice (final total volume 400 Ill). The addition of
AGO14699 was to prevent further polymer formation during the exposure to PARG.
The permeabilised cells were warmed to 37°C and 6 mD PARG added. 1 D PARG is
defined as the amount of enzyme which will produce 1 nmol ADP-ribose per minute
of reaction at 37°C in a solution of 10 11M [32p] PAR. No oligonucleotide was added.
After incubation for 5, 10 or 30 minutes the cells were placed back on ice and blotted.
The cells where PARP-I had been inhibited prior to warming to a temperature at
which mammalian enzymes are functional gave a very low signal for polymer. This
low signal was further reduced by approximately 30% after incubation with purified
PARG, providing evidence that species bound by lOR is degraded by PARG and
therefore likely to be PARP. It proved much more difficult to significantly reduce the
much higher signal in non-inhibited control cells with the commercial PARG
preparations available.
5.7 Evaluation of PARP knockout cells or animal tissue using immunoblot
The gene coding for PARP-I has been successfully inactivated in mice and PARP-l-/-
BalbC mice are readily available. In addition there are established cells lines from
these mice which can be studied in vitro. This provides a further mechanism for
investigating the nature of the chemiluminescence staining detected using the
immunoblot. The other members of the PARP enzyme family are intact in the PARP-
1 knockout animals/cells, so poly(ADP-ribose) can be formed in response to the
correct stimulus. PARP-2 is the only other PARP enzyme in the cells known to be
activated by DNA damage, however PARP-2 activity is not stimulated by blunt ended
oligonucleotide, the activator in the permeabilised cell assay (de Murcia, personal
communication).
In the first series of experiments PARP-l-/- cultured mouse fibroblasts were grown in
Eagles medium and harvested at a cell density of 8 x 106/ml, L1210 cells were used
as a positive control as there were no available stocks of PARP-l +/+ cells. The cells
were harvested, washed and permeabilised with 0.15 mg/ml digitonin as described
before. Triplicate samples were set up including + oligo (oligo, reaction buffer,
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NAD+) - oligo (NAD+, reaction buffer and PBS control) and inhibited (~AD~, oligo,
reaction buffer, with AG014699 stop solution added prior to permeabilised cells).
Following cell warming and the 6 minute reaction period blots were loaded including
a PAR standard curve, TO samples in triplicate (permeabilised cell suspension only,
pre-warmed then replaced on ice) and each reaction tube. 100,000 cells were loaded
per replicate; larger numbers were used because of the expected low levels of polymer
formation by the PARP-1-/- cells. It was accepted that 100,000 L1210 cells would
take the chemiluminescence out of the range of the standard curve, however the
known linear relationship between cell number and chemiluminescence at this number
of cells meant a valid measure of polymer formation could be made and enabled
comparison of like numbers of cells for the positive and negative groups.
The data from the PARP-1-/- and L1210 cells are shown in table 5.6. Mean and
standard error of triplicate samples are given. It can be seen that the levels of
chemiluminescence detected from PARP-1-/-cells were very low when compared to
similar data from the positive controls. There was some background (TO) endogenous
polymer present, it would appear that there was some increase in the polymer present
when the cells were warmed to 26°C for the reaction, the differences between the
+oligo, - oligo and inhibited columns were not statistically significantly different from
one another (p=0.09, one way ANOYA). Polymer in these cells would largely be
formed by PARP-2, which is not stimulated by blunt ended oligonucleotide. In this
experiment the amount of polymer formed by 100,000 PARP-1-/- cells in the
presence of oligonucleotide was 2.5 ± 1.2 pmol; in the absence of oligonucleotide it
was 1.2 ± 0.5 pmo1l100,000 cells with a similar amount being made in those cells
where the PARP-1 inhibitor was added to the reaction mix prior to the addition of the
cells (1.7 pmo1l100,000 cells). This compared to an average polymer formation of
22.0 pmol by 5000 L1210 positive control cells (440 pmoVIOO,OOO Ll210 cells) in
the presence of oligonucleotide, indicating <1% of the measured polymer formation
was due to PARP-2 activity.
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Table 5.6
LAU/mm2/IOO,OOO cells
Ll210
I
PARP-/-
I
TO 50697 1941
+oligo (-TO) 146719 ± 53122 3964 ± 1426
- oligo (-TO) 73218 ± 99499
i
1539 ± 627 i
I
+699 (-TO) -5228 ± 18313 1889 ± 1176 l
These preliminary experiments suggested that the polymer detected using the
immunoblot was largely formed by PARP-1 when stimulated by oligonucleotide.
Studies using the PARP-1-/- knockout model were extended to include a comparison
of PARP-l activity in mouse PBLs and homogenised liver from matched groups of
PARP-l-/- mice and PARP-l+/+ mice treated with saline vehicle or AG014699.
These experiments were performed as part of the validation process for the
immunoblot PARP activity assay in homogenised tissue, and also to establish whether
PARP activity and inhibition could be measured in mouse PBLs after
lymphopreparation.
PARP-l-/- and PARP-l +/+ male and female mice were obtained from Gilbert de
Murcia and housed under standard conditions. Groups of three PARP-1-/- male and
female mice were sacrificed by cervical dislocation, then immediately exsanguinated
by cardiac puncture. A total of 4-5 ml of whole blood was obtained from the group,
pooled and then diluted 1 to 1 with PBS and lymphopreped using the method
described for human blood in chapter 3. The PBLs were frozen in medium + 10%
DMSO as described in the method. Groups of three PARP-1+/+ male and female
mice were treated with a single intra-peritoneal injection of AGO 14699 dissolved in
sterile water (or vehicle control) 30 minutes prior to sacrifice. Blood was obtained
and prepared as described above. Murine PBLs are smaller than human PBLs, and
mouse-specific lymphoprep is available. However, for reasons of expediency and
consistency the human lymphoprep was used to prepare the mouse cells. The
difference in density between the two lymphopreparations is small, and adequate cell
harvests were made with the human preparation.
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oFrom one animal in each group the liver was removed and snap frozen for later
homogenisation and assay.
The results from the mouse PBLs for all groups is shown in figure 5.14, all values are
expressed in terms of pmol PAR formed by 106 cells in the 6 minute reaction time.
Mean and SEM of triplicate readings are given. It can be seen that in the control
PBLs from PARP-1-/- mice there was again little polymer formation when stimulated
with blunt ended oligonucleotide. The measured polymer formation appeared higher
in the male animals when compared to the females in all treatment groups. This
observation is, however, based on a small sample size and did not reach statistical
significance. There was no evidence of a variation of PARP activity in human PBLs
with gender. Inhibition of PARP-1 with AGO 14699 was demonstrated, being more
profound in male compared to female animals at both doses of AG014699.
Figure 5.14
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Figure 5.14 Polymer formation in mouse PBLs in PARP -/- animals and PARP +/+ animals treated
with AG014699. Mean and SEM of triplicate samples expressed as per million cells
Frozen livers were defrosted, weighed and homogenised as described in section 3.7.
An initial dilution of 1 in 1000 was made with isotonic buffer. However the PARP
activity in the inhibited livers was undetectable with this standard dilution. The
samples were re-assayed using a 1 in 100 and 1 in 50 but once again PARP activity
was undetectable. The results from the standard I in 1000 dilution are shown in
figure 5.15.
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Figure 5.15 Mean and SEM of triplicate reading from homogenised liver from PARP -/- and PARP
+/+ animals (+/- 699)
Data are expressed in terms of pmol PAR formed in the reaction period per mg
protein in the homogenate. Polymer formation was detectable in the homogenised
liver from PARP-1-/- animals using the immunoblot assay. This value represents
polymer formation during the reaction period as background TO (endogenous
polymer) chemiluminescence was subtracted in the usual manner. Homogenisation
introduces multiple DNA strand breaks, both single and double; during the reaction
period PARP-2 will be active in the presence of substrate (NAD+) and an activation
stimulus. This explains why in these knock out animals there was more polymer
formation in the homogenised liver than was detectable in permeabilised PBLs where
the stimulus to PARP activity is exogenous blunt ended double stranded
oligonucleotide. The amount of polymer formed during the reaction period (3.0
pmol/mg protein) was similar to that detectable in the unreacted homogenate (6.0
pmol/mg protein) which had been held on ice during preparation, warmed to 26°C for
7 minutes, and then replaced on ice. It is accepted that the warming period will allow
polymer formation using endogenous NAD+, hence the exclusion of this polymer by
the subtraction of the TO samples. In the case of the PARP-1-/- liver homogenate, the
amount polymer formed during the reaction period is low and the background
polymer detected similar, indicating that low PARP activity overall is seen in these
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cells compared to PARP-1 +/+ animals where the background polymer formation was
7.3 pmol/mg protein and that formed in the presence of added NAD- was 26.3
pmol/mg protein. All these observations are preliminary because of the small number
of animals studied.
It was unexpected that the degree of PARP inhibition in liver would be so great in the
animals treated with AGO14699 at 1 mg/kg and 10 mg/kg. Previous experiments
studying the degree of inhibition in human tumour xenografts in these animals had not
showed such dramatic inhibition at this time point. This marked inhibition, greater
than that observed in the PBLs could be due to first pass metabolism of the
AG014699. The drug was given as an intra-peritoneal injection; the liver will
therefore be the first organ to be exposed to inhibitor and would be expected to have
the most marked PARP-1 inhibition. It may also reflect the observed lower PARP
activity in normal liver compared to tumour xenografts. This observation is given
support by the finding that normal human liver biopsies have lower poly(ADP-
ribosylation) capacity than biopsies from hepatocellular carcinomas (Shiobara,
Miyazaki et al. 2001).
5.8 Discussion
The results presented in this chapter describe the development and subsequent
validation of an immunoblot PARP activity assay for use with human samples, both
PBLs and homogenised tumour. The established and validated radiolabel PARP
activity assay was initially considered for use in the PARP clinical study, however
there were problems with this assay which have been discussed in chapter 4 (section
4.7). It was because of these problems that a robust assay using fewer PBLs was
sought. The issues pertaining to validation of a pharmacodynamic biological assay
were also examined in section 4.7. During development of this new assay an attempt
has been made to address the principles to be used for establishing a valid method
defined in the 1990 AAPS International Workshop report (Shah, Midha et al. 1992);
see discussion of chapter 4. The way each of these principles has been addressed is
discussed below.
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a) Detailed Standard Operating Procedures have been produced for all
procedures.
b) The nature and degree of non-specific antibody binding, both of the primary
and secondary antibodies has been investigated. Levels of this are low, and have been
excluded from the calculation of polymer formed by the subtraction of background
chemiluminescence before generation of the standard curve and reading of results.
The major difference between this and the e2p] NAD+ incorporation PARP activity
assay is that the primary antibody (1OR) will bind to any polymer present, whether
formed during the reaction period, during cell preparation or prior to blotting on the
membrane. Attempts have been made to reduce this endogenous background by
maintaining all cells on ice except during the warming and reaction phases, and
changing the permeabilisation technique to minimise cell handling. The loading of
identical numbers of unreacted cells allows exclusion of any endogenous polymer
from the analysis of enzyme activity thus reducing the influence of these variables.
Without these TO samples there would be much greater for potential variation
between samples, in particular when considering PBLs. The lymphopreparation
method introduces some DNA damage, the fact that during the clinical trial this will
be done at three centres, by different personnel and with potential variation in the time
whole blood is held on ice before processing would mean that the scope for variation
in endogenous polymer would be very high and it is important to exclude this.
c) The pharmacodynamic effect which is measured by the immunoblot PARP
activity assay is the number ofpmol polymer formed during the 6 minute reaction
period over background endogenous polymer. The assay, therefore, directly measures
the product of PARP activity and is specific for PARP-l alone (PBLs stimulated with
oligonucleotide) or with a minor contribution form PARP-2 (homogenates). The
activity of the drug which the assay has been designed to assess is inhibition of the
PARP-l enzyme and thus a reduction in the ability to form polymer.
The nature of lOR binding is well established in the literature. Attempts have been
made to examine this further in the immunoblot assay by the addition of additional
PARG to alter the balance between polymer formation and breakdown, and also by
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the use of PARP knockout animals and cells. It would appear that the primary
antibody binds to purified polymer in a reproducible way, and that it binds to the
reaction product formed when permeabilised cells are incubated with a powerful
PARP-1 activator (oligonucleotide) and the PARP enzyme substrate (NADj. It is
therefore concluded that the major ligand-receptor binding species detected with
chemiluminescence is poly(ADP-ribose) bound to 10H antibody. This conclusion is
supported by the work of Affar et al (Affar, Duriez et a1. 1998) who demonstrated the
detection of purified poly(ADR) using a similar immunoblot using both 10H and a
polyclonal antibody against PAR, L896-1 O.
e) One issue for concern with the immunoblot assay is the degree of variation
between assays. There was reasonable reproducibility with replicate samples
performed on the same day within the same assay, and between standard curves but
considerable variation could be seen between different assay runs studying activity in
similar cell samples (for example QC cells). This highlights again the difficulty of
standardising a biological assay, Miller et al (Miller, Bowsher et a1. 2001) state that
"detection of a macromolecular analyte generally occurs in a complex biological
milieu ....methods tend to have poorer batch-to-batch reproducibility. During analysis
of clinical trial samples attempts have been made to reduce factors which typically
affect reproducibility (listed in Huber 1998), by defining a detailed SOP with
consumable sources prescribed, one operator for all samples and use of a water bath
to avoid room temperature variation. It is impossible to exclude all external variables,
different personnel who prepare the blood samples, transport of these samples may
take varying times and inter-patient variability is an unknown quantity at any given
dose of the PARP inhibitor. It is recognised that inter-assay variation is the greatest
source of imprecision in immunoassays (Findlay, Smith et a1. 2000). The AAPS
Bioanalytical Methods validation workshop reached a consensus opinion that minimal
acceptance limits for ligand-binding assays should be set at 30% for accuracy (mean
bias) and precision with greater limits being permissible if agreed upon by the end
users of the data.
f) A standard polymer curve has been established which is reproducible and
allows quantification of the results in terms of pmol polymer formed. The validation
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of the assay has been audited by Cancer Research UK and by Pfizer GRD and found
to be suitable for regulatory purposes and to be performed to GLP-like standards.
The established QC cell line (L1210) has been validated for use in this assay, the
more sensitive nature of the assessment means far fewer cells need to be blotted, only
5,000-10,000 cells being required to produce polymer within the limits of the standard
curve. PARP-1 activity in tissue homogenates again can be measured with the assay,
a 1 in 1000 dilution of the homogenate being required rather than 1 in 40 for the
radiolabel PARP activity assay.
Choice and definition of the reference standard are known to have a large impact on
the integrity of bioanalytical data (Miller, Bowsher et al. 2001) and it is suggested that
the reference sample be procured from a certified reference standard or commercial
supplier. The standard curve should contain 5 to 8 points, excluding blanks, with
single or replicate samples and covering the entire range of expected concentrations
(Shah, Midha et al. 1992; 2001). The mathematical model used to describe the
standard curve should be that which best describes the fit, rather than enforcing a
linear model. It is recognised that the concentration-response curve for a typical
ligand-binding assay is seldom linear throughout its range, but more frequently
hyperbolic (Findlay, Smith et al. 2000; Miller, Bowsher et al. 2001). In the
immunoblot assay the standard curve is of the appropriate number of points, it is
reproducible between assays (see figure 5.9). The number ofL1210 QC cells and
human PBLs which should be applied to give PAR formation within the standard
curve has been defined. When samples fall outside these limits the blot will be
repeated with an appropriate number of cells.
In conclusion an immunoblot method for the detection and quantification of,
poly(ADP-ribose) has been developed and validated. An appropriate standard curve
has been identified, QC samples established and the working range of the assay
defined.
Having established this pharmacodynamic assay potentially suitable for use with
clinical samples whilst the PARP inhibitor clinical protocol was still under
development it was felt that it would be valuable to be able to confirm the assay
1-l-l
validation using some clinical samples. At an early stage of the PARP inhibitor trial
protocol development the possibility of running a short pilot study prior to the main
trial protocol was discussed with the PARP development team. It was felt that such a
trial would be valuable for a number of reasons, and a phase II protocol using full
dose temozolomide alone in patients with metastatic malignant melanoma was
submitted to the Local Research Ethics Committees of the three centres who would be
participating in the main clinical study. Eligible patients would agree additional
blood tests on the first cycle for analysis of PARP activity and DNA damage and to
two tumour biopsies under local anaesthetic. It was hoped that the trial would address
the following points:-
1 It would allow the confirmation of PARP activity assay validation with
analogous clinical samples
2 It would give comparative data on DNA damage after temozolomide with
and without a PARP inhibitor
3 It would allow the three centres to work together before committing to a
clinical trial with complex pharmacokinetic and pharmacodynamic
sampling schedules.
This phase II preliminary study was conducted in 12 patients with malignant
melanoma, the further rationale for this trial and the results are discussed in chapter 6.
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Chapter 6
Clinical and Laboratory results for a Phase II mechanistic
study of temozolomide in advanced malignant melanoma
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6.1 Introduction
During the protocol development and preclinical evaluation of the PARP inhibitor
clinical candidate, AG014699, it was felt that a clinical study evaluating both D~A
damage and PARP activity after a standard dose of temozolomide in patients would
provide valuable information which could be used to interpret the results of the First-
in-Human PARP inhibitor study. The effect oftemozolomide alone on the two
pharmacodynamic endpoints defined for the trial had not been determined and a phase
II study was designed to address these issues.
The mechanism of action of temozolomide has been discussed in chapter 1 of this
thesis. It is an orally available mono-functional DNA alkylating agent which is used
to treat gliomas and malignant melanoma. Temozolomide is rapidly absorbed and
undergoes spontaneous breakdown in the plasma to form the active species MTIC
(monomethyl triazene 5-(3-methyl-l-triazeno) imidazole-4-carboxamide). This forms
a number of DNA methylation products including 06-methylguanine, N7_
methylguanine and N3-methyladenine. There is evidence that the cytotoxic lesion is
0 6-methylguanine (Stevens, Hichman et al. 1987) which is repaired by ATase
(Margison, Koref et al. 2002); N7-methylguanine and N3-methyladenine lesions
rapidly being repaired by BER (as discussed in chapter 1). It is thought that the
potentiation of temozolomide cytotoxicity observed in preclinical work with potent
PARP-I inhibitors is largely due to the inhibition of BER increasing the level of
cytotoxicity due to incomplete processing ofN7-methylguanine and N3-methyladenine
lesions.
The First-in-Human study of a PARP inhibitor will be in combination with
temozolomide and a primary endpoint of the study includes the demonstration of
inhibition of PARP-l in human PBLs and tumour samples. It is not known what the
effect of dosing with temozolomide alone or indeed any cytotoxic agent has on basal
cell PARP activity. This enzyme is widely expressed throughout human tissues. It
would not be expected that chemotherapy-induced DNA damage would significantly
alter the PBL's ability to form poly(ADP-ribose) but there was no data from human
studies in the literature available. A secondary PD endpoint of the First-in-Human
study is the measurement of DNA strand breaks. It was also felt useful to evaluate the
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DNA damage caused by temozolomide in human PBLs as a surrogate tissue , but also
in tumour samples if pos sible . It was planned that this work would be carried in The
Cancer Research Laboratories in Oxford under the supervision of Dr Mark Middleton.
To address these issues a small phase II study in pat ients with metastatic malignant
melanoma was designed and submitted to the Local Research Ethics Committees at
the same three clinical centres cooperating during the First-in-Human PARP inhibitor
trial. The study was entitled "Temozolomide induced DNA damage in Advanced
Malignant Melanoma: A phase II study". The study was approved by the local ethics
committees and accrual began in June 2002.
Malignant melanoma is becoming increasingly more common as seen in figure 6.1.
The disease is more common in women than in men (57% versus 43%), the incidence
rising with age. Despite this it is the third most common cancer diagnosed in those
aged 15-39 (source www.cancerresearchuk.org).
Figure 6.1
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1971-2001
10
...
, .
8
c
.Q
~ 6
::>
a.
o
c.
o
o
o
o
o
Q;
c. 4
OJ
"§
. - .
.. '
, . ,
,
• - - males lnodence
- • • females ecceoce
- male s mortality
- females mortality
o h----r--.---,--.---.,.-,----r-r--,---.--.--.--.--.,....--..---.--r---r----.,.----,---.---.,.-,-..---.,....--=-~~=
1971 1973 1975 1977 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001
year of draqnosrs/c eath
14
It is estimated that 1600 lives a year are lost due to this disease, 1% of all cancer
deaths. The number of deaths and age specific mortality in the UK for 2001 is hewn
in figure 6.2. Survi val and risk of recurrence after primary resection are strongl y
associated with thickness of the tumour at the time of diagn osis. 5 year survival in
prim ary melanomas less than 1.5 mm thick is greater than 90% whereas 5 year
survival in tum ours thicker than 3.5 mm is approximately 45%.
Figure 6.2
Number of deaths and age specific morta lity rates per 100,000 popul ation,
malignant melanoma, by sex , UK, 200 1
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There has been some improvement in the 5 year survival over the last 15 years, this
has been largely due to improved awareness of the disease allowing primary resection
to be curative in a larger number of cases. There is some evidence that high dose
adj uvant interferon following resection of high risk malignant melanoma increas es
progress ion free and overall survival (Kirkwood, Ibrahim et al. 2001) but this therapy
has yet to be widely adopted in the United Kingdom. Treatment options for patient
with advanced metastatic disease are limited, with palliative chemotherapy with
dacarbazine (DTI ) or temo zolomide being the standard therapy, with re pon e rat
in the order of 15-20%.
149
The trial reported in the chapter offers patients treatment with a standard regimen for
malignant melanoma, all the patients were aware that therapy would not be curative
and at best would improve the length and quality of their survival. Patients with
asymptomatic brain metastases were allowed to enter into the study. There is some
evidence that temozolomide will cross the blood brain barrier more effectively than
the parent drug DTIC (Stevens, Hickman et al. 1987). There is, however, no
published clinical data to support this proposal. The phase II study of temozolomide
in malignant melanoma included 4 patients with brain metastases, a partial response
was seem only in one patient who had a small solitary brain lesion (Bleehen,
Newlands et al. 1995), patients with brain metastases were excluded from the phase
III study (Middleton, Grob et al. 2000). It was felt that patients with brain metastases
should not be excluded from this trial if their performance status was adequate to
justify palliative chemotherapy because of this theoretical benefit
Trial coordination, patient recruitment and analysis of PARP activity in both PBLs
and tumour biopsies were undertaken as part of this MD thesis. Analysis of DNA
strand breaks following treatment were performed by Anna Olsen in Oxford, and
changes in 06-alkylguanine-DNA alkyltransferase (ATase) levels analysed by Dr
Geoff Margison in Manchester. Data from these experiments are included for
completeness and to aid discussion of the study results.
6.2 Study Design
6.2.1 Protocol design
The study was a non-randomised trial involving 12 patients with advanced malignant
melanoma who had had no prior therapy for their metastatic tumour. All patients
received temozolomide at a dose of200 rng/mi/day for 5 days of a 28 day cycle.
Response to therapy was assessed every 2 cycles and patients were treated until
progression. Inclusion criteria included age ~18years, histologically proven
advanced metastatic melanoma, assessable disease, and adequate haematological and
biochemical parameters. Patients could have received previous radiotherapy or
adjuvant therapy with biological agents, must use an acceptable method of birth
control and give written informed consent to all study procedures. Patients with
uncontrolled vomiting such as to make treatment with an oral agent impractical or
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those who had received a biological therapy with 4 weeks of starting treatment were
excluded. In addition subjects who were known to be pregnant or breast feeding, or
HIV positive were not entered.
The primary objectives for the study were defined as:-
1 To assess DNA damage (06 and N7 methylation of guanine and single
strand breakage) in tumour biopsies and peripheral blood lymphocytes
after a single 200 mg/rn'' dose of temozolomide
2 To determine PARP activity and ATase activity in these tissues after
dosing
The secondary objectives were stated as:-
To determine tissue DNA repair capacity by observing changes in repair
protein level over time
2 To relate biological measures to clinical outcomes (toxicity and tumour
response)
6.2.2 Sampling schedule and methods
To achieve these objectives patients were consented to undergo a complex schedule of
additional blood tests on days 1 and 2 of the first cycle of treatment only. Patients
were assessed clinically on day 1 of every cycle and attended for weekly full blood
counts and toxicity monitoring throughout the study. In addition, the first 9 patients
treated agreed to two tumour biopsies under local anaesthetic, one prior to starting
treatment and a second biopsy either 4 or 24 hours after the first dose of
temozolomide. Repeat radiological assessment or clinical measurement by the same
method as that performed at baseline was performed every two cycles. All toxicity
was graded according to eTC criteria (version 2.0).
At each major sampling time point (baseline, 4-6 and 24 hours) 55 ml of whole blood
was drawn and divided between the various analysis sets, 5 ml being placed in pre-
chilled heparinized tubes and processed for temozolomide PK, and the rest being
anticoagulated in pre-prepared EDTA vacutainers and processed as described in table
6.1. Patients treated in Newcastle had temozolomide PK samples taken at the three
PD time points only. The six patients treated in Oxford had a more extensive
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temozolomide pharmacokinetic sampling schedule (pre, 30, 60, 120, 240, 360 and
1480 minutes after treatment) and the same PD sampling.
Table 6.1
Sampling time Pre-treatment
I
4-6 hours
I
--
-
24 hours
PARP activity 10 ml whole blood diluted with PBS and lymphopreped as
,
described in section 3.2 II
COMET assay 20 ml whole blood lymphopreped without dilution in PBS,
stored in PBS + 10% DMSO at -80GC
ATase assay 10 ml whole blood lymphopreped without dilution in PBS,
stored as a washed cell pellet at -80GC
DNA 10 ml whole blood frozen at -80GC
concentration
Temozolomide PK Plasma from 5 ml blood acidified in phosphoric acid and stored
at 20GC in pre-weighed containers
Following sample preparation at the clinical sites all temozolomide PK samples and
PBLs for PARP activity were transferred on dry ice to NICR, Newcastle, for
processing. COMET samples were transferred to Oxford and ATase and DNA
concentration samples to Manchester.
Where tumour biopsy specimens were available these were collected from the theatre
into sterile ice cold PBS. The sample was kept on ice and processed for storage as
soon as possible. The specimen was divided into two using a sterile scalpel blade,
and one half wrapped in aluminium foil, labelled and snap frozen in liquid nitrogen
before storing at -80GC for PARP activity analysis. The other half of the sample was
minced using crossed scalpels in a small volume of ice cold medium + 100/0 DMSO +
20% foetal calf serum. The suspension was centrifuged to precipitate larger particles
and the supernatant removed and frozen at -80GC. These samples were transferred to
Oxford for analysis using a COMET assay to assess the number of strand breaks
formed after treatment with temozolomide. Data from these samples was extremely
variable due to the problems with isolating intact tumour cells from the melanoma
tumour biopsy. Once it became clear that it would not be possible to perform this
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assay on these samples the final few patients were recruited to the study without
mandatory biopsies.
6.2.3 Laboratory methods
PBLs and tumour samples for PARP activity analysis were analysed as described in
sections 3.6 and 3.7. Temozolomide plasma concentrations were measured using a
published High Performance Liquid Chromatography method (HPLC) (Shen,
Decosterd et al. 1995). The pharmacokinetics of the drug have been characterised by
non-compartmental analysis with the calculation of the area under the plasma
concentration time curve (AVC).
6.2.2.1 Sample analysis performed outside NICR
The assays for DNA concentration, DNA methylation and COMET analysis were
performed by co-investigators on the clinical trial. Brief summaries of the methods
are given below although the practical work for these assays was outside the scope of
this thesis.
COMET analysis
The COMET assay is an established method for measuring DNA damage within
individual cells (Olive, Chan et al. 1988). Single cells are suspended in a thin layer of
agarose, lysed and an electrical current applied across the slide. Alkaline conditions
in the assay allow separation of the DNA strands so single strand breaks can be
estimated. Negatively charged DNA is drawn towards the anode by electrophoresis,
the distance moved being proportional to the size of the fragment of DNA.
Fragmentation of the DNA due to strand breaks therefore results in greater migration
in a given time and the "comet" or "tail" is formed ahead of the embedded nucleus.
The amount of DNA damage can be expressed either in terms of Olive Moment, the
product of tail length and the proportion of total DNA in the tail, or simply as % tail
DNA (Fairburn, Olive et al. 1995).
The method used was a modification of that described by Olive et al (Olive, Chan et
al. 1988) with assay conditions optimised for measuring substantial DNA damage
after chemotherapy. Stored PBMCs/tumour suspensions were thawed, diluted 1:4 in
phosphate buffered saline (PBS), and mixed with an equal volume of 20/0 low melting
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point agarose at 40°C. One ml of the suspension was layered onto polylysine coated
slides (BDH Laboratory supplies; Poole, U.K.), lowered into lysis buffer (0.3~1
NaOH/ 1M NaCl/ 0.1% N-lauroylsarcosine, pH 11.5) and left in the dark for one hour
to lyse cells and remove most of the proteins. Salt was removed with 2 x 30 minute
washes in 0.3M NaOH/ 2mM EDTA. This wash time provides 1 hour DNA
unwinding time which has been shown to be important in the detection of DNA
damage. The slides were electrophoresed at 40 rnA for 25 minutes in the lysis buffer
at pH 11.5 and the DNA was stained with 1% propidium iodide and examined under a
confocal microscope (MRC 600, excitation wavelength 480 nm, magnification x 100).
The area and mean pixel intensity of the head and the tail of the comets were
measured to determine the percentage DNA in the tail for each individual cell. In each
patient sample a total of 50 cells, from 2 slides, were measured and the mean DNA
damage determined from all the cells examined.
DNA methylation (06methyl guanine)
The method used has been previously published (Middleton, Lee et al. 2000). Briefly
DNA was isolated from whole blood using a modified phenol extraction method.
DNA concentration was estimated as below. Various quantities of DNA, made up to a
standard final concentration with calf thymus DNA, were incubated with recombinant
human ATase under substrate limiting conditions at 37°C for 1 hour before the
addition of an excess of eH]methylated DNA substrate and further incubation for 30
minutes. The radioactivity transferred to protein was plotted against sample DNA
concentration and the concentration required to halve the radioactivity transferred
determined. This was compared with the corresponding value with a standard DNA
preparation to determine the sample 0 6-methylguanine content, which was expressed
as finole/mole deoxyguanosine.
ATase measurement
The method involved measuring eH]methyl group transfer to ATase protein from
eH]methylated DNA substrate under protein limiting conditions (Lee, Thatcher et al.
1991). The substrate provided was diluted to a concentration of 100 ug/ml and 100 ml
incubated at 37°C for 30 minutes with varying amounts (up to 200 ul) of tissue
extract. At least three different volumes were used for each extract. In each case, the
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total volume was made up to 300 ul with bovine serum albumin (BSA) 1 mg/ml in
buffer 1. After incubation 100 ul BSA 10 mg/ml in were added with perchloric acid
(100 ul of 4 M acid and 2 ml of 1 M). The mixture was incubated at 75°C for 50
minutes to hydrolyse the DNA substrate. Protein was recovered by centrifugation at
2100g for 10 minutes at room temperature. The resulting pellet was resuspended in -+
ml 1M perchloric acid and centrifuged at 21OOg for a further 10 minutes at room
temperature. The second pellet was resuspended in 300 ml NaOH 10 mM and 3 ml
Ecoscint scintillation fluid added (Mensura Tech) before thorough mixing. Samples
were counted over 5 minutes each on a Rackbeta (LKB) scintillation counter. Counts
per minute were plotted against the volume of extract used and specific activity
calculated from a minimum of three points on the linear part of the curve. Activity
was expressed as fmoles eH]methyl transferred to protein per ug DNA in the extract.
DNA concentration measurement
The quantitative fluorescent DNA stain Hoechst 33258 was prepared as follows: 1 ml
Hoechst 33258 (bisbenzamide; Sigma, UK) 1 mg/ml diluted 1 in 100 in double
distilled water and added to 1 ml lOx TNE buffer (100 mM Tris, 10 mM EDTA, 2
mM NaCl, pH 7.4) and 9 ml double distilled water. The DNA content was measured
by adding 2 III of extract to 2ml of dye solution and measuring the fluorescence in a
TKO 100 mini-fluorometer, which was calibrated using a calf thymus DNA standard
with each use. Measurements were taken in duplicate for each sample, with the
machine reading giving an estimate of DNA concentration in ug/ml.
6.3 Patient demographics and clinical data
6.3.1 Patient demographics
12 patients with advanced metastatic malignant melanoma were recruited. 5 female
and 7 male patients were treated with temozolomide. The mean age of the patients
was 57, and the predominant site of metastatic disease was in the liver. All patients
had undergone previous surgical excision of their primary tumour and had
subsequently developed metastatic disease. The median time to development of
metastatic disease was 24 months. However, excluding the one patient whose disease
recurred more than 13 years after the primary was excised, the mean time to
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development of metastatic disease is much shorter, 10.8 months, range 1-44. These
data are summarized in table 6.2. The performance status of all patients was good on
entry into the study.
Table 6.2 Patient demographics
Number %
Mean age (range) 57 (39-82) -
Male/female 7/5 -
WHO Performance status at entry (0/1/2) 4/6/0 (2 not -
stated)
Site of metastatic disease Liver 8 67
Lung 5 42
Bone 1 8
Skin/lymph nodes 6 50
Brain 2 17
Four patients had received adjuvant biological therapy and one patient adjuvant
radiotherapy to the axilla, this is documented in table 6.3. 2 patients had received
radiotherapy in the palliative setting, one to whole brain following resection of an
isolated brain metastasis and one to a painful bone lesion. All patients were
chemotherapy naive.
Table 6.3 Previous therapy
N° of patients
Adjuvant high dose interferon 4
Adjuvant radiotherapy 1
Palliative radiotherapy 2
No previous therapy 6
Although this is a small study this patient group would appear representative of
patients who accept palliative chemotherapy for metastatic malignant melanoma.
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6.3.2 Treatment and toxicity summary
All patients completed their first cycle of treatment, allowing collection of all the
planned pharmacokinetic and pharmacodynamic blood samples. Two patients were
withdrawn after one cycle of treatment with early progressive disease, in previously
resected brain metastases and liver metastases respectively, one patient withdrew after
the first cycle because he could not tolerate oral medication but not due to nausea. 9
patients received at least 2 cycles of treatment and had objective response assessment.
The number of cycles given is summarised in table 6.4.
Table 6.4
Number of Cycles 1 2 4 6 >6
Number of 3 5 2 0 2
patients
The treatment was well tolerated with no incidence of greater than eTC grade 1
nausea and vomiting. Fatigue was the most commonly reported adverse event with
two patients grading this as grade 2. One patient required a dose reduction for
myelosupression with grade 2 neutropaenia and grade 3 thrombocytopaenia on the
first cycle. Her second treatment was delayed by 10 days and she received a dose
reduction to 150 mg/rn/day as per the protocol. One patient had a prolonged
response to temozolomide and went on to receive a total of 9 cycles of full dose
treatment without significant myelotoxicity being observed, having two brief,
uncomplicated records of grade 3 neutropaenia during the 9 months treatment. All
eTC grade 3 toxicity and greater is listed in table 6.5.
Table 6.5
Toxicity N° patients with CTC 0/0 of cycles given (32)
grade 3/4 toxicity
Thrombocytopaenia 1 3
Neutropaenia 2 6
Headache (disease related) 1 3
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The degree of toxicity observed is in line with that published (references as below).
The phase II study of temozolomide in metastatic melanoma reported mild toxicity
with 3% grade 4 thrombocytopaenia and 3% grade 3 neutropaenia with no grade 4
neutropaenia. Grade 1 nausea was the most common adverse event, reported in 30%
ofpatients (Bleehen, Newlands et al. 1995). The larger phase III study of
temozolomide against DTIC reported 2% grade 4 neutropaenia and 5% grade 4
thrombocytopaenia (Middleton, Grob et al. 2000). Nausea was again the commonest
non-haematological toxicity, but was mild in the majority of cases, being grade 2 in
one patient, grade 1 in two patients only; there was no vomiting reported.
6.3.3 Response data
All patients were assessed for response after every two cycles of treatment unless they
had been withdrawn from treatment because of clinical deterioration and early disease
progression. Response was assessed either by clinical measurement of skin
lesions/lymph node recurrence or by radiological documentation of disease. Where
radiological assessment of response was made the same scanning modality was used
throughout treatment, and scans were evaluated according to WHO Guidelines.
9 out of 12 patients were assessable for response. Three patients did not receive their
second cycle of treatment as documented above and are therefore not assessable for
response. 5 patients demonstrated progressive disease after 2 cycles and were
withdrawn from treatment. A further 2 patients had disease stabilisation after 2 cycles
but progressive disease after 4 months of treatment. 1 patient had a prolonged
response achieving a PR and received 8 cycles of treatment and 1 patient had an
excellent response to treatment with a complete radiological response in her lung
metastases, and resolution of subcutaneous metastases. Her scan showed continuing
response after 6 cycles of treatment, she had suffered no haematological toxicity and a
decision was made to treat with 3 further cycles of temozolomide. A CT scan after 9
cycles confirmed the resolution of lung metastases, but showed a fracture through an
isolated pelvic bone metastasis. She was withdrawn from the study at this point to
receive palliative radiotherapy to this painful area.
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The overall response rate was 22%, with a clinical benefit rate (response plus disease
stabilisation for at least 2 months) of 44% in the assessable patients. However
including those with early proven progressive disease the response rate fell to 18%
with 36% clinical benefit.
The phase II study of temozolomide in metastatic melanoma reported a response rate
of21% with an overall clinical benefit rate of36% (Bleehen, Newlands et al. 1995).
In the phase III study comparing temozolomide with DTIC the overall response rate
to temozolomide was 13.5% and 12.1% to DTIC, with clinical benefit in 31.4% and
27.9% of patients respectively (Middleton, Grob et al. 2000).
6.4 Plasma temozolomide pharmacokinetics
Plasma temozolomide levels were measured in all patients. A limited sampling
schedule only was passed by the ethics committee in Newcastle so 5 of the 6 subjects
recruited in this centre had acidified plasma samples for temozolomide analysis at
base line, 4 and 24 hours after temozolomide dosing on day 1 of cycle 1 only (4 hour
data included in table 6.6). PK samples were not available for one patient recruited at
this centre. Limited conclusions can be drawn from these data. The 6 patients
recruited in Oxford had more extensive pharmacokinetic sampling and concentration
time plots can be calculated. These are shown below in figure 6.3. The limited data
available shows a pattern of absorbtion and rapid clearance similar to that observed
and published in the phase I (Newlands, Blackledge et al. 1992), and phase III studies
oftemozolomide (Middleton, Grob et al. 2000) although in the later study PK
sampling was done on day 4 of treatment.
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Figure 6.3
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Figure 6.3 Plasma temozolomide concentrations against time from dosing. Co ncentration /time curve
for 6 patients. Note pat ient HR35 received second dose oftemozol omid e before 24 hour PK sample
take n.
Plasma temozolomi de concentrations 4 hours after drug administration for all patients
are given in table 6.6. In all patients no temozolomide was detectable by HPLC
measurement before treatment and in 11 patients 24 hours after first dose and before
receipt of the second dose ; consistent with the published clearance of this drug (NB 1
patient inadvertently took his tablets prior to the 24 hour sample). The values
measured at 4 hours are consistent with those found in the patients with more
extensive sampling.
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Table 6.6 Plasma temozolomide at 4 hours in aU patients
Patient code Plasma temozolomide concentration
at 4 hours (ug/ml)
SA11* 3.67
HS12* 3.72
RQ13* 2.12 --
UD14* 2.70
JOCP16* 2.55
CN31 3.50
AN32 2.52
TB33 1.79
JR34 2.23
HR35 1.04
DB36 2.82
* Limited sampling patient
6.5 PARP activity in human PBLs and the effect of temozolomide
Isolated PBLs were obtained from all patients at baseline, 4 and 24 hours after the
first dose of temozolomide. When the study was initiated it was hoped that the
radiolabel PARP assay used in all the preclinical studies would be suitable for a
clinical PD assay. It became clear that low cell harvests compromised the
reproducibility of the radiolabel PARP activity assay and the immunoblot assay was
developed during the recruitment of this precursor study. The first 3 patient samples
were initially analysed using the radiolabel assay, the cell recovery was so low that a
range of between 0.015 x 106 to 0.366 X 106 cells could be loaded. All these values lie
outside the validated range of cell numbers for the assay. PBLs were prepared from
10 ml whole blood in this study, it was proposed that only 5 ml of blood would be
available for lymphopreparation during the Phase I PARP inhibitor study to minimise
the total blood volume drawn from patient whilst maximising the number of different
PK and PD assays. The problem of low cell harvest would be more acute with the
lower volume of blood therefore it became clear that a change in assay technique was
required.
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The duplicate samples from these first three patients were analysed on a prorotyp of
the immunoblot assay. The assay methodology was identical to the final validated
version and appropriate QC samples loaded; however the purified PAR standard
curve had not been established at this stage so polymer formation can not be
expressed in terms of pmol PAR formed for these three patients. It is, however,
possible to compare changes in pol ymer formation over the baseline value, expre mg
chemiluminescence detected as a percentage baseline.
All other patient samples were analysed using the final validated protocol for the
immunoblot with QC samples and a PAR standard curve (sect ion 3.6). All samples
from each patient were loaded in triplicate onto one blot so the any variation in
processing and washing was eliminated. A typical blot and Aida output are show in
figure 6.4.
Figure 6.4
No Grp Grp Name Type Area Integral Inlegral- Bkg InlegraVArea Integl1ll/ArH-Bkg
[mm'] [LAUI [LAU] [LAUInvn'J (LAU/lnm')
1 0 Group 0 184.8 113577469 0 99348230.2 614469 .20 537487.13
2 0 Group 0 186.0 64482856.0 50167660.5 346766.06 269783.99
3 0 Group 0 186.0 28997359.0 14682163 .5 155931.51 78955.50
4 0 Group 0 184 .8 17069522.0 2840283 .2 92348.38 15386.31
5 0 Group 0 184.8 145281730 2989342 78599.35 1617.27
6 0 Group 0 186.0 1425554 7.0 -59646 .5 7666 1.30 -320.77
7 1 0 Group 0 186.6 14790280.0 425320.0 79261.37 2279.30
8 1 0 Group 0 186.6 1 14853923.0 488963 .0 79602.43 2620.36
9 1 0 Group 0 186.6 I 14958252.0 593292 .0 I 80 161.S4 3179 .48
10 0 Group 0 186.6 52721424.0 383564640 282535.04 205552 .96 1
11 0 Group 0 186.6 53292030 .0 38927070.0 I 285592.93 20861085
12 0 Group 0 186.8 61337679.0 469727 19.0 328709.10 I 25172753 I
Figure 6.4 Illustrative blot showing standard curve (wells 1-6), TO samples (7-9, 13-15,19-21 ).
triplicate patient samples (10-12, 16-18, 22-24) and QC samples (25-30). Areas 31-34 represent
background areas for the blot subtracted from all readings. The Aida digital readout is illustrated
below the blot, the final column of data (Integral/Area-bkg, LAU/mm2) is used in all subsequent
calculations.
The results from all 12 pati ent s are summarised in table 6.7. Data are e pre d both
as amount of PAR form ed per 106 PBL s and also as a percentage of the ba elin lev I
for eac h individual patient.
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Table 6.7
Patient Mean PAR formed per 20,000 As % baseline
ID PBMCs/pmol monomer equiv
Baseline 4 hours 24 hours Baseline 4 hours 24 hours !
CN31 100 275 No cells
in sample
AN32 100 91 I 43
TB33 100 No cells 105
in sample
JB34 20 130 10 100 603 55
HR35 135 695 195 100 515 144
DB36 20 100 15 100 447 75
SAIl 90 75 20 100 84 20
HSl2 165 225 70 100 136 42
RQl3 170 205 275 100 122 165
UDl4 285 555 500 100 197 177
JRl5 185 1160 100 100 636 55
JOCPl6 120 80 No cells 100 66 No cells
in sample in sample
The mean baseline PARP activity in this patient population who had not previously
received chemotherapy was 130 ± 185 pmol/l 06 cells (mean ± SD) with a range 20 -
285. These values are similar to those observed in healthy volunteers with a mean
PAR formation of 160 ± 145, range 15-615 pmol/Iu" cells (Dr Chris Jones, personal
communication). A significant increase in PARP activity was detected at 4 hours
(p=0.033: 2-tailed Wilcoxon signed rank test) at the time when temozolomide-
induced DNA strand breaks would be expected to peak. There was no statistical
difference between the paired baseline and 24 hour samples.
6.6 PARP activity in homogenised human tumour biopsies
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9/12 patients consented to tumour biopsies under local anaesthesia before and at one
time after receiving their first dose of temozolomide. Patient RQ13 had a groin node
biopsy prior to treatment which bled significantly after the procedure and required
hospitalisation. It was felt inappropriate to ask him to undergo a further biopsy and
risk of re-bleeding.
All experiments were performed using the method described in section 3.7. The
results following immunoblotting of the tumour homogenate are shown in table 6.8.
Data are expressed in term of the mean amount of PAR formed per mg protein in the
tumour homogenate from triplicate samples.
Table 6.8
Patient ID Mean PAR formed per mg As % baseline !
protein(pmol monomer equiv)
Baseline 4 hours 24 hours Baseline 4 hours 24 hours
eN31 463.4 495.5 100 106.8
AN32 2.5
-
TB33 1.65 18.4
JB34 2754.2 29.3 100 1.1
HR35 818.6 2926.2 100 375.7
DB36 606.1 2875.0 100 474.5
SAIl 1311.2 258.7 100 19.7
HSl2 3609.1 2058.9 100 57.2
RQl3 3596.2 No biopsy
taken
Note TB33 had melanotic tumour, results given but companson not made, see below. AN32 baseline
biopsy too small to homogenise
There was a considerable range of values for PARP activity in the homogenised
tumour samples. This could be due to true variation in the amount of PARP active in
the tumour, or due to the biopsy process.
Where two biopsies were obtained these were either different subcutaneous nodules,
or in the case of two patients liver biopsies with a tru-cut needle. Tumour
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heterogeneity would mean that, even if the same lesion had been biopsied there could
be significant variation in the amount of viable tumour in the sample. To allow
comparison between samples all data were expressed in terms ofmg protein added to
the blot. The protein concentration varied between tumours with a range of 0.031-
0.55 mg/ml in a 1 in 1000 homogenate. The majority of values lay at the lower end of
this scale. One patient (TB33) had a very melanotic tumour and it may be that the
pigment interfered with the protein assay giving an unreliable reading. Although
there was variation in protein concentration between patients, when the two samples
from the same patient were compared there was no significant difference in the
protein concentration of their biopsies (p=0.81, Wilcoxon signed rank test, 2-tailed p
value). The variation in protein levels should not, therefore affect the comparison of
PARP activity between tumour biopsies on the same patient.
When tumour PAR formation was expressed as a percentage of the control there was
no clear pattern of change in PARP-1 activity at either 4 or 24 hours after dosing.
Although the ability to form polymer varied between tumours comparison of the
paired samples showed no significant difference after a dose of temozolomide (p ::::l,
Wilcoxon signed rank test, 2-tailed p value).
6.7 Investigation of DNA damage and repair
6.7.1 COMET assay for DNA breaks
Initially both PBLs and tumour samples were prepared for analysis of DNA strand
breaks by COMET assay. However it proved impossible to obtain a suitable
preparation of isolated tumour cells and there are no data from this matrix. Frozen
PBLs were transferred from the clinical centres to the laboratory in Oxford where the
COMET assays were performed by Dr Anna Olsen. The summarised results are
shown below.
The results from the 12 patients treated are shown in figure 6.5. giving the mean Olive
moment at the three time points from individual patients. The mean of 50 COMETs
with the standard error of the mean is shown. In the 6/10 of patients the expected rise
in DNA damage was observed 4 hours after dosing with temozolomide with a fall
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towards baseline at 24 hours, prior to the next dose. The mean values confirmed a
general trend towards increased strand breaks at 4 hours (table 6.9). However, due to
the variability of the data this increase was not significant (p=0.15: Student's t test).
Figure 6.5
-baseline
rs
s
- ~4 hour
~24 hou
-
t'v
t' J
- v vt- v
t\ It
ii~~ i~ t- I vv 1/v
-
t- t- v 1/
30
o
RQ13 UD14 JR15 JCOP'CN31 AN32 TB33 JB34 HR35 OB36
Patient
Figure 6.5 Olive tail moments for patient samples at baseline, 4 and 24 hours after 200 mg/rrr'
temozolomide. Mean and SEM, 50 COMETs measured. Data from 10 patients, 2 sets of samples
unsuitable for analysis
Table 6.10
Time point Mean Olive moment 95% confidence interval
Baseline 12.2 6.1-18.2
4 hours 15.7 10.5-20.9
24 hours 12.3 7.1-17.5
6.7.2 ATase
PBLs were prepared by lymphopreparation and washed cell pellets frozen for ATase
measurement. All assays were performed by Dr Geoff Margison at the Paterson
Institute for Cancer Research, Manchester. As discussed in chapter 1 0 6-alklguanine
alkytransferase (ATase) is a DNA repair protein which is endogenously expressed and
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removes methyl groups from 06methyl guanine after exposure to temozolomide.
ATase levels would be expected to fall after induction of DNA damage by
temozolomide as this protein is also the acceptor for the methyl group in the repair of
cytotoxic lesions and once methylated becomes a target for proteolytic degradation
(D'Incalci, Citti et al. 1988; Lee, Thatcher et al. 1994).
The results obtained from the patient samples are summarised in figure 6.6, mean and
SEM are given, with ATase activity expressed in terms of fmol/ug DNA. The
expected fall was seen at 4 hours and levels had not recovered to baseline by 24 hours
post treatment.
Figure 6.6
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Figure 6.6 Mean and SEM of ATase activity in human PBLs after temozolomide dosing (n=8)
Comparison of change in ATase level at 4 hours and pre-treatment is shown in figure
6.7, no correlation has been observed with these samples.
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Figure 6.7
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Figure 6.7 Correlation between Initial ATase level and the change 4 hours after treatment with
temozolomide. ATase expressed in fmol/ug DNA, (n=7)
6.8 Discussion
This chapter reports the clinical and laboratory results of a small phase II study of
temozolomide in patients with advanced metastatic melanoma. The study was
proposed as a precursor study to the main PARP-1 inhibitor/ternozolomide
combination study to obtain clinical data to aid validation of the laboratory methods
to be used in that study. Additionally it was intended to provide control data for the
PD endpoints for the First-in-Human study of AG014699 in combination with
temozolomide.
The clinical efficacy and toxicity data obtained in this study is in line with that in the
published literature meaning this small study is representative of the typical toxicities
and responses reported. The dose limiting toxicity of temozolomide is
myelosupression (reviewed in (Newlands, Stevens et al. 1997) and other toxicities are
mild. This was borne out in this study where only one patient required a dose
reduction for myelosupression and otherwise the treatment was well tolerated. The
response rate observed was similar to that published for the phase II and phase III
trials of this drug (Bleehen, Newlands et al. 1995; Middleton, Grob et al. 2000) with a
number of patients deriving clinical benefit from the treatment. The relatively high
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rate of early withdrawal from the study (after 2 or fewer cycles) confirms the poor
prognosis of this disease, rather than being a reflection on toxicity of the treatment.
The limited pharmacokinetic results are consistent with the well established profile of
this compound (Newlands, Blackledge et al. 1992; Danson and Middleton 2001). All
patients absorbed the oral preparation rapidly, and no subject showed prolonged
retention of the drug in the plasma. It is unfortunate that the only patient who showed
significant myelosupression on the first cycle had their PK sampling omitted.
PARP-l activity was measured in PBLs from all patients and in tumour samples in 9
out of 12 patients. The variation in this untreated patient population was similar to
that observed in healthy volunteers. An important piece of information gained from
these results is that PARP-l activity shows a small but significant increase at 4 hours
after a single exposure to temozolomide. It is unclear why this should be, there being
no other data available measuring PARP-l activity in patients receiving
chemotherapy.
PARP-l retains its activity following a round of activation, automodification and
removal of the polymer. Therefore, it would not be expected that this enzyme would
be depleted following DNA damage. In fact, a small rise in maximally stimulated
PARP-l activity was observed is this study. There is no comparable data in the
literature. In a study of the potentiation of temozolomide by the novel PARP inhibitor
CEP 6800 a similar increase in PAR accumulation in xenografts was observed 4 hours
after treatment with a single dose of temozolomide or irinotecan compared to vehicle
control (Miknyoczki, Jones-Bolin et al. 2003). These authors measured endogenous
PAR in xenografts as a measure of enzyme activity. This differs from the
experiments reported above where the ability of the enzyme to form polymer ex vivo
was measured
PARP-l is a nuclear enzyme which is constitutively expressed in the majority of
human cells with an average of one copy per 1000 base pairs. Following activation
by DNA single strand breaks there is rapid synthesis and degradation of polymer and
proposed re-cycling of the enzyme. The half-life ofpoly(ADP-ribose) is known to be
a matter of minutes, with the polymer rapidly removed from its acceptor proteins by
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PARG. Given the high endogenous expression of enzyme and this dynamic
equilibrium it would not be expected that further enzyme would be synthesised in
response to DNA damage. It could be either that there are inactive PARP-1 enzymes
sequestered within the cell which are released following temozolomide that could
explain the small rise in maximal ability to form polymer or post-translational
modification (?phosphorylation) that activates PARP-1 after temozolomide exposure.
The vital piece of evidence gleaned from this study is that there was no fall in PARP-
1 activity with cytotoxic drug treatment. In the first in human PARP inhibitor study
the primary endpoint is proof of PARP inhibition by the novel agent. For ethical
reasons a combination study with a cytotoxic agent is being proposed rather than a
single "novel agent" study. Hence it was important to prove that the cytotoxic
treatment on its own would not cause a depletion of PARP-1 activity and hence
potentially confound the results of the inhibitor study. The fact that a small rise is
observed will allow greater certainty of the effect of AGO14699 when PARP
inhibition is achieved in human PBLs with this drug.
PARP activity was also measured in human tumour samples. There was wide
variation in the amount of PARP activity detected in the tumour biopsies, reflecting
the heterogeneity of tumours. Preclinical data in human tumour xenografts indicated
that there were high levels of PARP activity in tumours when compared with a
"standard" tissue such as liver when PARP activity was measured using the e2p]
NAD+ incorporation PARP activity assay and with the immunoblot (table 5.5). There
is also evidence to confirm this from human liver biopsies, where normal liver shows
lower levels of PARP-1 activity than hepatocellular cancer (Shiobara, Miyazaki et al.
2001). The majority of the melanoma biopsies obtained in this study also showed
comparatively high levels ofPARP enzyme activity. If this high PARP activity
contributes to tumour resistance to temozolomide then it is hoped that use of a PARP
inhibitor in combination with temozolomide will allow increased tumour effect
without increased toxicity.
Pre-clinical evidence shows that inhibition of PARP and hence BER following
temozolomide treatment increases peak levels of strand breaks and the persistence
from repair of intermediate N-methyl purines (Boulton, Kyle et al. 1999). However,
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results from the analysis of DNA single strand breaks with the alkaline COMET assay
show a disappointing level of variation with this method. Nevertheless it would
appear that there was some evidence of the expected rise in the amount of DNA
damage after temozolomide and that this was repaired over the 24 hour period before
repeat dosing. It is hoped that further validation of this method will allow its use in
studies to support the First in human study of a PARP-l inhibitor with temozolomide.
The inherent variability in the assay is an important reason why this
pharmacodynamic endpoint was defined as a secondary not primary endpoint in the
PARP-l inhibitor study.
The primary endpoints of the study have been achieved with the assessment of the
DNA damage caused by full dose temozolomide and measurement of PARP-l and
ATase activity after treatment. These enzymes are involved in the two major DNA
repair pathways utilised by cells after temozolomide to repair methylated DNA, BER
and direct repair. ATase is inactivated by this process hence a fall in levels after
treatment is observed, to approximately 60% at 4 hours.
In the phase II study reported here ATase levels fell by ::::40% 4 hours after
temozolomide therapy. Similar observations were made by Lee et al (Lee, Thatcher
et al. 1994) who found that where ATase levels were measured in PBLs from 8
patients after dosing with temozolomide (150 mg/m) depletion of ATase was
observed within 4 hours of the first dose of temozolomide with a median nadir of
52.9% baseline 2-6 hours post-treatment with levels not returning to normal by 24
hours. This earlier study showed an eight-fold variation in pre-treatment levels of
ATase (69 to 593 fmol/mg protein) The different units of measurement do not allow
direct comparison with the values found in the current study for the majority of
patients, pre-treatment values range from 12.6-22.8 fmol/ug DNA. In the final 4
patients data was expressed in terms of fmoVmg protein and a similar range is
observed to that published (81-535). A similar time course of depletion in tumours
has been demonstrated in a mouse xenografts model (Middleton, Kelly et al. 2000)
with complete depletion of the enzyme by 4 hours after a single i.p. injection of 100
mg/kg temozolomide. When animals received 5 daily doses oftemozolomide (same
dose and route) ATase recovery was not complete until day 16 after treatment.
Previous studies have demonstrated a relationship between the extent of ATase
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depletion and the pre-treatment values in patients receiving temozolomide (Lee,
Thatcher et al. 1994). However, in the study reported here, there was no correlation
between initial ATase activity and the extent of its depletion (see section 6.7.2), which
was largely a reflection of the limited samples points. .
The secondary objectives of the TemoCOMET trial included relating the biological
measures of DNA damage and PARP activity to clinical outcome. This has proved
difficult because of sample handling problems, however limited conclusions can be
drawn. In terms of toxicity there was little significant toxicity observed in this small
group ofpatients. The drug was well tolerated. A correlation has been demonstrated
between level of DNA damage and toxicity, in particular nausea (Braybrooke,
Houlbrook et al. 2000). No significant emetogenesis was observed in this study. The
one patient who developed dose limiting myelosupression had low mean Olive
moments without a significant increase after temozolomide (patient JR15).
4 patients demonstrated clinical benefit with disease stabilisation for 4 months or
more. Two of these patients had baseline ATase levels at the bottom of the range
observed (13.3 and 12.2 fmol/ug DNA) and one at the upper end (17.7 fmol/ug
DNA), no data is available for the patient who had a prolonged response due to a
sample transport problem. The two patients who had early progression of disease
(after 1 cycle of treatment) had high/normal initial ATase levels (20.7 fmol/ug DNA
and 219fmol/mg protein respectively) and high PARP-1 activity at baseline (135 and
120 pmol PARI106 cells). A correlation has previously been demonstrated between
high tumour ATase activity and poor response to temozolomide in patients with
malignant glioma (Friedman, McLendon et al. 1998) but no correlation with response
in biopsy samples from patients with metastatic melanoma (Middleton, Lunn et al.
1998).
In conclusion this Phase II study has provided a valuable forum for the clinical centres
to work together, ironing out problems in the complex sampling schedules which it
planned to use as part of the dose defining process in the novel PARP inhibitor study.
Additional data in human samples has been obtained to complete the validation of the
immunoblot as a suitable method for measuring PARP-1 activity to an acceptable
standard of accuracy. It has also been shown that PARP-1 activity shows a small
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increase after doing with temozolomide, meaning that there will be greater certainty
that any measured decrease in the inhibitor study is due to AG014699.
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Chapter 7
Summary
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7.1 Introduction
Inhibition of PARP was suggested as a potential clinical drug target in 1980, when the
first evidence that poly(ADP-ribosylation) was involved in DNA repair was reported
(Durkacz, Omidiji et al. 1980). Development of potent PARP inhibitors was identified
as one of the Newcastle University Cancer Research Unit's drug development targets
in 1990. Over the next 13 years potent inhibitors were developed, latterly in
collaboration with Agouron Pharmaceuticals (currently part of Pfizer GRD) and the
clinical candidate to emerge from this research entered First-in-Human clinical trials
in 2003.
The work described in this thesis was performed during the late stages of the drug
development project and included the drafting of the First-in-Human phase I trial
protocol and close involvement with the design of this trial. Laboratory studies were
based around the validation of an established assay of PARP activity for use as a
clinical pharmacodynamic method and the subsequent development of a quantitative
immunological PARP-1 activity assay based on polymer detection. A small phase II
clinical trial has been supervised to obtain suitable clinical samples which have
provided additional validation evidence for the assays but also clinical data to support
the subsequent First-in-Human PARP-1 inhibitor trial.
7.2 Protocol development
The development of the phase I clinical trail protocol for a combination study of
AG014699, a novel, potent PARP-1 inhibitor and temozolomide is discussed in
chapter 2. The final design was for a 2 part study, escalating first the dose of
AGO 14699 until PARP-1 inhibition was proven and subsequently escalating the dose
oftemozolomide to define a maximum tolerated dose. The majority of the work
performed during the early stages of this MD project involved authorship of the first
draft of the trial protocol, liaison with other investigators and final collaboration with
the teams both in the Drug Development Office, Cancer Research UK, and at Pfizer
GRD to produce a protocol for submission to Cancer Research UK's CIRB, the
Northern MREC and LRECs for Belfast, Oxford and Newcastle.
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There are a number of features in the final study design which are atypical, these have
been discussed in chapter 2 and are summarised below.
Unusual features of the study
1. Starting dose of AG014699 was not defined as is usual in a phase I trial as
i/ro" of the toxic dose low (TDL) in most sensitive species. Efficacy data
was taken in to account to suggest a lower starting dose which is 1I40th
TDL in rats.
2. The decision to stop escalation in part 1 of the study is defined by
pharmacodynamic indices rather than toxicity. It would not be anticipated
that AG014699 and half-dose temozolomide would cause significant
toxicity before a PARP inhibitory dose was reached. If significant PARP
inhibition is observed in PBLs, sustained out to 6 hours after dosing and
with a plateau in magnitude between 2 dose levels escalation of
AG014699 would stop at this point and phase 2 of the study entered even
if no significant toxicity were reported.
3. Single agent dosing with AG014699 is planned in a run-in period prior to
starting the combination to allow the generation of PK and PD single agent
data and avoiding the ethical difficulties of proposing a study of the novel
agent alone when this would be predicted to be ineffective.
7.3 Pharmacodynamic assay validation
The majority of the work undertaken has been directed towards establishing and
validating a pharmacodynamic assay which can be used with clinical samples, both
PBLs and tumour biopsy specimens.
Initially an assay based on the incorporation ofe2p] NAD+ into poly(ADP-ribose)
which was already well established in the Drug Development Laboratory, NICR was
adapted and validated for use with human PBLs. This assay proved robust and was
suitable for analysis ofPBLs and homogenised tumour, whether analysed on the day
of harvest or after storage for up to 3 months. However, during the validation process
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it became clear that the variability in results was unacceptably high if low numbers of
cells were harvested, subsequent experiments have suggested that similar increased
variability was an issue with tumour biopsy specimens that have been diluted below 1
in 80 and work is on-going to clarify this.
In the light of the problems with low cell harvest an alternative assay was sought and
an immunoblotting technique, first reported by Professor Burkle's group, adapted for
use with human PBLs and tumour homogenate. The various stages of this assay were
examined and modified to reduce potential variability, a standard polymer curve
established to allow quantification of results and the direct comparison of data from
different patient samples.
The salient facts established during the validation of these two assays are listed below.
Salient features established during assay validation
1. PARP enzyme activity in isolated cells, snap frozen tissue or homogenised
tumour is not destroyed by freezing at -80°C for up to three months,
allowing storage and transport of clinical samples from disparate clinical
sites for analysis. Additionally, the degree of enzyme inhibition with
AG014699 and AG014361 appears to be preserved when frozen, meaning
there is no concern that variation in storage time might affect the degree of
inhibition measured in clinical samples.
2. The e2p] NAD+ incorporation PARP activity assay is a robust assay
giving reproducible results providing sufficient cell numbers are available
for analysis.
3. A mouse leukaemia cell line, L1210, has been established as suitable cells
to use as QA samples to validate an individual assay run.
4. Purified poly(ADP-ribose) can be commercially obtained and used to set
up reproducible standard curves allowing quantification of the immunoblot
and hence inter-blot comparison.
5. Studies using PARP-l "knock-out" animals have demonstrated that PARP-
1 activity is detected and measured with the immunoblot.
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7.4 Assay evaluation within a phase II clinical trial
Having established a potential PD assay which could be used in the First-in-Human
PARP inhibitor clinical trial a phase II mechanistic study of temozolomide in patients
with advanced malignant melanoma was written and submitted to LREC in
Newcastle, Belfast and Oxford. The aims of this study were to investigate indices of
DNA damage and PARP activity following full dose temozolomide in a small cohort
of patients.
The clinical and laboratory results of this study are discussed. The observed toxicity
and response rates were comparable with those reported in the literature,
temozolomide at a dose of 200 mg/m2 x 5 days every 28 days was well tolerated and
>30% patients gained a clinical benefit from treatment.
Pharmacodynamic assays were performed using isolated PBLs. Maximally
stimulatable PARP-I activity increased slightly 4 hours after temozolomide dosing,
falling to baseline prior to re-dosing on day 1 of cycle I. COMET assay analysis of
DNA single strand breaks suggested that these peak at 4 hours after dosing consistent
with reports in the literature. ATase levels fell after temozolomide exposure and had
not recovered by 24 hours.
The critical piece of data generated by this study was that maximally stimulated
PARP-I activity did not fall following treatment with temozolomide. During the
First-in-Human PARP inhibitor trial study endpoints rely on the demonstration of the
degree ofPARP inhibition caused by AG014699, it would be more difficult to define
these endpoints if they were confounded by changes in enzyme activity due to the
chemotherapeutic agent.
7.5 Conclusions and future directions
The development of 2 different pharmacodynamic assays alongside the authorship of
the phase I protocol in which the assays would be used allowed the maximum
consideration of the practical issues surrounding the treatment of patients at a
vulnerable stage in their lives whilst ensuring that scientifically valid endpoints were
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defined, appropriate sampling times were selected and translational research was
facilitated.
The conduct of a "run-in" study not only provided valuable information but also
encouraged co-ordination between the centres and built up an understanding between
key personnel in the three centres. This meant that a good working relationship was
established before the centres embarked on a complicated trial taking a drug from a
new class of agents into the clinical for the first time with all the associated risks.
The final few patients were recruited on to the TemoCOMET study as the First-in-
Human study of AG014699 and temozolomide commenced in June 2003. This study
is recruiting successfully, PARP inhibition has been demonstrated in PBLs using the
immunoblot assay and the study should move into its second stage early in 2004.
On-going laboratory work is focussing on the reproducibility of the assay, in
particular that of the standard polymer curve and the background polymer staining in
homogenised tissue samples. It is planned that a second phase I combination study of
AG014699 with irinotecan will start soon after completion of the temozolomide
combination study.
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